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“This is the essence of science. First you think of something that could be true. Then you see if it is the case and 
in general it is not the case.” 
 
„Science does not aim at establishing immutable truths and eternal dogmas; its aim is to approach the truth by 
successive approximations, without claiming that at any stage final and complete accuracy has been achieved.” 
 
--- Bertrand Russell (1872-1970), British philosopher, mathematician and Nobel Laureate for Literature 
 
 
 
 
„There are two kinds of truth: the truth that lights the way and the truth that warms the heart. The first of 
these is science, and the second is art. Neither is independent of the other or more important than the other. 
Without art, science would be as useless as a pair of high forceps in the hands of a plumber. Without science, 
art would become a crude mess of folklore and emotional quackery. The truth of art keeps science from 
becoming inhuman, and the truth of science keeps art from becoming ridiculous.”  
--- "Great Thought" (19 February 1938), published in The Notebooks of Raymond Chandler (1976) 
 
 
 
 
„Not only is the universe stranger than we think, it is stranger than we can think.” 
 
--- Werner Heisenberg (1901-1976), German scientist, physicist and Nobel Laureate in Physics 
 
 
 
 
„Science starts getting interesting where it ends.” 
 
--- Justus von Liebig (1803-1873), German chemist and friend of Emanuel Merck 
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Abstract 
 
The present work focuses on understanding the mechanisms of action of two pharmaceutically relevant inhibitor 
protein systems. Understanding the mechanism of how drugs or drug candidates are affecting their molecular 
target is of vital importance in order to develop a promising drug candidate into a valuable medicine. Nowadays, 
such understanding is mainly gained from computational studies, better known as molecular modelling 
approaches, which are an essential part of every drug development campaign. 
 
Using the example of two distinct protein ligand systems, respectively consisting of a target protein and an 
appropriate binding molecule, we aimed at elucidating the intrinsic subtype specificity determinants inherent in 
interacting biological systems by employing up-to-date computational techniques.  
 
The first part of the thesis focuses on the subtype-specific interaction of the cyclic depsipeptides YM-254890 
(YM) and FR900359 (FR) with the alpha (α) subunit of a heterotrimeric G protein. Through this interaction 
with the α subunit of the Gq G protein subtype the immanent G protein function of GDP/GTP exchange is 
hampered and thus intervenes the associated signal transmissions within and between cells. So far, the direct 
targeting of intracellular Gα subunits by chemical tools represents a novel promising pharmacological approach 
for e.g. targeting oncogenic Gq/11 proteins as a potential therapeutic option for cancer treatment of the adult 
eye.1-5  
Here, we thoroughly analyzed novel FR900359-based analogues from natural sources, synthetic cyclic peptides 
as well as all so-far known Gαq inhibitors in a comprehensive computational study. Using molecular docking 
we have identified unique features in the macrocyclic FR/YM structures responsible for the binding to the 
target protein and correlating with their inhibitory activity.5 We hence could elucidate the FR/YM specific 
characteristics that determine their interaction with the Gq binding pocket.5 
Our main findings suggest key regions in Gq, more specifically two major anchor positions at the joints of the 
G protein α subunit, namely residue Arg60, situated at a protein region called “linker 1”, as well as the two 
adjacent residues Ile190 and Glu191 located close to a protein region called “switch 1”. The fixation of these 
two hinge points by the crucial N-MeDha5 and the opposite β-hydroxyleucine residues in YM/FR inhibits their 
intrinsic mobility and thus counteracts the opening movement of the Gα subunit which is relevant for 
GDP/GTP exchange. An additional feature attributed to the YM/FR inhibitor is the associated stability of its 
backbone structure, which enables it to fit into the binding pocket of the G protein and thus address said critical 
positions. 
Although our computational data were in agreement with experimental results that no other inhibitor exceeded 
the biological activity of wild type FR, the question remains whether FR analogues represent valuable chemical 
tools for the targeted and specific inhibition and whether they constitute suitable natural lead structures for the 
development of novel compounds to target Gα subunits apart from the Gαq subtype.5 
 
The second part of this work focuses on the investigation of voltage-gated ion channels and their – equally 
subtype-specific – conotoxin blockers, venoms that are obtainable from the marine cone snail. We herein mainly 
focused on voltage-gated sodium (NaV) and potassium (KV) channels both of which are mainly found in the 
central nervous system (CNS). Their selective blockage prevents the reciprocal ion flux across the membrane 
that separates a neuron from its adjoining synaptic cleft. The flow of ions, in case of resulting in a potential 
difference between the nerve interior and the outside, finally accounts for the so-called resting potential. This 
potential difference is a natural property that is usually provided by selectively permeable membranes and makes 
up an essential prerequisite for the initiation of stimuli conductions. Understanding the subtype-specific ion 
channel block by such natural peptide-based toxins can therefore provide essential guidance for the further 
advancement of such compounds into promising drug candidates.6 
 
The first associated study comprises a docking study of 15 different disulfide bond isomers of the μ-conotoxin 
PIIIA to the sodium channel subtype NaV1.4 of the NaV1 sodium channel family, for which a subtype-specific 
block by the native μ-PIIIA isomer was observed from experimental data. 
Using a sophisticated docking approach, we achieved to demonstrate a correlation between the μ-PIIIA disulfide 
bridge pattern and the toxin’s capability to block NaV1.4. Since the structural conformation of a toxin and the 
associated flexibility results from its internal disulfide bridging pattern, the extent of the pore block can be 
directly attributed to the toxins’ structural properties.  
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Here, through our docking approach we were able to gain further information on which toxin parts of the 
isomers address certain parts of the pore surface. It could be demonstrated that there is an ultimate correlation 
between the cysteine disulfide bridge pattern of a toxin, which determines its structure and flexibility, and finally 
its extent of ability to block certain channel subtypes. In contrast to active isomers, the moderate or poorly 
active isomers either lack the central pore contact and/or the distributed covering contacts to the outer pore 
surface. In particular, it could be shown that a channel is effectively blocked by a full pore coverage, whereas 
only partially covered in weaker blocks. 
In these respects, the docking experiments were in accordance with laboratory generated data, pointing out a 
specific binding pose of the most active native μ-PIIIA isomer, comprising coincident contacts with the inner 
central pore duct, addressing the very well-known “DEKA” selectivity filter motif and the outer located loop 
regions of the channel. Due to the more globular fold of the native μ-PIIIA isomer, which is caused through its 
unique disulfide pattern, the acidic pore residues are primarily addressed by the basic arginine residues of the 
toxin, stabilizing the central pore-covering toxin position on the channel.        
 
The anticipated importance of the toxins’ flexibilities and how they influence the different bioactivities is 
explored in more detail by our second study on subtype-selective ion channel blockage through μ-conotoxins, 
where, apart from docking studies, molecular dynamics simulations are employed. 
Here, an extensive molecular dynamics analysis of the μ-PIIIA, μ-SIIIA and μ-GIIIA conotoxins on the voltage-
gated KV1 potassium channel family subtypes KV1.1, KV1.5 and KV1.6 and on further artificially created chimeric 
models is given. In order to more thoroughly understand the dynamics and binding states of these ion channel 
toxin systems, we correlated them with their experimental activities which were recently reported by Leipold 
et al.6, 7 As for all channel-bound toxins investigated herein, a certain conformational flexibility that reflects the 
individual pore blocking potencies could be observed through our molecular dynamic simulations, the necessity 
of considering dynamic data for the understanding of subtype-specific blocking events and concomitant activity 
deviations can be assumed.6  
Consistent with our previous studies on the NaV1.4 blockage by various μ-conotoxin PIIIA isomers, our data 
suggest an unambiguous and unique binding mode of active μ-PIIIA on KV1.6 and KV1.1, made up by 
concomitant hydrogen bonds contacts towards the outer and the inner channel pore loops.6 Here, a plethora of 
hydrogen bonds is formed in particular by the toxin’s centric arginine and lysine residues within the helical μ-
PIIIA core region towards the central pore residues.6 In this context, a special, symmetrically designed toxin 
segment in the central μ-PIIIA core region, was identified, which contains the motif Arg12-Ser13-Arg14-Gln15 
shown to be crucial for ion channel binding.6  
 
Finally, it is worth noting that for all systems considered, we were able to determine structural reasons for the 
subtype-selective inhibition or blocking processes. Here, the subtype-specific binding of µ-PIIIA to the KV1 
family members does not tolerate positively charged amino acids in both the inner and outer pore loops, as 
shown by comparison of KV1.6, KV1.3 and KV1.1. Additionally, the lack of the essential third aspartic acid residue 
in the outer P1 loop of KV1.3 further strengthens the exclusive µ-PIIIA binding to KV1.6 and KV1.1.  
 
However, considering the active inhibition of G proteins as well as the effective blockage of ion channels, the 
essential specificity determinats can be broken down into definite, unique attributes. 
Highly interesting and instructive in this context was the apparent interdependence of all these critical 
determinants in both systems considered that were decisive for their subtype-specific blockage or inhibition: It 
was found that in the absence of at least one of these criteria, the functioning of an active system or its subtype-
specific working mechanisms can no longer be maintained. Such insights can provide comprehensive support 
for the development of novel and highly specific drug agents. 
 
Last but not least, our explorations resulted in the successful generation of reliable data sets that are in 
accordance with to date published literature from laboratory experiments and might even be able to lay the 
foundation of learning or training data sets required for further computer-based investigations on similar 
systems. 
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Zusammenfassung 
 
Die vorliegende Arbeit konzentriert sich auf  das Verständnis der Wirkmechanismen von zwei pharmazeutisch 
relevanten Inhibitor-Protein-Systemen. Das Verständnis des Mechanismus, wie Medikamente oder 
Medikamentenkandidaten auf  ihr molekulares Ziel einwirken, ist von entscheidender Bedeutung für die 
Entwicklung eines erfolgsversprechenden Medikamentenkandidaten zu einem nützlichen Medikament. 
Heutzutage wird dieses Verständnis hauptsächlich aus rechnergestützten Studien gewonnen, besser bekannt als 
molekulare Modellierungsansätze, die ein wesentlicher Bestandteil jeder Medikamentenentwicklungskampagne 
sind. 
 
Anhand zweier betrachteter Beispiele von Protein-Ligand-Systemen, jeweils bestehend aus einem adressierten 
Zielprotein und einem entsprechenden Bindungsmolekül, wird die natürlich intrinsische Eigenschaft der 
Subtypspezifität, welcher biologische interagierende Systeme unterliegen, mit Hilfe moderner 
computerbasierter Technologien entschlüsselt.  
 
Der erste Teil dieser Arbeit widmet sich den zyklischen Depsipeptiden YM-254890 (YM) und FR900359 (FR) 
und deren Zielprotein, der alpha- (α) Untereinheit eines heterotrimeren G-Proteins. Ihre subtypspezifische 
Bindung an besagte α-Untereinheit des G-Protein-Subtyps Gq verhindert dessen eigentliche Funktion; den 
Austausch von gebundenem GDP mit GTP, womit weitere Signalübertragungswege innerhalb und zwischen 
Zellen unterbunden werden. Bisher stellt die direkte Adressierung intrazellulärer Gα-Untereinheiten mittels 
chemischer Werkzeuge einen neuartigen, vielversprechenden pharmakologischen Forschungsansatz dar, um z.B. 
onkogene Gq/11-Proteine als potenzielle Therapieansatzpunkte für die Krebsbehandlung des erwachsenen Auges 
zu nutzen.1-5 
Im Rahmen einer umfassenden Computerstudie haben wir hier neuartige FR900359-basierte Analoga aus 
natürlichen Quellen, synthetische zyklische Peptide sowie alle bisher bekannten Gαq Inhibitoren eingehend 
analysiert. Mit Hilfe molekularer Dockingberechnungen konnten wir einzigartige Merkmale in den 
makrozyklischen FR/YM-Strukturen identifizieren, die für die Bindung an das Zielprotein verantwortlich sind 
und in direktem Zusammenhang mit deren hemmender Wirkung stehen.5 Wir konnten somit die FR/YM-
spezifischen Besonderheiten ergründen, die ihre Interaktion mit der Gq-Bindetasche ausmachen.5 
Unsere Haupterkenntnisse zeigen für die Hemmung kritische Schlüsselpositionen in Gq auf: insbesondere 
handelt es sich hierbei um zwei wichtige Ankerpositionen an Gelenkteilen der Gα-Untereinheit, nämlich das 
Residuum Arg60, welches sich am sogenannten „Linker 1“ befindet, sowie die beiden nebeneinanderliegenden 
Aminosäurereste Ile190 und Glu191, die in der Nähe der Proteinregion namens „Switch 1“ lokalisiert sind. Die 
Fixierung dieser beiden Scharnierpunkte durch die entscheidenden Residuen N-MeDha5 und die 
gegenüberliegenden β-Hydroxyleucinreste im YM-/FR-Molekül hemmt deren intrinsische Mobilität und wirkt 
damit der für den GDP/GTP-Austausch relevanten Öffnungsbewegung der Gα-Untereinheit entgegen. Ein 
weiteres Merkmal, welches den Inhibitoren YM und FR zugeschrieben wird, ist ihre stabile Rückgratstruktur, 
die es ihnen ermöglicht, passgenau die Bindungstasche des G-Proteins zu adressieren und so die kritischen 
Positionen innerhalb dieser Bindungstasche anzusprechen. 
Obwohl unsere Daten in Übereinstimmung mit den experimentellen Ergebnissen nachweisen konnten, dass kein 
anderer Inhibitor die biologische Aktivität des FR-Wildtyps übertrifft, bleibt dennoch die offene Frage, ob FR-
Analoga wertvolle chemische Werkzeuge für die gezielte und spezifische Hemmung darstellen und darüber 
hinaus auch, ob sie als geeignete natürliche Leitstrukturen für die Entwicklung neuer Substanzen zur 
Adressierung anderer Gα-Untereinheiten als die des Gq-Subtyps fungieren können.5 
 
Der zweite Teil dieser Arbeit konzentriert sich auf  die Untersuchung spannungsgesteuerter Ionenkanäle und 
deren – ebenso subtypspezifischen – Kegelschneckentoxinblocker, auch bekannt als Conotoxine, also 
spezifischen Giften, die aus marinen Kegelschnecken gewonnen werden können. In diesem Teil haben wir uns 
hauptsächlich auf  spannungsgesteuerte Natrium- (NaV) und Kalium- (KV) Kanäle fokussiert, die beide 
hauptsächlich im zentralen Nervensystem (ZNS) vorkommen. Deren selektive Blockierung verhindert den 
bidirektionalen Ionenfluss durch die Membran, die ein Neuron von seinem angrenzenden synaptischen Spalt 
trennt. Der transmembranöse Ionenfluss, der zu einer Potentialdifferenz zwischen Nervenzellinnerem und dem 
außen liegenden synaptischen Spalt führt, trägt schließlich zur Aufrechterhaltung des sogenannten 
Ruhepotenzials bei. Diese Potentialdifferenz ist eine natürlich gegebene Eigenschaft selektiv-permeabler 
Membranen und bildet eine wesentliche Grundvoraussetzung für die Initiierung der Reizweiterleitung.  
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Das Verständnis der subtypspezifischen Ionenkanalblockierung durch diese natürlichen peptidbasierten Toxine 
kann daher wesentliche Orientierungshilfen für die Weiterentwicklung solcher Peptide zu vielversprechenden 
potentiellen Medikamenten leisten.6 
 
Die erste zugehörige Studie umfasst eine Docking-Studie an 15 verschiedenen Disulfidbindungsisomeren des μ-
Conotoxins PIIIA am Natriumkanal-Subtyp NaV1.4 aus der NaV1-Natriumkanalfamilie, für welche 
experimentelle Messungen eine subtypspezifische Blockierung des NaV1.4-Subtyps durch das native μ-PIIIA-
Isomer nachweisen konnten. 
Unter Verwendung ausgereifter Docking-Methoden ist es uns gelungen, den eindeutigen Zusammenhang des 
nativen μ-PIIIA-Disulfidbrückenmusters und der Fähigkeit des Toxins, den NaV1.4-Kanal zu blockieren, 
nachzuweisen. Da die strukturelle Konformation eines Toxins und seine damit verbundene Flexibilität 
unmittelbar aus dessen internem Disulfidbrückenmuster resultiert, kann das Ausmaß der 
Kanalporenblockierung direkt auf  die strukturellen Eigenschaften der Toxine zurückgeführt werden. 
Unsere Docking-Ergebnisse konnten Aufschluss darüber geben, welche Toxinanteile der Isomere bestimmte 
Teile der Porenoberfläche ansprechen. Es konnte gezeigt werden, dass eine eindeutige Korrelation zwischen 
dem Cysteindisulfid-Brückenmuster eines Toxins, das auch seine Struktur und Flexibilität bestimmt, und 
schließlich seiner Blockierungsfähigkeit bestimmter Kanalsubtypen besteht. Im Gegensatz zu aktiven Isomeren 
zeigen mäßig oder schwach aktive Isomere keine Kontakte zur Porenmitte und/oder gleichmäßig verteilte, 
abdeckende Kontakte zum Außenbereich der Porenoberfläche auf. Insbesondere konnte gezeigt werden, dass die 
Kanalpore bei effektiver Blockierung vollständig und bei schwächerer Blockierung nur teilweise abgedeckt wird. 
In dieser Hinsicht stimmten die Docking-Experimente mit den laborgenerierten Daten überein und zeigten eine 
spezifische Bindungsposition des am stärksten blockierenden nativen μ-PIIIA-Isomers auf; diese wird durch 
gleichzeitige Kontakte zum Poreninneren im Kanalzentrum, in welchem auch das sehr bekannte 
Selektivitätsfiltermotiv "DEKA" enthalten ist, und zu den außen liegenden Loop-Regionen des Kanals 
ermöglicht. Durch die eher globulärförmige Toxinfaltung, die das native μ-PIIIA-Isomer durch sein 
einzigartiges Cysteindisulfidmuster annimmt, werden die sauren Porenresiduen vorwiegend durch basische 
Argininreste des Toxins adressiert und die zentrale porenabdeckende Toxinpositionierung auf  dem Kanal 
stabilisiert. 
 
Die vorweggenommene Bedeutung der Toxinflexibilitäten und deren Einfluss auf  die verschiedenen 
Bioaktivitäten wird in unserer zweiten Studie zur subtypspezifischen Blockade von Ionenkanälen durch μ-
Conotoxine näher beleuchtet, in welcher neben Docking-Studien auch molekulardynamische Simulationen 
eingesetzt wurden. 
Hier wird eine umfassende Molekulardynamik-Analyse der µ-PIIIA, µ-SIIIA und µ-GIIIA Conotoxine auf  den 
spannungsgesteuerten Kaliumkanalsubtypen KV1.1, KV1.5 und KV1.6 der Kaliumkanalfamilie KV1 und virtuell 
erstellten Chimärmodellen geliefert. Um die Dynamik und Bindungszustände dieser Ionenkanal-Toxinsysteme 
besser zu verstehen, korrelierten wir sie mit ihren experimentellen Aktivitäten, die kürzlich von Leipold und 
Mitarbeitern7 berichtet wurden.6 Da mittels unserer molekulardynamischen Simulationen für alle hier 
untersuchten kanalgebundenen Toxine eine gewisse Konformationsflexibilität und die dadurch adäquate 
Wiedergabe ihrer individuellen Blockierungsvermögen beobachtet werden konnte, ist davon auszugehen, dass 
die Berücksichtigung dynamischer Daten zum Verständnis subtypspezifischer Blockierungsereignisse und 
damit einhergehender Aktivitätsabweichungen notwendig ist.6 
In Übereinstimmung mit unseren vorangegangenen Studien zur NaV1.4-Blockade durch verschiedene  µ-PIIIA-
Isomere suggerieren unsere Daten einen eindeutigen und einzigartigen Bindungsmodus des auf  KV1.6 und 
KV1.1 aktiven µ-PIIIA, der sich aus gleichzeitigen Wasserstoffbrückenkontakten zu den äußeren und inneren 
Loop-Teilen der Kanalpore zusammensetzt.6 Hier wird insbesondere durch die zentrischen Arginin- und 
Lysinreste des Toxins innerhalb der helikalen µ-PIIIA-Kernregion eine Vielzahl an 
Wasserstoffbrückenbindungen zu den mittig liegenden Porenresiduen gebildet.6 In diesem Zusammenhang 
wurde ein spezielles, symmetrisch gestaltetes Toxinsegment in der zentralen Kernregion von µ-PIIIA 
identifiziert, das das Motiv Arg12-Ser13-Arg14-Gln15 enthält, welches sich auch als entscheidend für 
Ionenkanalbindung erwiesen hat.6 
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Zum Schluss ist anzumerken, dass wir einheitlich für alle betrachteten Systeme strukturelle Faktoren, in 
welchen die subtypselektiven Hemm- oder Blockierungsprozesse begründet liegen, ermitteln konnten. Dabei 
werden für die subtypspezifische Bindung von µ-PIIIA an die KV1-Kaliumkanalfamilie keine positiv geladenen 
Aminosäuren, weder in den inneren noch in den äußeren Loop-Teilen der Pore toleriert, was anhand des 
Vergleichs von KV1.6, KV1.3 und KV1.1 festgestellt werden kann. Die Ausschließlichkeit der Bindung von µ-
PIIIA an die Kaliumkanalsubtypen KV1.6 und KV1.1 wird zudem durch das Fehlen des essentiellen dritten 
Asparaginsäurerests in den äußeren P1-Loopregionen des KV1.3-Subtyps weiter untermauert. 
 
Unter Berücksichtigung der aktiven Hemmung von G-Proteinen sowie der effektiven Blockierung von 
Ionenkanälen können die wesentlichen spezifitätsbestimmenden Faktoren jedoch auf  konkrete, einzigartige 
Attribute heruntergebrochen werden.  
Hochinteressant und lehrreich in diesem Zusammenhang war die scheinbar gegenseitige Abhängigkeit all dieser 
kritischen Determinanten in beiden betrachteten Systemen, die für ihre subtypspezifische Blockade oder 
Hemmung ausschlaggebend waren: Es stellte sich heraus, dass bei Fehlen mindestens eines dieser Kriterien die 
Funktionsfähigkeit eines aktiven Systems bzw. seiner subtypspezifischen Wirkmechanismen nicht mehr 
aufrechterhalten werden kann. Solche Erkenntnisse können die Entwicklung neuer und hochspezifischer 
Wirkstoffe ganzheitlich unterstützen. 
 
Nicht zuletzt führten unsere Untersuchungen zur erfolgreichen Generierung zuverlässiger Datensätze, die 
literarkonform zu bisher veröffentlichten Labordaten sind und möglicherweise sogar den Grundstein für Lern- 
oder Trainingsdatensätze legen können, mit welchen weitere computergestützte Untersuchungen an ähnlichen 
Systemen wie sie hier betrachtet wurden möglich sind. 
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1. Introduction 
 
Understanding chemical reactions by illustrating their underlying mechanisms on an atomistic level depicts an 
essential step towards giving an explanation for distinct and measurable observations generated by laboratory 
experiments. The fact that such dynamic interplays are not visible to the naked eye to date motivates numerous 
researchers in natural sciences and engineering to develop computer-based representations of biochemical 
systems. Virtual investigations and the behavioural prediction of such systems are of high interest, especially 
when trying to explain or substantiate results gained from experimental studies. Particularly in today's new 
development possibilities for the prevention and therapy of diseases, diverse alternative but also cooperative 
perspectives with experiments on living animals can arise. This certainly affects not only ethical but also a 
number of economically important issues. 
 
Intrinsically, a chemical reaction or process depicts a time-dependent mechanism. Hence, time parameters are 
to be taken into account to be able to provide accurate descriptions of aforesaid processes in silico, besides the 
inclusion of the respective in vitro conditions. 
 
A prominent example of application is the deployment of computer-assisted processes in the pharmaceutical 
research area, where the investigation of drug-target interactions, their dynamics as well as of the resulting 
structure activity relationships (SAR) plays a key role. In these contexts, chemical properties of the agents that 
make up their subtype-specific binding towards the respective target molecules are important to be deciphered. 
As a huge variety for the rational composition of more complex molecular structures is naturally provided, 
numerous tests are required for the assessment of specific impacts on a reaction that may result from particular 
modifications on the molecule. Thus, it can be determined for instance which atom groups or amino acid residues 
should definitely be present in a considered agent molecule, intensifying or maintaining its binding affinity 
towards the target, and which ones that weaken the binding effect should equally be avoided.  
 
Nowadays, there are many ways to address the challenging discovery of novel active substances, for instance by 
virtually or experimentally mimicking molecules that naturally bind to the target due to their intrinsic subtype 
specificity. It is obvious in these contexts that the researcher can learn from this nature-provided capacity when 
trying to revise or optimize particular agents. This approach is also known as ligand-based drug design.8, 9 
A further method is represented by the highly automated testing of vast amounts of molecules from molecular 
libraries containing different substances which may bind to the target, also known as high-throughput screening 
(HTS).10 This technique can help for the fast and targeted identification of active biological agents among large 
molecular datasets. 
The third and in this work primarily applied approach depicts the so-called virtual screening (VS): here, the target 
molecule and the inspected ligand substances are artificially recreated as 3D objects and the corresponding 
interactions are simulated by computers.11, 12 Especially in this scope of applications the three-dimensional 
structural information of the investigated molecules is of crucial importance, because generally speaking most 
of these computational prediction approaches rely on the known spatial configuration of the input molecules. 
This explains why these methods are also often referred to as rational structure-based drug design approaches.9, 13 
 
One of the best-known and to date widely applied VS techniques is represented by molecular docking. The main 
idea in solving the docking problem is to determine the optimal positioning and the associated mutual 
orientation of the target and the ligand structure as a bound complex, i.e. in a preferably adopted state of the 
system’s global energy minimum.14, 15 Molecular or macromolecular interacting complexes in these contexts can 
be represented by protein-protein-, protein-ligand-, DNA- or RNA-complexes.16 – The associated terminologies 
are designated accordingly, as protein-protein-docking, protein-ligand-docking and docking of DNA- or RNA.  
 
Since then, different approaches for solving the docking problem and thus for predicting preferred target ligand 
constellations have been established. "DOCK", for example, approaches this optimization problem by clique-
search in a graph generated from the input data, which is the first docking approach not based on energy 
minimization calculations.17 Another method used by “AutoDock” is based on the principles of simulated 
annealing, a heuristic approximation method for solving optimization problems.18 "GOLD" is based on an 
inherent implementation of a genetic algorithm19 and “FlexX”'s particularly fast procedure predicts the optimal 
position of the ligand through its incremental reconstruction.20, 21 Obviously, the possible approaches can thus 
be of distinct variability.  
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The predicted mutual positioning, a so-called mode of binding usually holds the corresponding estimated value 
of the resulting binding free energy of the system, depending on the applied prediction method. As the complete 
molecular structural information is quite complex for computers to handle and requires huge computing 
capacities, modern search algorithms presently applied implement computational approximations, where only 
the surface coordinates of the involved molecules is taken into account.22, 23 Thus, the huge amount of complex 
data is massively reduced though having ensured to keep the critical information of the 3D objects. According 
to the employed algorithm, the related binding free energy of a certain complex mode is estimated by an 
optionally included scoring function that is executed on the previously docked complex. 
Both, the docking algorithm as well as the scoring function nowadays hold various employable approaches. 
The simplest and most straightforward way to address the docking problem is to keep the considered molecules 
as rigid participants, based on the assumption that the spatial shapes of the molecules are maintained as they are 
provided by the pure input structures and do not change when interacting with one another. This approach is 
also known as rigid docking.  
 
In contrast to rigid docking methods there are also established flexible docking approaches, where both or one of 
the considered molecules are computationally modelled including movement-related parameters. Allowed 
variations in bond lengths, torsion or bond angles ultimately affects the overall molecular geometry. 
 
Conformational changes during a binding event are for instance of vital importance in induced-fit binding 
systems.24 
 
Obviously, the complexity of rigid but especially of flexible docking increases in proportion to the size of the 
considered molecules or more precisely of the considered molecular surface areas. For this reason, flexible 
docking approaches are predominantly applied in protein-ligand docking issues where a small, “drug-like” 
ligand-molecule is “flexibly” docked to a larger protein. 
However, meanwhile there also exist more recent approaches that are even able to include the flexibility of the 
larger protein target structures. One of those methods is represented by the so-called ensemble docking strategy. 
Here, the ligand can be simultaneously docked to an ensemble of multiple target protein structures and the protein 
structure of highest fit to the ligand can be found (by optimizing operations on the structural parameters of the 
ligand and protein ensemble).25 
Nowadays, there are numerous implemented docking variations available – be they offered as web services (e.g. 
Haddock) or also as part of installable software. The same holds true for the variety of the applied algorithms. 
 
However, the previous explanations indicate the fundamental significance of flexibility information in a 
considered system. Concerning the ensemble docking approach just mentioned, the protein structure ensemble 
can also be obtained by molecular dynamics simulation.26 It is plausible and obvious, that not only rigid states 
of the system under consideration are of high interest, but also the dynamic development of the complex 
resulting from its varying inter- and intramolecular interactions. Especially for the description of the activity 
and thus the binding capacity of a ligand molecule, the dynamic information of the complex gives far-reaching 
statements about the ligand’s binding strength: while weak bonds result in high complex dynamics, strong 
chemical bonds allow the system to remain more rigid (for longer periods of time) in an energetically favourable 
state. Dynamic information thus does not only result in specific binding modes, but also in complete modes of 
motion of a considered system, which should aimed to be modelled. 
This is where docking and experimental approaches reach their limits in terms of their ability to describe and 
illustrate a system under consideration, and computer simulations must be used to do justice to the real 
conditions as far as possible. 
 
The methodologies of molecular dynamics (MD) are capable to master the problem by iterative motion 
calculations of the investigated system. The spatial movements of atoms and molecules in turn result from the 
particular interactions that occur in each time step. Consequently, the next state results recursively from the 
respective previous one. 
 
In a preceding artificial equilibration, the steepest descent minimization, the complete system is first brought into 
the state of thermal equilibrium and thus the initial position of each particle is determined for the further 
simulated movement.  
In the actual simulation that follows, Newton's equation of motion is applied iteratively to the position vector of 
each particle in the system and thus its (subsequent) position is redetermined per time step. 
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In general the equation of motion for a particle of mass 𝑚 is given by  
 
?⃗? = 𝑚 ∙ ?⃗? 
 
and with proper arguments applied 
 
?⃗?(𝑟(𝑡)) = 𝑚 ∙ ?⃗?(𝑡) , 
 
where 
 
?⃗?  denotes the force that acts on the particle and is made up by the sum ∑ ?⃗?𝑖𝑖  of all inner and outer forces 
     ?⃗?𝑖  that affect the particle, 
 
𝑟   designates the position vector of the particle, 
𝑡  denotes the time and  
?⃗? the motion acceleration of the particle moved. 
 
Newton's equation of motion thus depicts a descriptive formula that is able to delineate the development process 
of a physical system on a spatial and temporal level, taking into account the totality of all external and internal 
forces acting on it. Accordingly, a particle or mass point of mass 𝑚  moves on a physical orbit 𝑟 ⃗⃗⃗(𝑡) under the 
influence of a force field ?⃗?. 
 
Numerous current simulation programs provide different applicable force fields, which allow for additional 
geometry optimizations of very large macro- or biomolecules. Here, intramolecular geometry parameters such 
as bond angles, i.e. torsion and dihedral angles and bond lengths between atoms are included. 
Generally, the description of the force field is given by the potential energy 𝐸 of the whole system. In order to 
avoid misunderstandings regarding the use of a potential energy equation to describe a force field, it should be 
noted here that the force results directly from the equation as a derivative of the potential in relation to its 
position.27 The force field thus directly results from the system’s potential energy. 
In general, for molecular and macromolecular systems, their total energy 𝐸𝑡𝑜𝑡𝑎𝑙 results from the sum of the 
partial binding energies 𝐸𝑏𝑜𝑛𝑑𝑒𝑑 and 𝐸𝑛𝑜𝑛𝑏𝑜𝑛𝑑𝑒𝑑 , arising from (covalent) binding interactions and non-covalent 
interactions of the system, respectively: 
 
𝐸𝑡𝑜𝑡𝑎𝑙 =  𝐸𝑏𝑜𝑛𝑑𝑒𝑑 + 𝐸𝑛𝑜𝑛𝑏𝑜𝑛𝑑𝑒𝑑 
 
Here, the total energy for covalent interactions (𝐸𝑏𝑜𝑛𝑑𝑒𝑑) is calculated as the sum of the energies, respectively 
resulting from the bond lengths (𝐸𝑏𝑜𝑛𝑑 ) as well as from the bond angles (𝐸𝑎𝑛𝑔𝑙𝑒 ) and the torsion angles 
(𝐸𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙) between atoms or atom groups: 
 
𝐸𝑏𝑜𝑛𝑑𝑒𝑑 =  𝐸𝑏𝑜𝑛𝑑 + 𝐸𝑎𝑛𝑔𝑙𝑒 +  𝐸𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙  
 
All electrostatic and non-covalent van der Waals forces are considered as non-binding interactions, yielding 
 
𝐸𝑛𝑜𝑛𝑏𝑜𝑛𝑑𝑒𝑑 =  𝐸𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐 + 𝐸𝑣𝑎𝑛 𝑑𝑒𝑟 𝑊𝑎𝑎𝑙𝑠 
 
to describe the non-binding energy 𝐸𝑛𝑜𝑛𝑏𝑜𝑛𝑑𝑒𝑑  that is calculated as the sum of energies arising from 
electrostatic interactions (𝐸𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐) and energies emerging from van der Waals forces (𝐸𝑣𝑎𝑛 𝑑𝑒𝑟 𝑊𝑎𝑎𝑙𝑠). 
 
 
In most standard force field programs harmonic potentials (derived from Hooke's law) are used to characterize the 
particular potential binding energies 𝐸𝑏𝑜𝑛𝑑𝑒𝑑, given by 
 
𝐸𝑎𝑏 =  𝑘𝑎𝑏(𝑟𝑎𝑏
0 − 𝑟)2 
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for a particular potential binding energy term of 𝐸𝑏𝑜𝑛𝑑𝑒𝑑  between a pair of atoms 𝑎 and 𝑏, where  
 
𝑘𝑎𝑏 defines the force constant, 
 
𝑟𝑎𝑏
0  delineates the atomic pair distance regarding the considered parameter, assumed that bound 𝑎 and 𝑏 are in    
       the resting position (an imaginary definite position and zero momentum) and 
 
𝑟 is the actual (equilibrium) distance (regarding the parameter under consideration).  
  
This approach relies on an assumption of “genuine” bond lengths and angles and can be used, for example, to 
describe the potential energy resulting from the bond lengths of a bonded pair of atoms and there are analogous 
description formulas also for the bond angles (torsion and dihedrals).  
 
Using the example of the basic equation of the AMBER force field (Assisted Model Building with Energy 
Refinement) used in one of our MD study, under which it was first published in 1995,28 one can see the concrete 
application of the above-mentioned interrelationships and thus obtain the potential total energy 𝐸, also simply 
potential, of a system of 𝑁 particles at particular positions 𝑟 through: 
 
𝐸(𝑟𝑁) = ∑ 𝑘𝑏
𝑏𝑜𝑛𝑑𝑠
(𝑙 − 𝑙0)
2 + ∑ 𝑘𝑎
𝑎𝑛𝑔𝑙𝑒𝑠
(𝛳 − 𝛳0)
2 + ∑ ∑
1
2
𝑛𝑡𝑜𝑟𝑠𝑖𝑜𝑛𝑠
 𝐸𝑛[1 + cos (𝑛𝜔 − 𝛾)] 
 
 
 
 
+ ∑ ∑ 𝑓𝑖𝑗
𝑁
𝑖=𝑗+1
𝑁−1
𝑗=1
{𝜀𝑖𝑗 [(
𝑟0𝑖𝑗
𝑟𝑖𝑗
)
12
− 2 (
𝑟0𝑖𝑗
𝑟𝑖𝑗
)
6
 ] +
𝑞𝑖𝑞𝑗
4𝜋𝜀0𝑟𝑖𝑗
} 
 
 
 
 
 
 
 
28 
 
where 
 
𝑘𝑎 and 𝑘𝑏 designate the particular force constants (𝑘𝑎 for the calculation of the energy resulting from the bond 
length distances and 𝑘𝑏 for the energy calculation from the bond angle differences), 
 
𝑙 determines the bond length of the bound atomic pair, 
 
𝛳 the bond angle difference between covalent bond pairs (i.e. bonds to two neighboring atoms) of the atom, 
 
𝜔, 𝛾 torsion angles (dihedrals in a protein backbone), 
 
𝑟0𝑖𝑗 the equilibrium distance, 
 
ε the well depth and 
 
𝑞 the (atomic) charge (𝑞𝑖 the charge of atom 𝑖 and 𝑞𝑖 the charge of atom 𝑗 accordingly). 
 
 
𝐸𝑏𝑜𝑛𝑑𝑒𝑑 
𝐸𝑛𝑜𝑛𝑏𝑜𝑛𝑑𝑒𝑑 
𝐸𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐𝑠 (𝐶𝑜𝑢𝑙𝑜𝑚𝑏
′𝑠 𝑙𝑎𝑤) 𝐸𝑣𝑎𝑛 𝑑𝑒𝑟 𝑊𝑎𝑎𝑙𝑠  
(𝐿𝑒𝑛𝑛𝑎𝑟𝑑 − 𝐽𝑜𝑛𝑒𝑠 𝑝𝑜𝑡𝑒𝑛𝑡𝑖𝑎𝑙)  
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It is well known that a system is in the most energetically favourable state if its (potential) energy is minimal. 
This principle also comes into play when a force field is applied to a molecule: if the sum of the partial energies 
describing a force field is kept to a minimum and distributed to the molecule in as many small components as 
possible, this results in a deformation of the molecule in favour of its energetic state. 
 
To come back again to the solution of Newton’s equation of motion, the key issue in molecular dynamics, our 
formula considered, ?⃗? = 𝑚 ∙ ?⃗?, transforms into a complete system of differential equations, since usually many-
particle systems are considered in a simulation. Since the computational effort to solve such a system of equations 
is generally much too high, numerical approximation methods must be used at this point to solve the equation of 
motion (in the form of a differential equation system).  
There are several algorithms to master numerical approximation, such as the well-known and frequently used 
Velocity Verlet algorithm. This algorithm utilizes the principles of Taylor series development to approximately 
calculate an atomic position 𝑟𝑖 of a molecule 𝑖  at a preceding time 𝑡 − 𝛿𝑡  and at a subsequent time 𝑡 + 𝛿𝑡 , 
respectively. According to the Taylor approximation by summing up the (derivative) polynomials (in the case 
of Velocity Verlet, the Taylor development is carried out up to the third degree), one obtains: 
 
𝑟𝑖(𝑡 + 𝛿𝑡) = 𝑟𝑖(𝑡) + 𝛿𝑡?̇?𝑖(𝑡) +
1
2
 𝛿𝑡2?̈?𝑖(𝑡) + 
1
6
 𝛿𝑡3?⃛?𝑖(𝑡) + 𝑂(4) 
 
for the atomic position at the next point in time and accordingly 
 
𝑟𝑖(𝑡 − 𝛿𝑡) = 𝑟𝑖(𝑡) − 𝛿𝑡?̇?𝑖(𝑡) +
1
2
 𝛿𝑡2?̈?𝑖(𝑡) −  
1
6
 𝛿𝑡3?⃛?𝑖(𝑡) + 𝑂(4) 
 
for its position at the previous point in time.  
By summing up both of the above approximation equations one obtains 
 
𝑟𝑖(𝑡 + 𝛿𝑡) = 2𝑟𝑖(𝑡) − 𝑟𝑖(𝑡 − 𝛿𝑡) +  𝛿𝑡
2?̈?𝑖(𝑡) + 𝑂(4) , 
 
which greatly simplifies the equation by eliminating the third-degree terms. Thus the accuracy is maintained by 
approximating the motion up to the Taylor development of the third degree, however, without having to 
consider the corresponding terms again. Thus, the equation of motion can be successively and approximately 
integrated without serious loss of precision. 
The recalculation of such an approximation algorithm (iteration per time step) takes place as long as it is 
considered reasonable by the user – in the case of macromolecular complexes, the simulation time usually 
amounts to nano- or even microsecond ranges. 
During such an approximation in discrete time steps, a so-called statistical ensemble consisting of different possible 
configuration states of the considered system is generated (under artificially set physical conditions). This 
ensemble ultimately forms a real subset of the complete system phase space, i.e. the set of all possible system 
states.  
 
Depending on the setting of the external physical parameters, there are different types of ensembles producible 
in which certain physical quantities are kept constant by respective controlling calculations (while the other 
parameters have more degrees of freedom).   
So for example the NVE ensemble (constant-energy, constant-volume ensemble), also known as the 
microcanonical ensemble, which is characterized by the maintenance of constant energy and volume during the 
solving process of Newton's equation. Here, no pressure or timing parameters are considered in the 
approximation run to guarantee energy and volume consistency. 
Analogously, NVT ensembles (constant-temperature, constant-volume ensemble) or canonical ensembles provide 
constant volume and temperature during the simulation. The maintenance of the constant temperature despite 
"disturbing" external influences is provided by a so-called heat bath or thermostat.29 The NVT ensemble depicts 
the most commonly used default-set ensemble in numerous simulation programs. 
Also worth mentioning is the NPT ensemble (constant-temperature, constant-pressure ensemble), where, in 
addition to temperature controls, pressure consistency is obviously ensured by volume adjustments, as well as 
the NST ensemble (constant-temperature, constant-stress ensemble) that further allows for an extended 
pressure control by regulating its particular dimension components.  
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Finally, the NPH ensemble (constant-pressure, constant-enthalpy ensemble), in reverse manner to the NVE 
ensemble, preserves the stability of pressure by volume adjustments and thus also the persistence of enthalpy.30 
Due to technical limitations, only a "restricted" part of reality can be represented in the simulation, so a system 
of finite size has to be chosen. From this system it is in turn possible to draw conclusions about larger units 
from reality. 
So-called periodic boundary conditions are used for this purpose, the intention of which is to describe a system as 
an infinite number of equivalent finite systems.30 The objects to be modelled are positioned in a simulation cell, 
which represents a finite volume. The simulation cell, in turn, is replicated in the entire simulation space, which 
concurrently ensures that each system property is represented equally in all replicas.30 
 
Finally, the successive numerical solution of the equation of motion yields a time-dependent trajectory within the 
phase space, which describes, so to speak, a motion path through this phase space that steadily traverses the 
calculated configurations at the various time steps. Therefore, the resulting trajectories can also be understood 
as emerging molecular configurations (ensembles) as a function of time. 
From the trajectories, the movement paths of the individual atoms through the phase space and thus the overall 
behavior of a molecule can ultimately be deduced – for example, by reducing the determined overall movement 
trajectory of a certain system to definite movement modes. The motions can also be analyzed on a number basis, 
e.g. as changes in the distances of atomic positions of specific (Cα -backbone) atoms over time or as changes in 
the (free) binding energy or enthalpy of the overall system as a function of time. In addition, the trajectories 
may also provide information on the overall flexibility of the system due to variations in fluctuation values. 
All in all, the ultimate goal is to obtain an overall understanding of the essential macroscopic properties of the 
system under consideration by analysis of the individual atom trajectories. In addition, comparative simulation 
series should help to gain an extended comprehension of different (macroscopic) system behaviours in 
correlation with the differences in the respective system compositions. 
 
Two invaluable approaches for the analysis of simulation-generated trajectories constitute the so-called 
Principal Component Analysis (PCA) and the Normal Mode Analysis (NMA). Both techniques are able to determine 
definite or discrete motion modes of any system of consideration. Therefore they are also suitable for the analysis 
of motion data, such as conformational changes of more complex biomolecular systems from md-generated 
trajectories.31 
 
The basic principle of PCA is to reduce the dimensionality of the space containing the data set of the system-
describing properties by a resulting (data) space of lower dimension that should give an equally appropriate 
picture of the system on the basis of the reduced set of properties. This means that only so much information 
may be reduced, so that no essential characteristics of the system are lost, or simply: keep as much data as 
necessary, delete as little data as possible.  
Detected redundancy in the data is eliminated by a summarizing operation on correlating data points. 
The set of remaining, linearly uncorrelated property variables are designated as principal components. Each 
component must be orthogonal to all others, so the resulting vectors describing the properties end up 
representing an orthonormal base set. 
In the case of trajectory analysis from an MD simulation, the set or ensemble of constellations traversed by the 
trajectory describes the full set of system properties that can then be reduced to the essential characteristics of 
the system using a PCA. For example, different conformations of a protein (e.g. change of the mutual position 
of its subdomains) can be unraveled and their transition states can be derived.  
 
According to methodologies of Normal Mode Analysis, it is assumed that the system under consideration 
oscillates back and forth. On the assumption that these movements of the system occur uniformly, i.e. in a 
consistent manner, the term "mode" means a sinusoidal harmonic form of motion. Here, the individual 
movements of the particular system components are independent of each other and are then referred to as 
"normal", but are however all carried out with the same frequency in a certain form of movement (mode). 
An eigen or normal mode hence designates a certain type of natural vibration movement of a system in which all 
its parts move together at the same frequency.32, 33 Thus, each normal mode has its own characteristic frequency, 
also called eigenfrequency or eigenvalue.  
All possible observable configurations of a system can be derived from its normal modes. 
As each movement mode of the system can be described by an equation of motion, for all movement modes of 
the system an equation system results from the individual equations of motion. The independent normal modes are 
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thus derivable from the eigenvectors of this system of equations, where their respective eigenvalues describe the 
particular vibrational frequencies, also eigenfrequencies, of the associated normal modes. 
 
In the usual procedure of a normal mode analysis for a protein, the Hessian matrix is first calculated after energy 
minimization and divided by the mass matrix (since ?⃗? = 𝑚 ∙ ?⃗?  and one wants to obtain the values of the 
accelerations). By diagonalizing the resulting matrix one then obtains its eigenvectors, whose eigenvalues, as 
already mentioned, in turn indicate the oscillation frequencies. The eigenvectors ultimately indicate the different 
directions of motion, which can then be visualized again. 
From the above statements it follows that a high eigenvalue of an eigenvector indicates a low force constant of 
the respective normal mode, i.e. a low frequency. Since low frequencies are particularly relevant for the analysis 
of protein movements, low normal mode analysis is often invoked for the determination of protein motion modes. 
Finally, this form of analysis can provide information on the flexibility of the objects considered in the system. 
In summary, it can be stated that the PCA concentrates more on determining representative states of the moving 
system, while the NMA focuses more on uncovering representative motion modes (forms of movements) of the 
system and thus drawing conclusions about its intrinsic flexibility. 
 
It is thus apparent that the large amount of data generated by the simulation represents new challenges for their 
downstream data mining processes, for example in their automated handling or in their statistical evaluation. 
However, large and reliable simulation data sets may also offer further basic support in general machine learning 
or corresponding methods of classification, even up to their use as learning data sets (e.g. for the problem of 
protein structure prediction). Learning data sets for predicting the motion behaviour of specific (not yet tested) 
systems could also be generated from carefully prepared and evaluated simulation series. 
The large amount of simulation data could further represent a useful completion for molecule databases and 
thus for the entire virtual screening area. This is especially true in view of the fact that different (energetically 
favourable) states of a molecule can be determined by simulation, which may not yet be available in the databases. 
 
In addition to the numerous analysis possibilities of the results, there are today all the more possibilities for the 
actual simulation management, which - based on variations of the above-mentioned basic principles - offer 
differentiated and more sophisticated simulation alternatives. 
The above mentioned combinations of defined parameters and the resulting different ensembles allow a wide 
range of (meanwhile very established) simulation methods. The algorithms used are also constantly revised and 
optimized. To name a few simulation variants at this point, the best-known ones are briefly listed below. 
 
Ab initio molecular dynamics are primarily used in the field of quantum chemistry. As their underlying principle 
depicts the approximative solvation of the Schrodinger equation34 and the only inputs designate physical 
constants35 the computational costs are very high so they are only able to treat systems of smaller sizes. As a 
prescribed potential such as used in classical MD (as described above) is not used in this case, we will not got 
into further detail at this point, since there are no direct comparison parameters for both methods.  
 
Further, modern simulation programs provide the ability to perform membrane simulations, i.e. to simulate the 
system of consideration within a membrane (of different possible compositions), if desired. 
 
Steered Molecular Dynamics (SMD) allows the use of an additional, external artificial force applied to selected 
system atoms (also acceleration),36 which in total can lead to an acceleration of the executed simulation, i.e. to 
faster recognizable effects. The latter is also possible, for example, using higher simulation temperatures. 
 
The Replica Exchange Molecular Dynamics Simulation (Replica Exchange MD, REMD) also makes use of 
variations in the simulation temperatures:37, 38 here, several simulation runs are executed in parallel at different 
temperatures, the algorithm that searches for the global energy minimum state of the system, can more easily 
overcome local minima when traversing the (thus extended) energy landscape. As the overall search space is 
expanded, the global minimum state of the system can thereby be reached more likely. 
 
Numerous software (open source and commercial) have already been developed over the past decades which 
offer different versions of implemented MD applications. A few examples to be mentioned are the software 
GROMACS,39 LAMMPS,40 NAMD,41 ORAC,42 Schroedinger Maestro43 and the YASARA molecular modelling 
software,44 to name but a few. The latter has been used for the studies conducted in this work. 
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These explanatory notes demonstrate that the field of molecular dynamics is very broad, based on the 
fundamental principles. New simulation approaches and associated algorithms are still being realized today 
while the development process is subject to continuous optimizations.  
The computational techniques mentioned and their stated extensions however still depict a great time- and cost-
saving support for the wet laboratory tests in the pre-clinical development phase of active substances (Figure 1).  
 
Findings from the associated basic research equally form important pillars for related test and development 
questions. Therefore, computer-aided methods such as docking and molecular dynamics simulation are very 
often used today in the development of novel drugs, even in combination. – Here, it is particularly important to 
be able to assess and evaluate the effects of modifications in a biological system (such as target mutations or 
modifications of the binding ligand molecule) in advance or in cooperation with the ubiquitously established 
methods from the wet laboratory. However, as such a modification may bring along an improvement in one 
molecular property but however also a coincident deterioration in another one, the computer-generated results 
must also be repeatedly verified by experimental laboratory tests. Despite more cost-effective and faster than 
conventional wet laboratory methods, not all effects of a specific modification can be registered and assessed via 
the methodologies offered by computer-based mimicking. Animal experiments are always necessary, for example 
to determine the length of time a newly created substance remains in the body. In case of a too rapid degradation 
by the body's own enzymes, the corresponding, degradation-sensitive site in the molecule must be found, 
modified and re-tested. This stage of development is also referred to as lead optimization. 
 
For the reasons stated, the optimization path can end up in a very protracted and time-consuming up and down 
process and the complete pre-clinical test phase can take up to 12 years until a suitable candidate can ultimately 
be approved for further clinical studies (Figure 1). This fact requires a very close and constructive cooperation 
between interdisciplinary sciences, on the part of the life sciences as well as the computer sciences. 
 
Figure 1 shows that the entire test phases (pre-clinical and clinical) can take a total of 11 – 16 years before a 
drug is actually approved for the market.  
 
 
 
During the development phase, particularly during lead optimization, there may even be cases where it can be 
concluded that the naturally existing lead structure (or a hit) already represents the molecule of the highest 
binding quality (Figure 1). This was the case with the study by Reher et al.5 which is closely linked to chapters 
3.2 and 3.3 of this thesis. 
 
Phase III in particular takes up most of the time in the clinical test phase, in which several hundred to thousand 
patients (300 - 3000 according to current status) are involved in order to test core aspects with regard to drug 
efficacy and safety. This phase can last from 1 to 4 years (Figure 1). Even when the medication is finally on the 
market, ongoing controls and surveillances are still necessary (Figure 1) – analogously to the continuous 
optimization efforts regarding the simulation algorithms. 
 
In spite of permanent revision, computer-based methods cannot replace laboratory experiments until today. 
However, since new computer technologies are constantly evolving and are even approaching this challenges45, 
there is still hope that animal trials will one day be completely superseded. 
Figure 1: Main stages in drug development; the field of application on which this work focuses is bordered in orange. 
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Moreover, although such a mutual development process between natural and computer sciences may take a long 
time, in silico methods have become an integral part of modern life sciences. Since the decoding of the human 
genome in 200 and the concomitant high amount of biological data, computer-based use has gained significantly 
in importance in the life science areas. The application in the natural science fields reach beyond the topics 
covered in this thesis and ranges from data mining and management issues of gene data to applications in the 
medical imaging branch. 
 
Overall, virtual reality (VR) and simulation techniques have so far been able to achieve economic benefits as well 
as time and cost savings in many other areas of academic and industrial research. Due to their interdisciplinarity 
and their transferability of applications to all possible fields they are still successfully in use in various branches: 
For instance, simulation or computer-assisted design (CAD) techniques are used in many test phases for design 
revision and optimization purposes in the development and manufacturing of diverse industrial products. 
Further examples of VR applications include, for example, finite element analysis or technical applications such 
as flow and circuit simulation, building design, simulating production processes, aircraft simulators (or flight 
simulators for pilot trainings) or even game simulations. Areas of application range up to interfaces with topics 
of artificial intelligence or image recognition. These overarching advancements could be achieved thanks to the 
predictive power and the concomitant and error avoidances up to optimizations of entire business processes.  
All these facts indicate that the broad field of scientific computing will continue to evolve and be applied in all 
areas of the physical, natural and medical sciences. Here, however, the laws of physics will always lay the 
essential foundations for concrete applicability. 
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2. Motivation 
 
Understanding the mechanism of how potential drug candidates or drugs achieve their effects at their molecular 
target is of vital importance for a guided process to develop a promising drug candidate into a valuable medicine. 
Nowadays, such understanding is mainly gained from computational studies, better know as molecular 
modelling approaches, which are an essential part of every drug development campaign. 
 
However, the present work focuses on understanding the mechanisms of action of two pharmaceutically relevant 
inhibitor protein systems.  
 
First, the mechanism of inhibition of the heterotrimeric G protein (Gq) through the small cyclic depsipeptides 
YM-254890 (YM) and FR900359 (FR) shall be elucidated in order to guide rational-design based approaches 
for the development of more potent inhibitors and inhibitors with a different specificity regarding other G 
protein subtypes.  
Like GPCRs, which represent a major drug target class comprising the largest family of membrane protein 
receptors,46 the downstream G proteins represent promising drug targets.47 However, due to the lack of selective 
G protein modulators, their role in disease-related biology remains unclear. Selective G protein modulation will 
certainly shed light on their role in GPCR signalling.48 To date only a very few G protein modulators have been 
reported in the literature.1-3, 49-51 Among them, two natural products YM-254890 and FR900359, which serve 
as potent modulators for Gq/11-induced signalling to, e.g. target oncogenic Gq/11 proteins as a potential 
therapeutic option for cancer treatment of the adult eye.1-4 
 
As a second focus, this work intents to shed light on the question how peptide-based toxins, which are derived 
from the venom of marine cone snails block the ion flow through potassium and sodium channels and how these 
toxins achieve their great subtype specificity. 
Very recently, drug discovery research identified the voltage gated sodium channel subtype NaV1.7 as a major 
target for pain treatment.52 As venom-derived peptides are known to be very specific ion channel blockers, they 
per se represent promising drug candidates. However, in order to develop these kinds of compounds into a 
promising painkiller, it is important to understand how these peptides interact with their targets and how they 
achieve their subtype specificity.53 
 
With respect to the first major focus of the present thesis, the group of Stromgaard recently succeeded in 
developing the total synthesis of the two aforementioned natural products YM and FR and synthesized a set of 
approx. 40 analogues and experimentally determined their binding affinities towards Gq. This set of compounds 
will serve as a starting point for deciphering the specific features of recognition of the peptide-based ligands at 
their target site.  
As a first step for the anticipated structure relationship study, structural models for these analogues need to be 
built and a reliable docking protocol needs to be developed in order to investigate the ligand protein interactions 
in detail. Additionally, the structural integrity (conformational stability) of the inhibitor analogues should be 
verified through molecular dynamics-based approaches.  
Lastly, a pharmacophore model for this type of G protein inhibitors shall be created and be visualized.  
 
The second focus of this thesis, first aimed to understand how the disulfide bond pattern of the µ-conotoxin 
PIIIA alters the ability to block the voltage gated sodium channel NaV1.4. As µ-PIIIA harbors six cysteine 
residues, it can form 15 disulfide bond isomers. These isomers were recently synthesized by the Imhof group 
(University of Bonn) and their disulfide bond pattern was verified through a combined approach of mass 
spectrometry and NMR spectroscopy. Furthermore, their ability to block the NaV1.4 was accessed through 
electrophysiological experiments by the Heinemann lab (University of Jena) and their three-dimensional 
structures were elucidated (Tietze lab, TU Darmstadt)54 and will now serve as the starting point for a 
comparative docking study perusing to correlate their structure and bioactivity. As there is no crystal structure 
available, a suitable molecular model of NaV1.4 must be developed. In a second step a reliable docking protocol 
will be established and validated with respect to the bioactivity of the µ-PIIIA isomers.  
 
As µ-PIIIA shows some inhibitory activity towards NaV1.7 it was considered for having a potential as analgesics 
as long as it is specific.55, 56 Unlike, the conotoxin μ -GIIIA, which exclusively blocks skeletal muscle voltage-
gated sodium channel NaV1.4, the conopeptides μ -PIIIA and μ -SIIIA additionally inhibit the neuronal sodium 
channels NaV1.2 but were recently shown to be not exclusively specific for NaV channels.7, 57-59 As μ -SIIIA only 
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partially inhibited KV1.1 and KV1.6 μ -PIIIA blocked both channels, but were both inactive on the subtypes 
KV1.2 to KV1.5 and KV2.1.7   
 
Consequently, the last part of this thesis sought to unveil the mechanism of subtype-specific inhibition of 
potassium channels by μ -conotoxins. Based on the experimental data published by Leipold et al.,7 docking and 
subsequent MD simulation experiments will be performed, which are intended to illustrate the dynamic 
interplay between μ -conotoxins PIIIA, SIIIA and GIIIA at the potassium channels KV1.1, KV1.5, KV1.6 and two 
chimeric channel constructs. For reasons of comparison, µ-SIIIA was investigated as a partially channel blocking 
semi-active system while µ-GIIIA as an inactive candidate. In particular, the different pore blocking modes – 
full or partial pore coverage – will be of special interest intending to achieve more insights about the origin of 
remaining currents, especially observable for the partly pore blocking toxins.  
As for the previous systems, a molecular model for the potassium ion channels will be established first employing 
the crystal structure of KV1.2-KV2.1 paddle chimera channel.60 The NMR structures of µ-PIIIA, µ-SIIIA and µ-
GIIIA will be used for the docking and simulation approach.  
 
 
Figure 2: Overview of in silico studies performed in this work; the aim of the studies was to investigate two different 
systems in terms of detecting key structural and dynamic properties in their interacting mechanisms. 
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3. G protein inhibition 
 
3.1. G proteins and GPCRs 
G proteins, guanosine nucleotide binding proteins undergo a close interplay with their G protein coupled 
receptors (GPCRs) since their mechanism of action is directly initiated by GPCRs. Due to their close 
cooperation, they both play an equally important role in many cell signalling processes, a large number of which 
is involved in the development and growth of cells. Such energy consuming processes of signalling are subject 
to the exchange of the G protein’s nucleotide GDP by GTP which, in simple terms, is triggered by the activation 
of G proteins through GPCRs.  
GPCRs themselves are heptahelical receptor proteins, meaning that they are constituted by seven 
transmembrane helices (TMs), wherein each transmembrane domain is composed of an about 20 amino acid 
long α-helical segment.61 The helical strands are in turn connected by three alternating intracellular and three 
extracellular loops.61 As the name of their bundle of transmembrane helices suggests, GPCRs are located in the 
cell membrane environment and therefrom they mediate numerous receptor-dependent downstream signalling 
pathways, being for instance responsible for the initiation of olfaction, taste, vision, slow neurotransmission or 
cell division processes.62, 63  
The activation of the majority of these cellular physiological responses in our living systems is due to their 
stimulation by external signals from heterogeneous ligands that bind to the receptors or by environmental 
stimulators.62 In particular these can be endogenous ligands such as hormones, drugs, odors, neurotransmitters, 
pheromones, photons, growth factors, ions or even proteases.62, 63  
 
The spectrum of activators is thus visibly large – no wonder, because the GPCRs constitute the largest and 
most diverse superfamily of membrane receptors represented in every eukaryotic cell, comprising more than 
1000 different members, encoded by just as many genes.62, 63 Further, it has been reported that the human and 
mouse GPCR repertoire for endogenous ligands comprises around 400 receptors.64 Due to their obviously huge 
variety, GPCRs are important targets for drugs and are therefore the subject of great research interest.64, 65 
 
Vertebrate GPCRs can be further categorized into six main classes on the basis of their sequence homology and 
their structural or functional similarity: Here, the rhodopsin-like receptor family constitutes Class A (GPCRA), 
secretin receptors represent Class B (GPCRB), the metabotropic glutamate or pheromone receptors rank among 
Class C (GPCRC), fungal mating pheromone receptors represent Class D (GPCRD), cAMP receptors define 
Class E (GPCRE) and finally frizzled/smoothened receptors constitute Class F(GPCRF).66-73  
Among all classes, the rhodopsin family depicts by far the largest and most diverse family, including 683 
members in humans62, 74 and was the first GPCR whose crystal structure was determined to high resolution.75 
Since then, further progresses concerning the understanding and functional characterization of GPCRs have 
been achieved, meanwhile providing high-resolution structural studies and insights into the molecular 
mechanisms for instance of ligand-activated GPCRs, such as the human β2 adrenergic receptor (β2AR), the 
avian β1AR and the human A2A adenosine receptor, or of opsin and an active form of rhodopsin.62  
Despite their structural uniformity, GPCRs bear individual combinations of signal transduction activities 
tailored to their multiplicity of addressed G-protein subtypes.62 Therefore, they can be classified alternatively 
by the properties of the bound G protein. The classification is then based on the equally diverse G proteins, 
namely into Gs-coupled receptors triggering a stimulating cascade, Gi-coupled receptors that induce an 
inhibitory cascade, Gq-coupled receptors, which activate protein kinase C via the second messenger pathway 
(phospholipase C mediated) via inositol trisphosphate (IP3) and diacylglycerol (DAG)76 and lastly Gt-coupled 
receptors that activate c-GMP-dependent phosphodiesterase in rod cells via the αt subunit of the G protein, 
called transducin.77 
Despite suggested by the huge variety of possible activation pathways by GPCRs just outlined, they exhibit 
structural uniformities, as do the GPCRs described above. Likewise, those structural features make a significant 
contribution to the basic function of G proteins. Generally, G proteins are heterotrimeric proteins, i.e. they 
consist of three different separate subunits α, β and γ.78 The α subunit has a GTPase-like function and contains 
a GDP/GTP-binding site, where the GDP-bound form constitutes the inactivated form of the G protein. Here 
the α subunit stays conjugated with the subunits βγ.79 The exchange of GDP with GTP, which is an important 
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part of any signal transduction cascade, takes place at this protein domain. More precisely, the GTPase function 
of the Gα subunit is fulfilled by its partial “Ras-like” domain, where the second part is made up by a unique α-
helical domain with five helices.79, 80 As the names imply, the Ras domain in contrast to the purely helical domain, 
consists of mixed β-sheet and α-helical segments and is conserved in all members of the GTPase superfamily.81 
Also, the α-helical domain is unique to heterotrimeric G-proteins.81 As will be outlined later in more detail, the 
Gα subunit is considered to be of central importance with regard to the activation state of the G protein. In this 
respect, it has been shown, that especially the helical domain of the Gα subunit enhances the efficiency of G 
protein signalling by serving as an intrinsic GTPase-activating protein.80, 81 More specifically, it showed 
accelerating effects on GTP hydrolysis81 and it is reported that changes in the helical domain, even far from the 
nucleotide-binding pocket, may profoundly affect the nucleotide-binding function of the G protein in general.82 
Due to the importance of the Gα subunit outlined before, the determination of the G protein subtypes is mostly 
determined on the basis of this subunit. 
 
Figure 3: 3D representation of heterotrimeric G protein structures (a) including all subunits α, β and γ (PDB ID: 3AH81) 
and (b) in complex with the membrane-bound G protein coupled receptor (GPCR) and detached helical domain (PDB ID: 
6DDF83). Colour scheme: Gα subunit Ras domain – yellow, Gα subunit α5 helix – deep purple, Gα subunit helical domain 
– magenta, Gβ subunit – red, Gγ subunit – blue, GPCR – orange, GPCR activator and cell membrane – gray.  
 
In addition to the proteins Gs, Gi, Gq and Gt, there are other G protein subtypes such as G12 and G16. Their 
activation is subject to similar mechanisms, however, not their recognition reactions with regard to effector 
molecules.  
 
All of these are similar in their sequence homology only to a limited extent, although there is a high degree of 
structural homology (as is the case with GPCRs) due to their equivalent functions for GDP/GTP exchange 
(Table 1). In terms of sequence similarity, Gβ and Gγ subunits can vary even more than the Gα subunits, 
further substantiating the importance and uniform function of the Gα subunit. 
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Table 1: percentage of pairwise sequence identities resulting from pairwise alignments; alignments were calculated with 
the SIM Alignment tool for protein sequences84 of the ExPASy Bioinformatics Resource Portal 
(https://web.expasy.org/sim/) 
    Family 
    
Gi Gs Gq G12 G16 
    (α-)subtype 
Organism ID Uniprot  Gαi Gαs-i2 Gαq Gα11  Gα12  Gα13  Gα16 (GNA15) 
Human P63096 Gαi 100,00% 45,30% 52,80% 51,70% 42,00% 39,90% 43,50% 
Human P63092-2 Gαs-i2  100,00% 40,70% 40,90% 39,70% 37,40% 37,20% 
Human P50148 Gαq   100,00% 90,30% 44,10% 45,70% 55,50% 
Human P29992 Gα11    100,00% 43,10% 45,10% 55,50% 
Human Q03113 Gα12     100,00% 66,70% 39,10% 
Human Q14344 Gα13      100,00% 39,10% 
Human P30679 Gα16       100,00% 
 
Certainly, GPCRs depict attractive therapeutic targets for numerous diseases and still bear a great potential as 
such due to their high diversity and involvement in a broad spectrum of signalling pathways, as mentioned 
before. Not surprising that about one third of prescription drugs work by GPCR modulation.85, 86 Examples of 
drugs based on interaction with GPCRs include beta-blockers and a subgroup of thrombocyte aggregation 
inhibitors.87, 88 Notwithstanding, this represents a challenging endeavor concerning their specific and targeted 
addressing. However, in this thesis we will discuss an alternative method to prevent unwanted downstream 
signalling processes based on the targeting of their directly coupled G proteins by specific ligands.  
 
Usually, GPCRs were preferred to their associated G proteins in drug development because it was hoped that 
their addressing would lead to the targeted manipulation of physiological processes controlled by individual 
receptors. However, such an approach can fail in more complex pathologies, for example when the malfunction 
in question is controlled by more than one receptor and its related signalling circuits. Such occurrences have 
been observed for several lung diseases, metabolic disorders as well as for certain types of pain and cancer.89-94 
 
Since G proteins – due to the close interaction – are just as relevant in physiological events as their associated 
GPCRs, an equally high potential for them to represent drug targets can be inferred. It is not without reason 
that the discovery of G proteins was awarded the Nobel Prize for Medicine in 1994. As furthermore G proteins, 
compared to the GPCRs, represent the actuators of the subsequent stage within the overall signalling cascade, 
a potentially superior approach of more targeted downstream regulatory modulation per G protein inhibition is 
emerging at this point. For example, it could be shown that among the four families of the Gα proteins Gαi/o, 
Gαs, Gαq/11 and Gα12/13 only members of the Gαi/o family can be specifically inhibited by pertussis toxin 
(PTX).95, 96 Such insights still serve today as a valuable basis for the analysis of GPCR signalling mechanisms 
and G protein-mediated cell reactions. The high pharmaceutical potential of G protein inhibitors is further 
underpinned by the crucial role that has been shown being played by GPCR-activated G proteins concerning 
tumor diseases.97, 98 Likewise, the controlled and specified inhibition and/or activation of G proteins is also 
motivated by their found contexts with apoptotic signalling pathways.99    
In all such approaches, however, it is always important to keep in mind that inhibitors of this type should have 
both cell permeability and selectivity for different G protein families in order to achieve potent efficacy. 
 
All in all, both GPCRs and G proteins show that understanding and taking advantage of their subtype specificity 
is of great importance for their activation, functioning and their controlled inhibition.  
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3.1.1. G protein activation 
The activation of G proteins by GPCRs depicts a fascinating and complex regulatory process that cyclically 
proceeds and can be broken down into several interdependent sub-steps. The propagation of the signal pulse is 
initiated by GPCR stimulation through extracellular actuators, such as the binding of an effector molecule to 
the GPCR. Upon this first event of activation a conformational change of the GPCR is triggered allowing for 
the transduction of the inducted stimulus to the G proteins which are attached to the inner membrane surface 
and thus to the GPCR. The G protein, still in its GDP-bound inactivated state, is also induced to undergo a 
massive conformational change, i.e. a large separation of the helical and Ras domain. This opening movement 
again promotes the release of GDP which was previously bound to the concerned α subunit. It has been shown 
through simulation studies that this internal unclasping motion of the α subunit, in particular the speed at which 
the separation movement of the helical and Ras domains takes place, is essentially dependent on the presence of 
a GPCR, which shows a catalyzing effect on the subdomains’ movement.100 Considered in more detail, the 
contact between a Gα subunit and an activated receptor is a major factor responsible for the displacement of the 
Gα C-terminal α5 helix.100 This change of position of the a5 helix is made up by a slight protrudition towards 
the receptor, so the position changes relative to the rest of the Ras domain.100 The direction of movement of the 
α5 helix is indicated in Figure 3 by the comparison of two G protein structures once in and once without the 
presence of a GPCR (Figure 3a and b). The docking of the helix into the GPCR promotes an internal structural 
rearrangement of the Ras domain that is directly accompanied by weakening effects of the binding affinity of 
the Ras domain towards the nucleotide. More precisely, the Ras domain’s structural reorganization ensures for 
the prevention of its (former) key interactions to GDP and thus for the accelerated nucleotide release.100 
Furthermore, it could be shown that in case of binding to the GPCR and the simultaneous absence of the 
nucleotide (within 25 microseconds of simulation), the domains stay separated from each other and the α subunit 
thus remains open – obviously thanks to the anchoring of the α5 helix with the receptor.100 However, even in 
the absence of a GPCR, an intrinsic natural opening and closing movement of the GDP-bound α subunit or a 
separation of the helical and Ras domains from each other can be observed, which could also allow for GDP 
release.100 Nevertheless, the extent of opening and its velocity are far from being as high as in the catalytic 
GPCR-bound situation.100 If both receptor and nucleotide are missing, this results (by simulation) in a strong, 
sudden opening movement starting from the initial closed state, due to a spontaneous adaptation movement of 
the a5 helix to a receptor-bound-like state.100 If GDP is now released and the Gα subunit is opened, the GDP to 
GTP exchange, i.e. the binding of GTP to the Gα subunit can thus take place more easily, finally bring the G 
protein into its activated (GTP-bound) state. The resulting activation leads to the dissociation of the Gβγ dimer 
from the Gα subunit and inducing their individual downstream signalling processes. After the signal 
propagation, the Gα bound GTP is hydrolyzed to GDP, resulting again in the inactive, GDP-bound form of the 
Gα subunit and coincidently leading to re-association of Gα with the Gβ/Gγ dimer.98, 101-107 The starting 
situation is now restored and a new activation cascade can begin.  
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Finally, two exemplary physiological processes which are triggered by G protein activation through a GPCR 
will shortly be outlined. 
 
An illustrative signalling pathway mediated by GPCRs is the slowing of heartbeat by activation of the 
muscarinic acetylcholine receptor, which is a GPCR of the heart muscle cells (M2 receptor).108 As the name 
suggests, it is stimulated by acetylcholine, which is released when the parasympathetic nervous system is 
activated.109 The GPCR in turn stimulates the β/γ complex of the Gi protein.110 This complex opens the 
potassium channels and thus enables the flow of K+ ions into the extracellular space.111, 112 
As previously indicated, G proteins also play an important role in the visual process: the excitation of the G 
protein transducin by the GPCR rhodopsin leads to phosphodiesterase activation.113, 114 Rhodopsin itself is 
Figure 4: Cyclic scheme of G protein activation by a GPCR and associated GDP/GTP exchange; inhibition points for 
preventing GDP/GTP exchange and downstream signalling cascades by the molecules YM-254890/FR900359 (YM/FR) 
or BIM-46174 (BIM) are indicated by purple arrows. (a) Activator ligand and inactive (GDP-bound) G protein bind to the 
GPCR; α5 helix docks into the receptor; pharmacological inhibition of the Gαq/11 subtype can be achieved at this point by 
YM/FR through inhibiting GDP release. (b) Ligand-bound activated GPCR triggering GDP release of the receptor-bound 
G protein; pharmacological inhibition of the Gαq/11 subtype can be achieved at this point by BIM through trapping the 
“empty pocket” conformation after GDP release and thus preventing exchange with GTP. (c) GDP/GTP exchange induced 
G protein activation; dissociation of the activated (GTP-bound) Gα subunit (in “on”-state) from the Gβ/Gγ dimer complex 
and full dissociation of the G protein subunits from the receptor; initiation of further Gα-induced signastranduction 
cascades. (d) Re-associaton to heterotrimeric G protein complex and GTP hydrolysis to GDP induced by GAP (GTP-ase 
activating protein), resetting the G protein into its inactivated, GDP-bound “off”-state for renewed reactivatability.  
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located in the rod cells of the retina and is activated by light stimuli.115, 116 The stimulated phosphodiesterase 
hydrolyses cGMP to GMP, which leads to the closure of cGMP-dependent sodium and calcium channels and 
thus to a decreasing of the cGMP concentration.113, 117 The membrane potential for stimulus transmission in the 
optic nerve is then predominantly determined by potassium diffusion, which accounts for an equilibrium 
potential of about -90mV, i.e. the initiation and transmission of the stimulus in the ocular nerve is triggered.118, 
119 
Both examples show that there is a connection between G protein activation and downstream regulated ion 
channels, which comprise the second system considered in this thesis. Complex signal transduction cascades can 
therefore be stopped, blocked or even redirected at different points of action. 
 
3.2. YM and FR – the ultimate Gq inhibitors 
 
As mentioned previously, the inhibition of Gα-induced GDP/GTP exchange to silence G protein signalling has 
a high pharmaceutical potential with respect to numerous diseases (for instance cancer120) associated with 
GPCR- and their related G protein activation cascades. However, only a few compounds that are able to 
modulate G protein activity are known these days and the targeting of G proteins unequivocally depends on 
their subtype.104 For instance, pertussis toxin and cholera toxin can modulate Gi and Gs proteins, respectively,49, 
50, 121 where in addition,  a small molecule, BIM-46187 was shown more recently to to trap the Gα subunit of 
the Gq subtype in its empty-pocket (nucleotide-free) conformation, i.e. after its activation and GDP release.51  
 
Further innovative discoveries concerning Gα modulators have also been made, including the discovery of the 
small depsipetides FR900359 (FR) and YM-254890 (YM) both of which are known to prevent G protein-
induced signalling by acting as guanosine nucleotide exchange inhibitors.  
 
BIM-46187 and FR/YM thus show their inhibitory effect on the G protein function by attaching at different 
action points in the activation cycle (Figure 4).  
 
In 1988, Fujioka and co-workers first extracted the cyclic depsipeptide FR900359 (FR) from the evergreen plant 
Ardisia Crenata sims, which showed inhibitory effects on platelet aggregation and decrease of blood pressure.107 
In 2003 the chemically and structurally almost identical platelet aggregation inhibitor YM-254890 (YM) was 
isolated from bacterial strain Chromobacterium species QS3666 by Masatoshi Taniguchi et al.2, 122 It has been 
shown that the inhibitory effect of YM and FR is underlying the immobilization of the Gα subunit opening 
motion of the G protein subtype Gq/11.1-3, 101, 104, 123 YM-254890 is currently accepted as the most efficient and 
selective inhibitor by Gαq/11.5 Since its discovery in 2003, YM-254890 has continued to attract great interest as 
this specific Gαq/11 inhibitor facilitates the understanding of the role of Gαq/11 in the GPCR transactivation of 
protein kinase receptors. Various studies have shown that YM-254890 could be a potential antihypertensive 
agent as it showed antithrombotic and thrombotic effects.124 For this reasons YM, FR and analogue structures 
thereof bear a great pharmacological potential. 
 
In 2016 and 2017, Xiong, Zhang and co-workers succeeded in producing YM, FR and analogues by total 
chemical syntheses starting first structure-activity relationships studies that were further continued by Reher 
and colleagues in 2018.5, 102, 104 However,  any attempts to improve the inhibitory activity of FR, YM or analogues 
derived thereof and to achieve some inhibitory activity towards any other G protein subtype failed, although the 
crystal structure of YM-bound Gq was solved by Nishimura et al. in 2010.1 In turn, we hypothesis, that the 
mechanism of G protein inhibition might not fully be understood further motivating our in silico analyses of 
Gq-inhibition by YM and FR. 
 
Both molecules are structurally very similar and only differ by three additional methyl groups in FR (Figure 
5). They are cyclic depsipeptides, i.e. ring-shaped, macrocyclic peptides consisting of eight amino acids each 
(Figure 5). 
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Figure 5: Chemical structures of FR900359 (left) and YM-254890 (right); FR additional methyl groups compared to YM 
are orbited in orange dotted lines. (Illustration modified from Xiong et al.104) 
 
FR and YM are small to medium-sized compounds, but with a high chemical complexity that should not be 
underestimated: they can assume specific three-dimensional conformations, which, together with a concomitant 
intrinsic rigidity of the molecule, results in a precise and targeted alignment of its backbone and side chain 
atoms. The typical depsipeptide structure is composed of a macrocyclic backbone surrounded by bound side 
chain residues and a β-hydroxyleucine tail (Figure 6). 
 
 
Figure 6: schematic view of the cyclic structure of the depsipeptides YM and FR shown on the structural basis of the FR 
molecule; the different molecular bond groups are indicated as bold lines. Colour scheme: cyclic backbone – blue, β-
hydroxyleucine tail – yellow, side chains – red. (Illustration modified from Xiong et al.104) 
 
Due to the high similarity of YM and FR and their respective capacities to selectively interfere with the function 
of Gαq/11, it can be concluded that their inhibitory mechanism at the Gαq subunit is identical and it makes them 
exceptional among G protein inhibitors.5 Ultimately, Gq inhibition by YM or FR is achieved by impairing the 
domain opening motion of the helical and the Ras domain of the Gαq subunit which prevents the release of 
GDP.1, 3 
According to the crystal structure of Gq-bound YM, the inhibitor resides in a hydrophobic cleft at the interface 
of the α helical and Ras domain (Figure 7). The helical and the Ras domain of the Gα subunit are linked together 
by two short flexible loop segments, called "Linker" and "Switch I", which enables the separation of the two 
domains from each other like through a hinge (Figure 7). In turn, YM most likely stabilizes the linker and 
switch conformation not allowing both domains to separate from each other preventing the nucleotide to escape. 
Therefore, FR and YM act as nucleotide dissociation inhibitors (GDIs).1, 3, 5 
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Figure 7: Localization of the G protein inhibitor binding site by the example of Gαq and interacting YM-254890 (PDB ID: 
3AH81). (a) Complete heterotrimeric complex. (b) Rotated and zoomed view pointing out the inhibitor binding site 
connecting the helical and the Ras domain of Gαq in an articulated way. Colour scheme: Gα subunit Ras domain – yellow, 
Gα subunit α5 helix – deep purple, Gα subunit helical domain – magenta, Gβ subunit – red, Gγ subunit – blue, linker – 
orange, switch – green. 
 
In the following chapter the structural and functional determinants of G protein inhibition by FR and YM will 
be computationally analyzed in detail in order to guide future rational design approaches on the development of 
FR/YM-derived G protein modulators.   
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3.3. In silico studies on Gq inhibition by YM, FR and analogues 
 
Molecular modelling and docking studies 
 
In order to accurately decipher the binding modes and ligand-Gq protein interactions, molecular modelling and 
docking studies for a large set of YM/FR analogues were performed (Figure 8) and analyzed with respect to 
their experimental biological activities. Therefore, we first grouped 14 new FR- and YM-derived compounds,5 
which were synthesized and characterized in the labs of Imhof, König and Kostenis at the University of Bonn as 
well as all 23 already published analogues102, 104 according to their potency to identify tolerated, partially 
tolerated, non-tolerated minor, and non-tolerated major modifications in the original sequence (Figure 8). To 
account for the slightly variable values of bioactivity obtained in different labs, the YM/FR analogues were 
grouped into compounds of high (IC50 < 5.0μM), medium (5.0μM ≤ IC50 ≤ 20.0μM) and low (IC50 > 20.0μM) 
binding affinity (Figure 8). 
 
Molecular modelling and docking studies were applied for the analogues 15, 17–27, and 29–36 (Figure 8) and 
were constructed from the Gq-bound conformation of YM-254890.1 The analogues were reconstructed 
according to their respective reported molecular chemical formulas, as they are described in their published 
syntheses performed by Taniguchi et al. in 2004,103 Kaur et al. in 2015,105 Rensing et al. in 2015,106 too, Xiong 
together with Stromgaard and co-workers in 2016104 and Zhang together with Stromgaard and co-workers in 
2017.102  
 
For FR-derived analogues 1–4, two conformations were built employing the solution NMR structure of FR in 
water, which was recently determined in the Tietze lab and the Gq-bound conformation of YM (further details 
are provided in chapter 5.1 in the methods section). The resulting structures were then docked to the 
heterotrimeric Gq protein in its original conformation, limiting the docking site to the interface of the α helical 
and Ras domain.  
For the analysis and scoring of the docking results, calculated binding energies which are expressed by VINAs 
scoring function as well as the structural deviation of the YM/FR analogues compared to the orientation of YM 
in pdb 3ah8 was considered. The later criterium was rationalized from the assumption that G protein inhibition 
can only be achieved when the relative orientation of the inhibitor in the binding pocket is similar to the 
orientation of YM as found in PDB 3AH8.1  
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Figure 8: Individual FR (left) and YM (right) analogues investigated. (a) Molecular structure view; positions of residue 
modifications are marked in color according to their type of structural modification they can affect (see legend, *:= 
according to Reher et al.5); Gq binding pocket interacting regions are indicated by green lines. (b) Sorted representation of 
the individual analogues according to their activity levels together with the corresponding indications of the individual 
modifications; sorted analogues are colour-labelled according to the type of structural alteration affected by their individual 
modifications (see legend, *:= according to Reher et al.5). (Illustration adapted from Reher et al.5) 
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After conducting a first series of docking experiments, it emerged that for some YM/FR analogues the predicted 
binding energy from the docking runs were either "too good" or "too bad" with respect to their experimental 
activity assuming a somewhat incorrect bound state (Table 10).  
 
However, there are relatively few outliers among the high affinity compounds, whereas medium and low affinity 
compounds almost always required additional revisory stepsto find a suitable representative structure. 
Altogether, this shows the tendency of a rather high prediction performance of the docking program for high 
affinity structures and a rather low prediction accuracy for structures with low binding affinity, which may be 
due to the intrinsic purpose of the docking program for ideal spatial positioning of ligand and target structures. 
 
Therefore, we refined our methodology to the effect that the selected outlier structures were equilibrated 
through a 100 ns molecular dynamics simulation to probe for their conformational integrity (Figure 9, Figure 
10) and to obtain a more accurate, docking result with respect to the experimentally obtained IC50 values. 
(Detailed information on the equilibrating simulations are given in chapter 5.1.3 in the methods section.)  
Therefore, an equilibrated structure of the inhibitor was extracted from the simulation data for each outlier, 
focusing on somehow stable conformations within the simulations (considering Cα backbone atom RMSD, 
(Figure 9, Figure 10). The selected inhibitor conformation was then re-docked as described above (see also 
chapter 5.1.2).  
 
The refinement together with the equilibration data of the individual structures shows us the relevance of 
including the intrinsic dynamics and the conformational integrity of the analogues in the evaluation of the 
docking experiments. For instance, for some structures two different but stable conformers are observed (Figure 
9e, Figure 10c). Furthermore, overall higher structural flexibilities of the outliers are especially observable for 
moderate and low affinity outlier compounds (Figure 9, Figure 10). 
 
Especially for all high affinity outlier compounds our pre-equilibration step consistently resulted in an 
improvement, i.e. an adjustment of the overall fit of the binding energy values with respect to the experimental 
IC50 values (Table 10, Table 2). 
 
The stronger impact of the equilibration step on the numerical values within the high affinity outliers compared 
to the medium and low affinity "outliers" also suggests the higher structural dynamics of the medium and low 
affinity compounds when bound to Gq and their more difficult reproducibility by the docking experiment (Table 
10). Particularly in these cases, subsequent simulation experiments would reveal a higher flexibility docked state 
– expectedly slower for moderately active compounds and faster for inactive compounds, i.e. accompanied by. 
Such insights on concomitant dynamics would compensate for the higher binding energies of docked low affinity 
cases that had beed obtained even after the intermediate equilibration (Table 10, 35 (YM-5) and 33 (YM-6)). 
This also shows that the inclusion of dynamic information is particularly important to achieve a more accurate 
in silico description, especially for medium and low affinity systems. 
 
However, the overall picture of in silico reflection per affinity group was not misrepresented and was altogether 
improved by the previous equilibrations. Table 2 lists the docking results and calculated binding energies of 
the final selected clusters, including structures with previously equilibrated compounds. 
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Figure 9: Overview of 100ns MD simulations of (a) YM and high/medium affinity outlier analogues (b) 23 (YM-1), (c) 30 
(YM-9), (d) 31 (YM-3) and (e) 29 (YM-385780). RMSD time trace of Cα atoms and per residue RMSF (first two panels 
from left) and structural ensemble (third panel, 10 structures, coloring scheme: carbon – green, nitrogen – blue, oxygen – 
red, hydrogens are omitted for clarity, hydrogen bonds are shown as yellow dashed lines) derived from the time interval 
indicated (green line) at the Cα RMSD-time trace. Fourth panel: Superposition of YM-254890 (carbon – light purple) and 
energy-minimized representative structure (carbon – orange/yellow) extracted from the simulation after a certain 
equilibration time, which is indicated by a yellow/orange label at the Cα RMSD-time trace and which was used for (re-) 
docking. (Illustration modified from Reher et al.5)  
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Figure 10: Overview of 100ns MD simulations of low affinity outlier analogues (a) 32 (YM-4), (b) 33 (YM-6), (c) 34 (YM-
17) and (d) 35 (YM-5). RMSD time trace of Cα atoms and per residue RMSF (first two panels from left) and structural 
ensemble (third panel, 10 structures, coloring scheme: carbon – green, nitrogen – blue, oxygen – red, hydrogens are omitted 
for clarity, hydrogen bonds are shown as yellow dashed lines) derived from the time interval indicated (green line) at the 
Cα RMSD-time trace. Fourth panel: Superposition of YM-254890 (carbon – light purple) and energy-minimized 
representative structure (carbon – orange/yellow) extracted from the simulation after a certain equilibration time, which 
is indicated by a yellow/orange label at the Cα RMSD-time trace and which was used for (re-)docking. (Illustration 
modified from Reher et al.5)  
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Table 2: Overview of the final docking results for the FR and YM analogues. The AutoDock Vina (referred to as Vina 
here) score is given for the best scoring cluster of each analogue. The structural deviation (all atom RMSD) of the selected 
cluster member of the Gαq-bound YM/FR analogue with respect to the orientation of Gαq–YM complex (PDB ID 3AH81) 
and the resulting conformation of the YM/FR analogue with respect to the YM conformation are calculated from the 
docking experiments. MD simulation derived structures of YM/FR-analogues are labeled with #. Alternative NMR-
derived conformations are indicated with *. (Table source: Reher et al.5) 
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It can be stated that among all the analogues investigated, compound 23 depicts the only analogue containing a 
modificaition on its backbone (namely N-MeAla3 to Ala) (Figure 6, Figure 8). All other considered YM-derived 
analogues 15, 17-22, 24-27 and 29-36 and also FR-derived analogues 1-4, include modifications within the side 
chain groups, more precisely at N-MeAla3, Ala4, β-HyLeu1/2 or at the acetyl group of Thr7/β-HyLeu7 (Figure 
6, Figure 8). Closer inspection of the respective Gq-bound inhibitor conformations yielded by the docking 
calculations showed only minor changes and the intramolecular hydrogen bonds as found in YM and FR 
remained intact (Figure 11a).5 This also resulted in a similar backbone conformation of the analogues and thus 
in a similarly high binding capacity as YM and FR indicating that the conformation and stability of the backbone 
structure forms an essential basis for a proper binding or fit of the molecule into the binding pocket (Figure 
11a). As has already been concluded for the similar binding behaviour of FR and YM due to the small structural 
differences, a similar positioning in the Gq binding pocket can also be deduced for the high affinity  analogues 1, 
2, and 15-23 (Figure 8, Figure 11a, b).5 
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Figure 11: Representative docking results. (a) Superposition of reference structures YM-254890 (PDB ID 3AH8,1 carbon 
– light purple) and FR9003593 (carbon – cyan) on the left, separate views of their individual binding modes on the right 
(coloring scheme: nitrogen – blue, oxygen – red, hydrogens are omitted for clarity, hydrogen bonds are shown as yellow 
dashed lines; Linker 1 surface – orange, Switch I surface – green, Gαq Ras domain β2 sheet surface – yellow, remaining 
Gαq surface – gray, hydrogen bond interacting residues – labeled and highlighted by element color, Gβ – red). (b) 
Superposition of FR900359 (carbon - cyan) with the docked conformation of two selected best inhibitory analogues 22 
(YM-18, carbon – yellow-green) and 1 (carbon – mint-green) (left) as well as separate views of their individual binding 
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modes (right); particular modifications are tagged by light orange circles or arrows. (c) Superposition of FR900359 (carbon 
- cyan) and the docked conformation of the selected representative moderately active analogue 31 (YM-3, carbon – pale 
yellow) (left) as well as separate view of its individual binding mode (right). (d) Superposition of FR900359 (carbon – cyan) 
and the docked conformation of two selected less active analogues 36 (YM-2, carbon – pale rose) and 3 (carbon – salmon 
pink) (left) as well as separate views of their individual binding modes (right). (Illustration modified from Reher et al.5) 
 
Moreover, for these compounds our data indicate almost identical hydrogen bond interactions with the target 
protein (Table 11). Similar orientations as found for YM within the YM-binding pocket on Gq are found when 
the alternative NMR-derived structures for FR and compound 1 (referred to as cis FR and cis 1 thereafter) were 
used for the docking experiments (Figure 12). A slightly different Gq-bound orientation was unveiled for the 
NMR derived structure of 2 (referred to as cis 2 thereafter, Figure 12d).5 
 
 
 
Figure 12: (a) Superposition of FR and cis FR bound to Gq as revealed from the docking studies.Orientation of (b) cis FR 
(c) cis 1 and (d) cis 2 bound to the Gq-FR/YM binding pocket. (Image source: Reher et al.5) 
 
In conclusion, our docking experiments indicate that the high affinity compounds are strongly oriented towards 
linker 1 and β sheet 2 of the Gα subunit. Especially, the hydrogen bonds of D-Pla6 or O-acetyl L-Thr7 of the 
YM analogue to Arg60 and Glu191 within the Gαq linker region and the hydrophobic interactions of the 
inhibitor residues Thr7 (YM) or β-HyLeu7 (FR) towards segments α1 (I56, K57), αA (F75) and switch I (V184), 
and inhibitor residues β-HyLeu1 to Ala4 with the protein residues (I190, Y192, P193) located at the β sheet 2 
region are essential features for an effective Gq inihibiton (Figure 13, Table 11).5 
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Figure 13: (a) and (b) Illustration of key interactions of the best inhibitory (high‐affinity) compounds exemplarily shown 
for YM‐254890 (residue numbers – italic; coloring: carbon – cyan, nitrogen – blue, oxygen – red) with Gq (residue numbers 
– regular, bold). (b) Network of hydrophobic interactions of D‐Pla of YM‐254890 within the hydrophobic cleft at the 
interface of the helical and Ras domain of the G protein. Intra‐ and intermolecular hydrogen bonds are indicated by magenta 
dotted lines; hydrophobic interactions between Gq and inhibitor are depicted by blue arrows between the interacting atom 
pairs (arrow thickness indicates the strength of interaction); Gq residues are coloured according to the sum of their 
hydrophobic interaction energy with the inhibitor, ranging from yellow (1 kJ mol−1, weak) to red (10 kJ mol−1, strong). 
(Figure adapted from Ref.5) 
 
Interestingly, all analogues of medium and low binding affinity, except of 32 (YM-4), lack the H-bonds with the 
β sheet 2 region (Glu191) (Table 11) suggesting an important anchor point for the inhibitor in order to 
effectively silence the G protein motion. In particular, the hydrogen bonds formed between D-Pla6 and Arg60 
in high affinity compounds seem to favor the hydrophobic interactions of D-Pla6 arising with other residues of 
the linker region around Arg60 and thus stabilize the inhibitory binding positioning of the ligand molecule 
within the pocket (Table 11, Figure 13b). This is exemplarily illustrated by Gq-bound YM-254890 and holds 
also true for β-HyLeu tail groups interacting with the β2 sheet region close to the switch 1 region (Figure 13). 
In particular, the fundamentally higher total fluctuation (RMSF) of Residue 6 (D-Pla6) for almost all outlier 
structures in comparison to YM is noticeable in this context when considering our equilibration simulations 
(Figure 9, Figure 10). 
 
As already indicated, for the evaluation of our docking studies of moderately or weakly active compounds with 
regard to the reduced binding affinity and the presumably associated higher inter- and intramolecular dynamics, 
the respective flexibilities should also be considered, which is also refrected by the particularly large number of 
outlier structuresin these groups (Table 2, Table 10). 
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For all moderately active analogues 29-31 our MD equilibration simulations yielded higher molecular 
flexibilities compared to YM/FR and thus a generally higher tendency to adopt different conformations (Figure 
9). This can also be explained by a higher flexibility of the backbone, which more likely allows for a transition 
into another conformatinal state including a different intramolecular H-bond pattern. The resulting different 
global conformations compared to the original starting conformation of course lead to altered H-bond 
formations compared to the high affinity interaction pattern and associated different positionings in the docking 
where the overall orientation of the analogue in the Gq binding pocket differs from that of YM or FR (Figure 
11, Table 2, Table 11). 
 
Equally noteworthy in these respects are the hydrogen bond contacts of the inhibitor compounds with Thr187 
of switch I and with Arg96 of the Gqβ subunit, which preferably arose within docked medium and low affinity 
analogues (Table 11) mainly formed by the β-HyLeu tail (Table 11). Moreover, our data indicate, that the 
ligands protrudes more from the binding pocket to the direction of the Gβ subunit and/or switch I 
simultaneously and are thus located further away from the previously addressed linker 1 and the β2 sheet of the 
Gaq Ras domain, as seen for the high affinity compounds (Figure 11c, d), clearly explaining their lower potency.  
 
Considering the low affinity compounds, i.e. analogues 3–14 and 32–36 an increased structural flexibility as 
revealed by our MD equilibrations (except of analogues 3 and 4) significant alterations of the global 
conformation and in the bound conformations compared to YM/FR were observed (Figure 9, Figure 10, 
Figure 11d, Table 2).5 
 
Upon closer inspection of the orientation of the low affinity analogues in the FR/YM-binding pocket of Gq, it 
becomes apparent that the phenyl ring of D-Pla altogether resides in the hydrophobic cleft, as consistently 
observable for the high and moderate active analogues (Figure 11d).5 However, the overall binding affinity 
towards linker 1 is weakend for the low affinity compounds', whereas the tendency of establishing hydrogen 
bonds with residues of the switch I region or the Gβ subunit seemed to be increased resulting in an even larger 
deviation from the high affinity binding pose  (Table 2, Table 11, Figure 11d). Except from compounds 3 and 
32, none of the low affinity analogues still shows H-bond contacts to Arg60 and the major partner for hydrogen 
bond formations is now represented by Arg96 of subunit Gβ (Table 11).5 
The modifications introduced into the low affinity analogues were sufficient to result in significant alterations 
of the molecular conformation of the inhibitor and thus to weaken its ability for a proper accessing of the rather 
cavernous Gq binding pocket.5 
 
Finally, for the design and synthesis of novel, YM/FR-like G protein inhibitors, these insights teach us to 
preferably preserve simultaneously formed contacts towards Arg60- and Glu191-corresponding residues at 
proportionate positions of other G protein subtypes as well as to avoid interactions with residues affecting the 
switch region or the Gβ subunit. 
 
 
Deviation of recognition determinants for inhibitor binding to Gαq 
 
Based on the previous analyses, another ultimate goal was to delineate distinctive recognition determinants that 
were characteristic for the inhibitory binding to Gαq. In this respect, we first approached our aim by identifying 
characteristic attributes of YM/FR that account for high levels of inhibitory activity and whose lack or 
modification would drastically reduce the effect of inhibion. In this respect we sampled the chemical space of the 
inhibitor compounds especially in order to determine molecular sites conceivable for eventual optimizations. As 
were seen from previous illustrations, YM and FR represent small to medium-sized macrocyclic compounds of 
particular three-dimensional conformations and a coincident high degree of chemical complexity.5 However, 
their intrinsic rigidity involves a quite concise overall backbone orientation together with a distinctive 
arrangement of the side chain groups (Figure 6, Figure 8).5 
 
Altogether our analyses could highlight molecular properties of three discinct categories whose changes affect 
the inhibitory capacity compared to the lead compounds.5 More specifically, these concern alterations of I) the 
backbone conformation, II) the backbone conformation that in turn influence the intramolecular hydrogen bond 
network, and III) the side chain constitution and orientation (Figure 14, Figure 8).5 
 
 
   31 
 
Figure 14: Structural classification of compounds with modifications at one site of FR and/or YM according to their impact 
on (a) backbone and intramolecular hydrogen bonds and (b) side‐chain modifications; that is, inactive analogues 5–14 
carrying more complex modifications at different sites are not considered here. Coloured bars next to compounds indicate 
acceptance of modifications (red: inactive compounds with minor non‐tolerated substitutions, yellow: moderately active 
compounds with partially tolerated substitutions, green: active compounds with tolerated substitutions). *Nomenclature 
refers to YM‐254890. 2,3‐Dab=2,3‐diaminobutyric acid; Sar=sarcosine; SMe‐Ac=methylthioacetyl.103 (scheme from Ref.5) 
 
Among analogues ranking among categories I or II, i.e. mainly containing alterations that cause a change in the 
backbone, which strongly decreases or in some extreme cases completely diminishes the activity are attributable 
to compounds 36, 35, 34, and 32 (Figure 8, Figure 14).5 Even minimal structural changes of a single atom or 
only a small functional group at positions 8 (N-MeThr(OMe)), 7 (Ac-Thr in YM), 5 (N-MeDha) or 4 (Ala) of 
the parent YM/FR structure could achieve those strong effects (Figure 8, Figure 14a).5 As already mentioned, 
among the general backbone-modified analogues, a further distinction can be made between compounds that 
only carry a pure (sole) conformational change of the backbone (category I) and compounds whose backbone 
functional impairment is caused by their intramolecular hydrogen bonding network (category II).5 For example, 
for analogue 34 in category I, the backbone conformational change is caused by inversion of the configuration 
of L-Ala4 to D-Ala, while the category II analogues 32, 35 and 36 show alterations within their intramolecular 
hydrogen bonds (Figure 9, Figure 10).5 These aspects were also revealed in our equilibration simulations for 
outlier structures 34 of category I and the two outliers 32 and 35 of category II (Figure 9, Figure 10). 
 
With respect to the individual binding modes of category I and II analogues, their structural integrity compared 
to YM and FR was generally disturbed.5 Nevertheless, these effects can be further broken down with regard to 
the position of the modified site in the molecule and its efficiency: for example, when comparing the inactive 
compound 32 with the still moderately active compound 31, it turns out that the substitution of an ester by an 
amide bond, can have different effects depending on the modification site. Whereas D-Pla6 has been modified to 
D-Phe6 in compound 31, retaining moderate activity, introduction of an amide bond at the proceeding amino 
acid position (Ac-β-HyLeu7) yielded only weakly active compounds (32 and 34-36, Figure 8, Figure 14b).5 This 
shows that the ester bond at position 7 is more prioritized with respect to the bioactivity of the macrocyclic 
conformation than at position 6.5 In contrast, modifications at opposite side of the macrocycle did not show such 
a large effect in view of activity attenuation, as can be seen by the example of compound 23, in which N-MeAla3 
was substituted by Ala (Figure 8, Figure 14).5 However, this backbone modification is also associated with a 
change in the internal hydrogen bond network.5  
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Concerning backbone modifications only the reduction of N-MeDha5 to N-MeAla had a significant effect on the 
biological activity (Figure 8, Figure 14).5 
All other structural changes as present in 27, 23, 20, 19, and 17, including configuration inversions (N-MeAla3 
to N-Me-D-Ala as seen in compound 20) or an increase in the molecular flexibility (e.g. by the modification Ala4 
to Gly in compound 27) were tolerated.5 
 
In summary, it can be stated that modifications within the region of the YM/FR molecule, comprised by residues 
N-MeAla3 and Ala4 were more accepted compared to modifications between N-MeDha5 to N-MeThr(OMe)8.5 
Probably because the latter are located closer to the protein surface and face the binding pocket to a larger 
extent, even small or marginal modifications at these positions are not tolerated (Figure 8, Figure 14).5  
 
The situation was somewhat different for analogues from category III. Detailed analyses revealed that all 
changes except from the modifications at the N-MeDha5 exomethylene group as seen in compound 4 and the 
Pr-β-HyLeu1 side chain in analogue 3 were partially or almost fully tolerated (Figure 8, Figure 14).5 
Noteworthy, the above-mentioned backbone-related criteria are preserved in these analogues which may be a 
major reason for the higher acceptance of this type of modifications.5 Moreover, equilibration simulations 
support these aspects, unveiling lower intrinsic per residue flexibilities for the side-chain modified analogues 30 
(Figure 9c) which is moderately active and 33 (Figure 10b) which ranks among the low affinity compouonds. 
In both cases, their higher rigidity is caused by stabilizing internal hydrogen bonds of the unaltered backbone 
similar to that of YM/FR (Figure 9, Figure 10). 
 
In addition, regarding the protein-facing residues 6, 7, and 8 in YM/FR no alterations were made or identified 
whereas at both ends spanning the sequence between residues 5 (N-MeDha) and 1, 2 (Ac-β-HyLeu) 
modifications maybe critical as can be proven with compounds 3, 4, 28, and 30 (Figure 8, Figure 14). 
 
For side-chain modified analogues, such infuences can especially be proven when considering compounds 3, 4, 
28, and 30.5 In particular, the low and medium affinity analogues 3 and 30 lack the crucial hydrogen bondings 
between the hydroxyl function of Ac-β-HyLeu1 and the Gq backbone residues Ile190 and Glu1915 that would 
provide a stabilizing effect of the compounds’ binding mode. On the other hand, but achieving a comparable 
effect, the prolongation of the N-MeDha5 residue in compound 4 leads to an unfavourable bulkiness of the 
affected residue and thus prohibits the equally important interactions for D-Pla6 at the binding site.5  
 
Possibly for similar reasons simultaneous exchange of Ac-β-HyLeu1 and Ac-β-HyLeu2 by the smaller Ac-β-
Thr resulted in total loss of activity for the side-chain modified analogue 33.5 Regarding our equilibrating 
simulations and docking data (Figure 10b) this modification may facilitate their reorientation towards the 
Arg96 residue of subunit Gβ,5 ending up in a similar situation as seen for the low affinity compound 36 (Figure 
11). Moreover, this reorientation would not only result in the loss of essential contacts to Ile190 and Glu191, 
as is the case with the moderately active compound 30 and the weakly active FR-analogue 3 (both side-chain 
modified), but also in the disappearance of hydrophobic interactions within this corresponding region.5 In the 
case of the side-chain modified compounds 24 and 26, each containing a separately mutation to Thr at one of 
the two β-HyLeu tail groups, the aforementioned steric reductions were not sufficiently large to achieve such 
reorientations and could thus preserve the critical hydrogen bond interactions with the protein, allowing for 
their higher activity (Table 11).5  
 
In conjunction with the analyses carried out on category I and II backbone-modified analogues it emerges that 
except of the two residues N-MeAla3 and Ala4, the remaining part of the FR/YM molecule can altogether be 
considered as “pharmacophore” scaffold for addressing the Gq binding pocket (Figure 13).5  
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3.3.1. Conclusions and future perspectives 
 
In conclusion, we were able to characterize the binding mode of the most potent inhibitors together with the 
detection of interaction patterns being critical for the inhibition of Gq. Based on the our modelling data of the 
macrocyclic depsipeptide structures of YM-254890 and FR900359 and related analogues, we could also obtain 
comprehensive and accurate insights into the underlying structure-activity relationships associated with 
effective Gq inhibitory mechanisms.  
 
In these respects we were able to identify at least two essential binding regions for YM and FR at Gq, namely 
residue Arg60 in the linker 1 region and Glu191 in the β2 sheet region of the Gα subunit, close to switch I 
region. 
 
Figure 15: Scheme of main inhibitory YM/FR interactions to the essential positions in the Gq binding pocket using the 
example of FR900359; hydrogen bonds are displayed as dashed lines (intermolecular – red, intramolecular – gray), 
hydrophobic interactions as orange curved lines. 
 
For the second essential binding site, namely Glu191 and also the neighbouring Ile189, it was shown that the 
shape, length and mobility of the β-HyLeu residues interacting with it is of essential importance for an inhibitory 
effect. It is absolutely necessary to mention that only the presence of the interactions with both important anchor 
points, Arg60 and Glu191, can achieve efficient inhibition. Since it could be shown that the inhibitory effect 
drops drastically to only moderate activity or even to complete inactivity as soon as at least one of these 
important contacts is missing, the necessity of the existence of both of these contacts must be assumed. 
 
Recently, data from our collabortors suggested a third essential binding site, which is formed mainly through 
hydrophobic interactions of Thr7 (YM) or β-HyLeu7 (FR) with Phe75 also play an important role (Figure 
15).125  
Thus our data suggested, that except of two residues, N-MeAla3 and Ala4, the remaining part of the YM/FR 
molecule represents the “pharmacophore” for this specific binding pocket on Gq (Figure 15). 
 
At the same time, the combination of docking and molecular dynamics simulation studies also showed that it is 
particularly important for medium and poorly binding compounds to consider dynamic information compared 
to active compounds for a more accurate in silico description. This is due to the fact that the computer-generated 
reproduction of a "representative binding" state by sole docking experiments is altogether more difficult for 
systems of higher dynamics. 
   34 
Lastly, our computational studies underpin the insight that both molecules YM and FR obviously represent the 
optimally designed compounds in respects of Gq inhibition: since none of the introduced modifications in the 
natural product structures yielded more powerful inhibitors – neither from an artificial perspective as seen in 
this work nor from a natural systhesis point of view as conducted by Reher and co-workers5 – YM and FR can 
be declared as the highest efficient and specific compounds for Gq inhibition known so far.5  
 
In view of the extensive evolutionary history that natural products bring with them and the associated recurring 
adaptations towards an ideal mode of action, the high specificity of YM and FR against Gq can also be made 
plausible: since YM and FR as natural products are equally subject to such an evolutionary optimization process 
of millions of years, even in co-evolution with their target protein,126, 127 their high specificity, which they have 
developed over time against Gq, can be conclusively explained.  
 
Hence, it seems unlikely that a significant improvement regarding Gq-inhibitors can be obtained with the limited 
opportunities provided by the YM/FR template(s), which already serve as suitable chemical tools in basic 
pharmacological studies.128-130 In terms of perspective, one conceivable task thus could be the implementation of 
strategies to target other Gα protein subunits based on the YM/FR natural models. 
 
Finally, regarding the conformation of FR in water, which differs from the Gq-bound conformation of YM as 
found in PDB 3AH8 it remained unclear, which isomer is preferabley bound or whether they exhibit different 
target affinities. However, attempts to address these questions are currently ongoing and were not completed 
when the thesis was written.  
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4. Investigations on the mechanism of ion channel block by conesnail toxins 
 
4.1. Voltage-gated ion channels 
Voltage-gated ion channels, especially specific for the flow of calcium potassium or sodium ions through cell 
membranes, are important components for the activation of excitable cells like neurons or muscle cells. They 
ensure for the selective permeability of biological membranes, a particular essential feature in synaptic nerve cell 
membranes. Generally, such channels can be in a closed, or open, inactivated state. Within nerve synapses, they 
directly contribute to the tension gradient between the nerve cell interior and the synaptic cleft, the border area 
between two neighboring nerve cells. This gradient is also known as resting potential and depicts an utmost 
prerequisite for the triggering and transmission of nerve stimuli. The maintenance of this basal voltage of 
approx. -70 mV is regulated by sodium-potassium pumps, i.e. sodium- and potassium-permeable ion channels in 
the cell membrane. The reciprocally controlled channel opening and closing is also indispensable for the actual 
transmission of stimuli between neurons, i.e. during depolarization, repolarization and hyperpolarization. The ion 
flow itself occurs along the specific concentration gradient, either from the extracellular space into the cytosol 
or in the opposite direction. Regarding stimuli initiations and transmissions, the ion flow through sodium 
channels into the nerve cell interior is crucial for the impulse and propagation of action potentials and the flow 
of potassium ions out to the extracellular space has a hyperpolarizing influence on the membrane voltage at the 
end of the transmission.7 This interplay clearly points out the physiological relevance of ion channels. 
 
The channels themselves are distinguishable by their selectivity towards different ion types, which they are able 
to transport through the cell membrane. The so-called "selectivity filter", named thereafter, predominantly 
consists of charged amino acid residues in the inside of the annular channel pore. The charged amino acids of 
the selectivity filter exhibit highly conserved patterns, for example the sodium-permeable channel is equipped with 
a “DEKA-motif” in its pore centre.131 Just like these amino acid residues, also the ionic radius as well as the 
charge of an ion represent important determinants for the channels’ selectivity. The selectivity filter thus serves, 
so to say, as narrow passage inside the channel. 
 
Correspondingly, the formal designation of ion channels is based on their selectivity for specific ions; for instance 
they are called calcium, potassium or sodium channels (CaV, KV and NaV channels), according to their respective 
permeability for calcium, potassium or sodium ions. As already indicated, they are very well-known channel 
types whose physiological relevance has already been proven by numerous scientific studies and they are still of 
great interest especially in the neuroscience area. Due to their high relevance in the initiation and propagation 
of action potentials outlined above, they are predominantly found in the presynaptic membrane, more specifically 
in the membranes of the axon terminal of a neuron. This area ranks among the so-called synaptic cleft, the 
intermediate space of two neighboring neurons, where the transmission of stimuli takes place. The following 
figure schematically illustrates a neural synapse, the point of junction of two neurons, including all associated 
entities (Figure 16, left side).  
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The individual channel types can be subdivided into subfamilies according to their individual compositions of 
amino acid sequences. Hence, potassium channels can be divided into 12 subfamilies KV1 – KV12 and further into 
subtypes according to their inactivation mode.7  
 
In structural terms, ion channels are proteins that form a ring-shaped channel pore through the cell membrane. 
These can be opened temporarily, whereby the opening and closing process ultimately results from a 
conformational change of the channel. It is assumed that the conformational change is triggered by a charge 
shift within or at the channel pore.132 
The ring-shaped complex of a channel is formed by four equally constructed homologous subunits, the monomers, 
and thus depicts a tetramer. The complex can occur as a tetramer of (sequentially) different monomers, i.e. as 
heterotetramer or of (sequentially) the same monomers, i.e. as homotetramer. Structurally, however, the subunits 
are always almost identical. As an example of a heterotetrameric complex the NaV channel can be named, 
whereas the KV channel is a homotetramer. Despite this difference and although not completely symmetric, a 
general similar basic structure of NaV and KV channels is presumed.7 In this context it has to be noted that X-
ray structural data is explicitly available for KV channels, but not for the mammalian NaV channels. Nevertheless, 
cryo-EM structures of the latter are present these days.6, 133 
 
Using the example of the KV channel, the general voltage-gated ion channel structure can be described in more 
detail: one monomer is formed by six transmembrane helices.7 According to their order arising in the channel they 
are designated as S1 – S6 (Figure 16, right side). Hereby the first four helices S1 – S4 constitute the voltage-
sensing domain, and are, considering the channel complex as a whole, located at the outside of the channel, 
adjacent to the surrounding cell membrane (Figure 16, right side). A change in the electrical field of the cell 
membrane leads to the opening of the channel. In this context, studies showed that the more outer and closer 
to the membrane located starting helical segments S1 – S3 seem control the adjacent S4 helix134, 135 which is 
further responsible for performing the opening movement of the channel.7, 134, 135 In this respect the term voltage-
gated ion channels is used.     
 
The highly conserved selectivity filter mentioned above is directly located within the center of the pore duct, 
more precisely it is embedded in the loop-like linker segment which forms a connection between helices S5 and 
S6.7 However, the linker segment also contains a short helical section, the so-called pore helix (Figure 16, right 
side), which is why the term "loop-like" is used here. 
 
Figure 16: Neural synapse in schematic representation (left) and zoomed view of a KV channel α 
subunit monomer in transmembrane topology representation (right). 
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The following Figure 17 shows the transmembrane domain's three-dimensional structure from above and in 
side view using the example of the cryo-EM solved KV1.2-2.1 paddle chimera channel (PDB ID: 6EBK136 – full 
channel including transmembrane and cytosolic domain or PDB 6EBM – transmembrane domain only).136 
 
 
Figure 17: Voltage-gated ion channel tetrameric structure in 3D representation including all domains in top (left) and side 
view (right). The channel structure is shown by the example of the voltage-activated KV1.2-2.1 paddle chimera potassium 
channel (illustration created from PDB ID: 6EBK136). Colour scheme: voltage-sensing domain (S1-S4 helices) – cyan, S5 + 
S6 helices – yellow, pore helices – green, turret domain (outer loop connecting S5 and pore helix) – dark blue, selectivity 
filter domain (loop connecting pore helix and S6) – light blue. 
 
 
4.2. Subtype-selective block of ion channels by conotoxins 
 
Conotoxins depict small polypeptide chains, mostly being composed of around 22—30 amino acid residues,137 
obtainable from the venom of marine cone snails. Despite being obviously small, they are quite effective 
substances: As for the majority of drugs their main target of interaction depict membrane proteins like 
transporters and receptors, but also voltage-gated sodium and potassium channels.138, 139 The latter in turn form 
key players in many physiological processes such as in the electrical excitability of neural tissue. Here they 
control interneural signal transmission by regulating the balance between action and rest potentials in the 
synaptic cleft (see chapter 4.1). 
 
Physically and specifically blocking those channels,137, 140 for instance by pore occlusions137 they offer great 
potential for their use as analgesics.139 Alternatively to the direct occlusions, channel deactivation can also be 
induced by affecting the kinetics of channel opening movenents137, 141-145 which prevents the controlled flow of 
ions necessary for many physiological processes (see chapter 4.1). Neither any voltage potential, nor any de- or 
repolarization effects on the neural membrane are enabled which however lastly are determined by this 
controlled ionic flux (chapter 4.1). Disabling these essential prerequisites will stop the initiation or prevent the 
entire transmission of any stimuli. 
 
Such deactivations of the natural channel function can take place in an agonistic or antagonistic manner and 
ultimately form the basis of analgesic effects.  
It has been suggested by French and colleagues146 that Na+ currents are inhibited by µ-conotoxins in at least 
two ways: While on the one hand the channel vestibule is sterically blocked by the physical mass of a µ-
conotoxin, basic residues on different sides of the toxin reduce the effective absorption volume of ions. 
 
Due to their known deactivating and blocking effects on ion channels, conotoxins are already widley applied in 
the area of neurosciences. Their use as local anaesthetics, antiarrhythmics or anticonvulsives147-149 for instance 
bears witness to their neurotoxic functions. Also, various conotoxins are currently in the clinical trial test 
phase.150 
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The wide range of potential conotoxin applications is, without doubt, a consequence of their intrinsic structural 
diversity, mainly formed by their pattern of internal disulfide bonds as a result of their high amount of 
cysteines.54, 151 For this reason, disulfide-rich conotoxins can be subdivided into superfamilies (α, µ, ω, δ and κ) 
based on their pattern of cystein-disulfide-bonds and further into subfamilies with respect to their interacting 
targets.152 Not surprisingly, the structure and flexibility of a conotoxin is also ultimately subject to its 
superfamily-specific disulfide bridge pattern. In view of the generally known structure-activity relationships of 
biomolecular complexes, it is now known that different disulfide binding patterns of one and the same amino 
acid primary sequence lead to different biological activities.151, 153-155 
The fact that the structure given by the disulfide bridge pattern is more essential in this context than the 
underlying sequence was further confirmed by Olivera et al. in 1991.155 This study suggested degenerated 
pathways for marine cone snail toxins to obtain congruent conformations, whereby it turned out that the amino 
acid identity at certain positions is not obligatory.155 
 
It is therefore well known that the identification of an individual disulfide connectivity represents an essential 
part in conotoxin research. Superfamilies containing more than four cysteine residues, i.e. more than two 
disulfide bridges, are particularly affected, since the structural variability increases with the number of possible 
disulfide bridge combinations, i.e. patterns. In addition, the occurrence of several conformational isomers of 
proteins and peptides with several disulfide bonds has also been reported, irrespective of their origin, e.g. 
synthetic production, recombinant expression or isolation from biological material.156-161 
 
Conotoxins from the μ superfamily, for instance, contain six cysteines and thus a special native disulfide bridge 
pattern ascribed to them, which consists of three disulfide bridges. Figure 18 gives an example of three 
representatives of the μ-conotoxin superfamily, showing μ-PIIIA, μ-SIIIA and μ-GIIIA as aligned amino acid 
sequences which will also be in the focus of our studies.  
 
 
 
Figure 18: Sequence alignment of the μ-conopeptides μ-GIIIA, μ-SIIIA and μ-PIIIA as published by Leipold et al.7 Dashes 
indicate gaps; the cysteine-formed (native) μ-conotoxin disulfide bridge pattern present in each of the three toxins is 
indicated by connecting lines at the bottom of the alignment; Z = pyroglutamate, O = hydroxyproline, * = amidation; 
amino acid single letters are coloured by type: alkaline – light blue, acidic – magenta, polar / neutral – green, non-polar / 
hydrophobic – orange. (Illustration modified from Leipold et al.7) 
 
These typically 16 to 25 amino acids long µ-conotoxins contain three disulfide bridges, which connecting Cys1 
– Cys4, Cys2 – Cys5 and Cys3 – Cys6 (cysteines numbered in order of their occurrence in the amino acid 
sequence).162, 163 They are known for their subtype-specific blockage of NaV channels.7 
 
The venom of each cone snail species is composed by up to 200 pharmacologically active components152, 164 and 
there are indications that each species has developed its own conotoxin mixture over the course of its 55 million 
years old evolution.165, 166 Currently there are ~9.000 entries stated in the conoserver database, covering ~242 
species (“http://www.conoserver.org/”). This manifoldness makes them at the same time so highly specific 
towards their targeted macromolecules.55, 56 
 
Likewise, figures confirm diversity and heterogeneity as well for the targeted potassium channels, of which more 
than 70 genes are known to encode for,167 40-50 of them known in the meantime to be present in humans and 
equally subdivided into 12 families.168 To affirm the importance of specificity also on the part of the targeted ion 
channels, there are known numerous diseases caused by channel mutations and their concomitant 
malfunctioning – so-called channelopathies.169, 170 The hereditary disorder cystic fibrosis, but also certain types 
of epilepsy, deafness or cardiac arrhythmia can be mentioned as examples here.170 Moreover, it is known that 
altered expression of KV1.3 and KV1.5 channels has been detected in several types of tumors and cancer cells171 
and furthermore mutations in the CaV2.1 gene cause familial hemiplegic migraine.172 
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Despite the potassium channels' high number, accompanied by their huge variety, there are only known few 
conotoxin family members of the equally diverse conopeptides interacting with or blocking those channels and 
much less their detailed mode of action (Table 3). 
 
Table 3: Overview of blockage activity levels of the μ-conotoxins μ-GIIIA, μ-SIIIA and μ-PIIIA on different potassium 
and sodium channel subtypes of the KV1, KV2 and NaV1 family and generated chimera KV1.6-5P1 and KV1.6-5P2; active ≙ 
subtype-specific inhibition or blockage, semi-active ≙ weaker inhibition but partial blockage occurs, inactive ≙ no blockage; 
an example of occurrence is given for each channel (CNS: central nervous system, PNS: peripheral nervous system); the 
last column displays the availability of experimental structural data published for the scientific community; systems treated 
in this work are highlighted yellow. 
 
 
μ-PIIIA 
 
μ-SIIIA 
 
μ-GIIIA 
channel 
occurrence 
channel structure data 
available 
KV1.1 active semi-active inactive CNS yes (PDB ID: 2AFL) 
KV1.2 inactive inactive inactive CNS yes (PDB ID: 2A79) 
KV1.3 inactive inactive inactive CNS yes (PDB ID: 4BGC) 
KV1.4 inactive inactive inactive CNS yes(PDB IDs: 1KN7, 1ZTO) 
KV1.5 inactive inactive inactive CNS no (model) 
 
KV1.6-5P2 
 
semi-active 
 
(presumably 
inactive or less 
active than on 
KV1.6) 
(presumably 
inactive) 
 
- 
 
no (model) 
 
KV1.6-5P1 
 
 
semi-active 
 
(presumably 
inactive or less 
active than on 
KV1.6) 
(presumably 
inactive) 
- no (model) 
KV1.6 active semi-active inactive CNS no (model) 
KV2.1 inactive inactive inactive CNS yes (PDB ID: 2R9R) 
 
NaV1.2 
 
semi-active 
(no specificity 
but better 
antagonists) 
semi-active 
(no specificity 
but better 
antagonists) 
 
inactive 
 
 
CNS 
 
 
no 
 
NaV1.4 
active 
(no specificity 
but better 
antagonists) 
active 
(no specificity 
but better 
antagonists) 
 
active 
(high specificity) 
 
 
skeletal 
muscle 
 
 
yes (PDB ID: 5XSY) 
NaV1.5 inactive inactive inactive cardiac 
yes (PDB IDs: 2KBI, 2L53, 
4DCK, 4DJC, 4JQ0, 4OVN) 
 
NaV1.7 
 
semi-active, 
(no specificity 
but better 
antagonists) 
semi-active 
(no specificity 
but better 
antagonists) 
 
inactive 
 
 
PNS 
 
 
yes (PDB ID: 5EK0) 
 
 
Despite the known high specificity and diversity associated with conotoxins, the underlying mechanisms of 
mutual interactions with their targets are not yet fully understood. Table 3 points out the still perpetual lack 
of knowledge considering subtype-specific channel blockage by μ-conopeptides and leaves very demanding and 
costly issues for the researcher when trying to explicitly explain a blockage event or the inactivity of a system 
by reasons of distinct interactions. Also and as a result, trying to detect regularities or similarities of blockage 
or inactive systems would require an all-system comparison with respect to individual binding modes and the 
concomitant dynamics. However, a more general determination of different classes of blockage mechanisms 
could be provided through this approach. Table 3 shows that this is very difficult to be unambiguously grasped: 
readily apparent, a particular conotoxin agent does not necessarily have to block a single channel subtype only, 
but is for instance also able to semi-actively bind to other channel subtypes than to its original target. The 
mutual blockage activities are therefore not precisely delimitable and there are fluent transitions observable in 
these respects. Unfortunately, various and severe adverse events may be caused by such unspecific inhibitory 
effects on diverse ion channel suptypes apart from the “actual” target channels7 or even by other off-target 
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interactions. Due to the high analgesic efficacy of the conotoxins mentioned above, these relationships are 
particularly relevant for the field of analgesic treatment. 
 
The representative ω-MVIIA from the ω-conotoxin superfamily, also known as ziconotide, can be cited as an 
example of painkilling drug associated with various side-effects that are suspected to be caused by such “off-
target” effects. Severe neurological side effects173-175 like dizziness, hallucinations, abnormal gait, ataxia, 
confusion, nystagmus, somnolence176-178, but also nausea and/or vomiting176 and even potential psychiatric side 
effects178, 179 are thus far known as side effects associated with ω-MVIIA treatment.  However, besides its 
intrinsic use as blocker of the N-type calcium channel CaV2.2 it thus far is only known to additionally show 
slight binding activities to the P/Q-type calcium channel CaV2.1177, 180-182 and, as analgesic it is still approved 
and applied as a drug for the treatment of severe chronic pain.183, 184 
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4.3. In silico binding studies of µ-PIIIA isomers on the sodium channel NaV1.4 
 
As already mentioned, the disulfide bond pattern is suggested to have a dramatic impact on the fold and the 
global shape of the conotoxin. As one can imagine, changing the dislufide pattern will also change the affinity 
towards the toxins target. As this was demonstrated for a conotoxin harbouring two disulfide bridges, it 
remained unclear, how the structure and activity of a conotoxin with three disulfide bonds is altered.151, 153-155 
As µ-PIIIA, which contains three disulfide bonds was suggested to represent a potential drug lead the structure 
and bioactivity of its 15 possible isomers was of special interest and the focus of our investigations.   
 
Studies on natural peptides with at least three, or broadly speaking more than two disulfide bridges and one pair 
of adjacent cysteines are particularly interesting because they have been shown to have a high therapeutic 
potential or important biological functions. Examples are the vascular endothelial growth factor A,185 resistin,186 
Norrin,187 insulin-like growth factor I,188 placenta growth factor,189 sarcospan,190 hepcidin,191 defensins192 and in 
part Kunitz-type protease inhibitors.193-195 
The elucidation of disulfide connectivity is therefore also one of the main objectives in current proteomics and 
bioanalysis studies of protein and peptide therapeutics, such as monoclonal antibodies.196 
Of course, the complexity of the possible structural arrangements also increases with the number of disulfide 
bridges which is a challenge for related research efforts: it was found that for about 30% of all NMR structures 
stored in the PDB database there is no nearer specified disulfide pattern present197 and furthermore, only studies 
on structural and functional effects of disulfide binding exclusively on peptides with only two disulfide bridges 
are known to date (albeit in large numbers).153, 154, 198 
 
In-depth insights into the correlations of cysteine-dilusfide patterns with their carrying conopeptides’ activity 
– especially that of more complex bonding patterns and architecture – will therefore provide important 
foundations for the rational design process of subtype-selective NaV channel addressing blockers. Since, 
experimental strategies addressing the structural analysis of cysteine-rich peptide isomers of intrinsic high 
conformational variability are largely missing,54 computer-based approaches will provide vital supports in these 
regards. 
 
This computational study was part of a highly collaborative project involving various groups at the University 
of Bonn (Imhof, Biswas, synthesis and MS characterization), Jena (Heinemann, electrophysiology), Lübeck 
(Leipold, Schmitz, electrophysiology) and from the Technische Universität Darmstadt (Tietze, modelling and 
NMR characterization). Recently, Heimer and co-workers54 succeeded to synthesize the fifteen possible disulfide 
isomers of the 22mer conopeptide µ-PIIIA.54 Applying a combination of various analytical methods such as 2D 
NMR spectroscopy and tandem MS further gave remarkable insights in the impacts on disulfide connectivity 
on a toxin’s global fold provided by this enlightening research study.54 The 3D structures of these 15 isomers, 
represented by their corresponding NMR ensembles (Figure 19b), strongly suggested that the global fold of a 
toxin is a direct consequence of its disulfide bond pattern. 
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Figure 19: (a) μ-PIIIA sequence. (b) NMR structures of all 15 μ-PIIIA isomers. For each isomer with the indicated 
disulfide-bond pattern, the solution NMR structures are respectively presented as ensembles of the 20 lowest-energy 
structures; structure 2 represents the so-called native μ-PIIIA isomer.199 (Image source: Heimer et al.54) 
 
The capability of the different µ-PIIIA isomers to block the NaV1.4 channel was assessed by current 
measurements with the whole-cell patch clamp method (data kindly provided by E. Leipold and S. S. 
Heinemann). The impact of  the toxin isomers on depolarization-elicited Na+ inward currents is expressed as 
the time course of  current block and the maximal block after long toxin exposure (Figure 20). Accordingly, 
currents were diminished by all 15 isomers, but to a different extend (Figure 20). 
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At a concentration of  10 µM, isomer 2, which harbours the native disulfide bond pattern of  µ-PIIIA (Figure 
19b, blue marked disulfide pattern indications), was the most potent in inhibiting NaV1.4 channels, followed by 
isomers 15, 11, 14, 1, 7, and 12. 
 
Interestingly, all of these pore blocking isomers have a disulfide bridge pattern in which (seen over the sequence) 
an overlap of all (three) possible disulfide bridging pairs is shown (Figure 19b). 
This may allow a particularly high stability in the spatial arrangement, which in turn can favour an efficient 
block, provided that a good fit is given on the channel surface.  
 
Further concentration dependence analyses yielded an apparent IC50 of 105.3  29.9 nM for the block of NaV1.4 
by isomer 2 (Figure 20b). However, even at a saturating concentration of 100 µM, a small current component 
of 7.2  2.2% remained for some isomers, showing that even by blockage through isomer 2, the channel is not 
covered to such an extent that the sodium ion flow is completely eliminated (Figure 20a, b). Additionally, the 
start time for the onset of the pore blockwas estimated with single exponential functions and yielded the fastest 
inhibition reaction for isomer 2 compared to the other, much slower interacting isomers 15, 11, 14, 1, 7, and 12 
of lower blocking potency (Figure 20c). The possibility of a precise evaluation of the channel block at 
concentrations lower than 10 µM and associated IC50 values was thus be excluded. However, sticking thus to 
the assessment at higher concentrations, it turned out that, despite their different disulfide connectivity patterns 
(Figure 19b), isomers 15 and 7 were especially interesting from the measurements’ point of view due to their 
almost identical total current block at 10 and 100 µM (15: 48.2  5.9% and 51.1  2.2%, respectively; 7: 32.3  
4.3 and 35.1  4.6, respectively) (Figure 20c). 
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Figure 20: Block of NaV1.4-mediated currents by disulfide isomers of µ-PIIIA. (a) Representative current traces of 
transiently expressed NaV1.4 channels evoked at a test potential of 20 mV before (black, control) and after (red) application 
of 10 µM of the indicated µ-PIIIA isomers. (b) Normalized peak current amplitudes obtained from repetitively evoked 
current responses were plotted as a function of time to follow the time course of current block mediated by various 
concentrations of µ-PIIIA isomers 2 and 15. Continuous lines are single exponential data fits used to characterize the onset 
of channel block. The time axis was split to illustrate that channel block by isomer 15 saturates at about 50% suggesting 
that isomer 15 seals the channel pore only partially. In contrast, isomer 2-mediated channel inhibition saturates at about 
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95% with an IC50 of 105.3  29.9 nM. (c) Steady-state block (bottom) as well as the associated single exponential 
time constant (top), describing the onset of channel block, for various concentrations of the indicated isomers. 
Lines connect data points for clarity. Symbols and colour-coding of data obtained with isomers 2 and 15 are as 
in b). (d) Steady-state block of NaV1.4-mediated currents by 10 µM of the indicated µ-PIIIA isomers (bottom) 
and the associated single exponential time constant, τblock, describing the onset of block (top). Numbers of 
individual experiments, n, are provided in parentheses. (Data kindly provided by E. Leipold and S. Heinemann) 
 
Analyses of the isomers 3-6, 8, 10, and 13, performed at 10 µM, identified isomer 13 as the still most active 
isomer among this group, showing an pore block of 24.6  3.0% (Figure 20). Isomers 6, 8, 5, and 10 reduced 
NaV1.4-mediated currents by less than 15% (Figure 20), and were thus considered as inactive peptides. 
 
In summary, isomers 2, 15, 11, 14, 1, 7, and 12 form the group of seven active isomers, isomers 13, 4, 9 and 3 
constitute another group of weaker but still moderately active pore blockers, and finally the remaining isomers 
6, 5, 8 and 10 represent the group of inactive compounds (Figure 20). 
 
Accordingly, the group of active isomers generally shows a more complex disulfide bridge patterns in which all 
three disulfide bridges either overlap at the same time (as for example with isomer 14) or at least still transitively 
a certain connection among all three exists via a disulfide bridge which crosses the other two separate bridges 
(as e.g. in the example of isomer 11) (Figure 19b). This connectivity pattern, which affects the entire peptide 
sequence, is supposed to be the reason for the low overall flexibilty of the toxin as can be accessed from the 
NMR structural ensemble (Figure 19b). This is further supported by the fact that all these isomers contain at 
least one disulfide bond that connects the N- and C-terminal sections of µ-PIIIA (Figure 19b). (Isomer 10, 
which nevertheless exhibits a moderately high flexibility with simultaneously low activitiy, can be regarded as 
a special case in this context.) 
In the moderately active isomers 13, 4, 9 and 3, isolated or separated disulfide bridges occur more frequently, 
i.e. they do not overlap with any other disulfide bridges (Figure 19b). This is particularly the case with the more 
(terminal) flexible isomers 4, 9 and 3 (Figure 19b). Nevertheless, the existing overlap of isomer 13 with the two 
other internal disulfide bridges, which, similar to the interconnectivity of the more active isomers described 
above, extends over the entire toxin sequence. This also demonstrates that isomer 13 is the only semi-active 
isomer that has an N- to C-terminal disulfide bridge, causing a higher rigidity of the toxin compared to the other 
semi-active representatives (Figure 19b, Figure 20). This also gives a possible and plausible explanation for 
the isomer 13 blocking activity, which is still highest within all moderate (and inactive) isomers.  
The low active or inactive isomers 6, 5, and 8 (with the exception of the special case isomer 10) continue this 
pattern of containing more isolated, i.e. non-overlapping disulfide bridges as far as possible together with the 
occurrence of higher intrinsic flexibilities (Figure 19b). Isomers 6 and 5 have particularly flexible N- and C-
terminal regions (compared to isomers 8 and 10) due to a connection between consecutive cysteines. In 
summary, these structure-activity correlations give evidence that the inhibitory capacity of µ-PIIIA isomers for 
the blockage of NaV1.4 channels increases with their rigidity (and decreases with increasing isomer flexibility), 
which can directly be derived from the structural deviation of the NMR structural ensemble (Figure 19b). 
 
In order to gain deeper insights in how the pore block is achieved by the different µ-PIIIA isomers, a detailed 
computational analysis was performed.  
 
Development of a Nav1.4 homology model 
 
Closer inspections of the particular µ-PIIIA isomers’ interactions with the NaV1.4 channel were performed on 
the basis of a homology model of the channel wich, similar to another model that has been previously established 
by us151 and others,200 merely encompassed the central unit of the pore. For the homology model a recently 
published structure of the voltage-gated calcium channel CaV1.1 (PDB ID 3JBR201) was defined as a suitable 
template for the creation of the NaV1.4 model. In this respect, it must also be mentioned that the recently 
resolved structure of the human voltage-gated Na1.4 channel (PDB ID 6AGF202) was not yet available at the 
beginning of this study. However, the chosen template also enabled us to model even the large pore-surrounding 
extracellular loops, which is usually a rather demanding task in homology modelling of proteins and was not 
included in the models generated so far. The inclusion of the extracellular loop parts also provided an 
advantageous basis for further analyses, since especially the extracellular loops are known to contain important 
interaction and recognitive sites for various µ-conotoxins. (For more detailed information on the modeling 
process, please refer to chapter 5.3 in the methods section.)  
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Figure 21: Alignment of the pore modules of the channel template CaV1.1 (PDB ID 3JBR203, uniprot ID P07293) and the 
target sequence of NaV1.4 (uniprot ID P35499) of all four domains. Conservation of the aligned residues is indicated in the 
histogram below the sequence and given as a numerical index reflecting the conservation of physico-chemical properties in 
the alignment employing the AMAS method204: identities score highest and the next most conserved group contain 
substitutions to amino acids lying in the same physico-chemical class. Regions from the template structure that were part 
of the final homology model are indicated by secondary structure elements, schematically outlined above (transmembrane 
segments – black box, loops - straight black line) the aligned amino acid sequences. Homology-modeled regions within the 
template structures are color-coded. Sequence alignments were created with Clustal Omega205-207 on www.uniprot.org. The 
alignment figure was created with JALVIEW 2.8.208 
 
 
 
Figure 22: Homology model of NaV1.4, selectivity filter residues are shown in stick representation (coloring scheme: carbon 
– cyan, nitrogen – blue, oxygen – red, calcium – yellow), subunits are indicated with roman letters.  
 
Docking of the µ-PIIIA isomers to Nav1.4 
 
Employing the previously generated homology model of the voltage-gated sodium channel NaV1.4, the 15 µ-
PIIIA isomers (Figure 19b) were docked to the channel model using the HADDOCK easy web interface.209, 210 
(For more details see chapter 5.4 the methods section.) The docking clusters were generated on the basis of the 
interface-ligand RMSDs of the individual docking results and then scored according to the HADDOCK scoring 
function yielding individual Z- and HADDOCK scores assigned to each cluster (Table 4). The individual best 
scoring channel–toxin complexes of the respective highest scoring cluster were subjected to further analysis 
(Table 4, bold lines).  
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Table 4: Summary of the HADDOCK docking runs. For each isomer docking run the three best-scoring clusters are 
outlined, starting with the highest scored (i.e. lowest Z- and HADDOCK score) cluster. Docking results relating to highly 
active isomers are highlighted in light green (very highly active isomer 2 - darker green), moderately active isomer results 
are highlighted in light yellow and docking results of weak or inactive toxin isomers are highlighted in light orange. 
Isomer Z-score HADDOCK score Cluster size 
RMSD from the overall 
lowest-energy structure [Å] 
Buried surface area [Å2] 
 -1.2 174.1 ± 6 25 3.2 ± 0.0 3114.0 ± 168 
1 -1.2 175.3 ± 17 19 0.7 ± 0.5 2888.9 ± 212 
 -0.9 181.9 ± 4 60 2.8 ± 0.1 2909.7 ± 72 
 -1.4 162.9 ± 20 41 1.3 ± 0.8 2877.3 ± 134 
2 -0.9 182.3 ± 5 18 2.5 ± 0.1 2961.9 ± 146 
 -0.8 183.6 ± 13 26 2.2 ± 0.2 2817.6 ± 121 
 -1.6 127.2 ± 11 45 1.2 ± 0.7 3349.9 ± 140 
3 -1.5 129.7 ± 2 92 3.7 ± 0.1 3435.1 ± 51 
 -0.8 151.2 ± 24 9 3.1 ± 0.0 3185.7 ± 201 
 -2.1 139.5 ± 5 89 1.4 ± 0.9 3239.6 ± 43 
4 -0.9 181.0 ± 3 20 3.5 ± 0.3 3078.0 ± 98 
 -0.3 202.0 ± 5 33 3.3 ± 0.1 2906.4 ± 142 
 -0.9 158.8 ± 3 41 3.2 ± 0.0 3237.1 ± 51 
5 -0.6 168.9 ± 11 55 3.1 ± 0.2 3038.7 ± 97 
 -0.6 169.6 ± 35 54 0.9 ± 0.6 3040.3 ± 44 
 -1.8 132.2 ± 8 42 0.5 ± 0.3 3360.5 ± 98 
6 -1.0 156.1 ± 16 19 3.0 ± 0.1 3120.9 ± 124 
 -0.8 163.2 ± 11 19 2.9 ± 0.0 3254.4 ± 35 
7 
-1.2 171.8 ± 7 38 0.7 ± 0.5 2913.6 ± 123 
-1.0 177.3 ± 10 40 2.5 ± 0.0 3028.1 ± 123 
-0.6 187.5 ± 7 18 2.5 ± 0.1 3056.5 ± 164 
 -1.4 151.5 ± 8 14 2.6 ± 0.1 3083.6 ± 141 
8 -1.0 162.9 ± 16 14 0.8 ± 0.5 3004.7 ± 138 
 -0.4 180.4 ± 8 58 2.4 ± 0.0 3120.0 ± 59 
 -1.3 162.1 ± 20 19 1.2 ± 0.8 3262.9 ± 243 
9 -0.9 169.3 ± 7 28 2.3 ± 0.2 3168.8 ± 80 
 -0.9 170.1 ± 23 40 3.0 ± 0.1 2912.1 ± 270 
 -1.6 142.2 ± 28 25 0.9 ± 0.7 3134.1 ± 52 
10 -0.9 165.1 ± 4 10 2.3 ± 0.1 3022.5 ± 110 
 -0.8 169.6 ± 18 28 2.2 ± 0.1 3057.6 ± 79 
 -2.2 131.2 ± 21 28 0.5 ± 0.3 3019.3 ± 99 
11 -0.8 164.1 ± 14 24 3.0 ± 0.0 3123.3 ± 62 
 -0.4 174.4 ± 14 30 2.2 ± 0.1 2967.6 ± 34 
12  
-1.9 123.5 ± 11 82 0.8 ± 0.5 3220.7 ± 55 
-0.7 169.6 ± 11 37 2.4 ± 0.0 3021.8 ± 110 
-0.7 171.4 ± 14 21 2.8 ± 0.1 2903.0 ± 155 
13  
-1.0 193.0 ± 19 22 2.8 ± 0.0 2913.5 ± 108 
-0.7 201.4 ± 29 78 1.1 ± 0.9 2858.1 ± 161 
-0.6 204.5 ± 4 21 2.1 ± 0.0 2891.9 ± 44 
 -1.8 181.0 ± 12 89 0.7 ± 0.5 2830.2 ± 41 
14 0 211.4 ± 6 45 2.5 ± 0.0 2713.1 ± 98 
 0 211.7 ± 21 34 2.0 ± 0.2 2679.1 ± 126 
 -1.5 162.2 ± 21 65 1.2 ± 0.7 2966.4 ± 186 
15 -1.3 168.1 ± 12 28 2.0 ± 0.1 3096.8 ± 29 
 -0.9 179.5 ± 13 9 3.4 ± 0.1 3146.3 ± 147 
 
At first glance, a pore-covering situation on the channel appears for all docked isomers, also with respect to the 
central pore interface (Figure 23, Figure 24), impeding a straight forward rationalization of the toxins’ 
individual bioactivities solely from the docked states. Moreover absolute pore block values under saturating 
concentrations at 100 µM were only determined for isomers 2, 15 and 7, while all other isomers did not show 
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saturation at 100 µM (Figure 20). (Higher concentrations could technically not be measured.) We will therefore 
orient our analyses to the docking predictions of isomers 2, 15 and 7 and use these as references. 
 
Upon closer inspection of the respective binding poses, the commonality of the arginines of these isomers, which 
simultaneously protrude into the pore and bind to the outer regions, can be determined (Figure 23a, b, f). Thus, 
our docking results suggest the presence of an arginine that prodrudes more deeply into the central pore duct, 
together with a simultaneous contact of the outer pore area (also by arginines or basic residues) to be critical for 
a proper pore-blocking formaion. The latter, outer located pore surface area mainly concerns the acidic residues 
in the S5-SS1 and SS2-S6 pore loops that might, together with the high number of acidic residues within these 
loop regions (Figure 21), indicate a key role for toxin affinity. 
 
When viewing all complexes from the top it can be noted that the binding of the toxin can be determined not 
only by the H bond contacts with the channel, but also by the orientation of its arginine residues. Here generally, 
arginine residues (Arg2, Arg12, Arg14, Arg20) turn out to be the key interacting residues, predominantly 
binding to aspartic acid in the loop regions (Figure 23, Figure 24). Also important are positions of the equally 
basic lysines (Lys9, Lys17) and Pyr1 with respect to the channel (Figure 23, Figure 24). The orientation of 
these residues is however not least a consequence of the spatial isomer structure predeterminded by the inherent 
disulfide bridges. 
 
In particular isomer 2 as the most active blocker can be observed to reside closest to the selectivity filter residues 
located at the center of the pore, occluding it by Arg20, while Arg14 and Arg2 contact the outer residues of the 
subunits (Figure 23a). Moreover, isomer 2 shows an even distribution of all its arginines over the whole surface 
of the channel (Figure 23a). 
 
In contrast, bound arginines of the majority of moderately active and inactive isomers can be stated to point 
away from the pore centre, being rather directed to the channel interfaces and no simultaneous contacts to the 
pore duct and the outer pore loops arise (Figure 24).  
 
The predicted binding poses of the high potency isomers 2, 15 and 7 might explain the decreasing blocking 
ability by showing less hydrogen bonds with residues close to the selectivity filter for 15 and 7 compared to the 
isomer 2 (Figure 23, Table 5). At the same time, for isomer 15 and 7 a smaller and less even spread of the outer 
binding arginine residues compared to the native isomer 2 can be observed (Figure 23). Here, isomer 15 is 
oriented a bit more towards domains I and IV and isomer 7 clearly points more towards the opposite moiety 
(domains II and III) of the channel (Figure 23), which nicely explains their partial pore block. 
 
Generally, for all pore blocking isomers a fairly even distribution of their basic or arginine residues across the 
pore entrance of the channel was observed (Figure 23), which was somehow lacking for the less active and 
inactive  isomers (Figure 24). 
 
Interestingly, among the remaining moderately blocking isomers (11, 14, 1 and 12), similar formations of 
simultaneous pore-diving and outer contacts as observed for isomer 2 can also be stated for isomers 1 and 12 
(Figure 23). Although isomers 11 and 14 still have an even pore coverage on the surface, they lack the contact 
of a basic residue to the inner pore center. (Figure 23). 
 
Among the the poor pore blockers (13, 4, 9 and 3) isomer 13 is observed to be the only isomer exhibiting 
simultaneous contacts to the pore outside and the centre (Figure 24). Notably, isomer 13 represents the still 
most potent isomer within this group (Figure 24). However, no even distribution of arginine or basic residues 
is observable in this group (Figure 24). Moreover, while isomers 4, 9 and 3 all lack the contact to the central 
pore duct, it can further be noted, that all their central and terminal arginine or basic residues (especially Arg2, 
Lys9, Arg12, Arg14, His19 and Arg20) address the outer pore loops of the channel surface, preventing the toxin 
to establish the simultaneous contact to the pore centre (Figure 24). Particularly, isomer 4 shows an 
inhomogeneous one-way orientation for its majority of arginine residues towards the pore loops linking 
transmembrane segments S5 with SS1 and SS2 with S6 of domains I and IV (Figure 24). It furhter shows a 
separate positioning of Arg2 together with Pyr1 away from the other arginines and towards pore domains III 
and II (Figure 24). 
As the remaining isomers 6, 8, 5 and 10 are considered as inactive, a bound state in this sense is not assumed 
and therefore the docked binding poses of these isomers are not further discussed in more detail. 
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Figure 23: Visualization of the best scoring µ-PIIIA–NaV1.4 complex conformations obtained from our docking 
experiments for pore blocker isomers (a, b, f – high potency; c - e, g – moderate potency). The four NaV1.4 domains are 
indicated by purple Roman numbers. Left panel – top view of the toxin-channel complex. The NaV1.4 channel surface (Van 
der Waals) is given in gray, the selectivity filter motif (DEKA) is highlighted in red. The toxin is shown in green with side 
chain atoms present (coloring scheme: carbon – cyan, nitrogen – blue, oxygen – red, sulfur – green). Middle panel – top 
view, right panel – side view of the toxin-channel complex. The toxin is shown in surface representation (Van der Waals) 
and colored according to amino acid properties (coloring scheme: basic – blue, acidic – red, polar - cyan, non-polar – gray). 
The number of hydrogen bonds formed by the toxin with each channel domain (loops/SS1-SS2) is highlighted in purple 
distinguishing between hydrogen bonds formed with the TM bridging loops (S5-SS1, SS2-S6) and the pore helices (SS1-
SS2). 
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Figure 24: Visualization of the best scoring µ-PIIIA–NaV1.4 complex conformations obtained from our docking 
experiments for poor pore blockers (a - d) and inactive isomers (e - h). The four NaV1.4 domains are indicated by purple 
Roman numbers. Left panel – topview of the toxin-channel complex. The NaV1.4 channel surface (Van der Waals) is given 
in gray, the selectivity filter motif (DEKA) is highlighted in red. The toxin is shown in green with side chain atoms present 
(coloring scheme: carbon – cyan, nitrogen – blue, oxygen – red, sulfur – green). Middle panel – top view, right panel – side 
view of the toxin-channel complex. The toxin is shown in surface representation (Van der Waals) and colored according to 
amino acid properties (coloring scheme: basic – blue, acidic – red, polar – cyan, non-polar – gray). The number of hydrogen 
bonds formed by the toxin with each channel domain (loops/SS1-SS2) is highlighted in purple distinguishing between 
hydrogen bonds formed with the TM bridging loops (S5-SS1, SS2-S6) and the pore helices (SS1-SS2). 
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However, our observations on the variety of binding poses are also consistent with further H bond analyses that 
suggest an individual distribution of hydrogen bonding contacts towards the channel. Upon calculating the 
percentage hydrogen bond distributions over the different halves of the channel – assuming that one half is 
defined by the adjacent domain pair with the largest proportion of hydrogen bondings – the general tendency 
of the toxin to be positioned more to one side on the pore for more inactive toxin isomers can be derived (Table 
5), which is compatible with the above stated findings. 
 
Conclusively, in order to rationalize the amount of pore block and bioactivity through computer-aided 
representations, information about the flexibility of the individual toxin segments is necessary. Although such 
approaches would be possible with simulation studies, one can already derive from our docking data that for 
some isomers (especially the poor binders), the pore is only covered by the flexible molecule part (Figure 19, 
Figure 24). Thus, an estimation how tightly a toxin part is able to bind to the channel can therefore be attributed 
to its particular flexiblilty.  
 
Finally, the unique isomer 2 and its noticeable binding mode should be mentioned again in particular, as its 
bound conformation (Figure 23a) is also consistent with the significance of distinct µ-PIIIA residues, e.g. Arg14 
and Arg2211, 212 (although Arg14 does not protrude into the pore). Another interesting aspect is the 
rationalization of available mutation data211, 212 by our docked isomer 2 on the NaV1.4 model, involving all basic 
residues in hydrogen bonding and keeping them distributed among the entire channel surface. This in turn 
agrees with the findings on the impact of basic residues in ion channel blocks, as formulated by French and 
colleagues.146 Furthermore, it can be concluded from this that the inhibitory effect of µ-PIIIA is not exclusively 
achieved by a single residue critical for a block, but always a combination of the interaction of several residues 
with the channel is essential for blocking. At the same time, this equally means that the inhibition of the current 
does not follow an all-or-nothing principle, but is rather gradually determined by distinct interaction modes. 
The special fact that the inhibitory binding of the µ-PIIIA isomer 2 to NaV1.4 (as well as the blockage of KV1.1 
and KV1.6 by µ-PIIIA) is determined by simultaneously existing contacts to the inside and outside pore area 
could not be fully rationalized by previous models so far, as in the respective homology model proposals the 
external pore loops were not considered.200, 211, 213, 214 
 
The coincident contacts of µ-PIIIA with the outer surface area of the NaV1.4 channel beyond the contact 
protruding into the pore through Arg20 is also shown by the slightly asymmetric pore coverage that µ-PIIIA 
exhibits on NaV1.4. In particular this can be seen by its predominance in hydrogen bond contacts to domains I 
and IV (8 in total) compared to domains II and III (4 in total) (Figure 23a, Table 5). In detail, Arg14 being 
hydrogen bound to the S5-SS1 loop of the NaV1.4 domain II suggests that this contact point (or at least a 
corresponding binding position within another domain since the channel is tetrameric) might provide an 
important anchor for efficient pore occlusions being lost upon mutation.   
 
From all these aspects it is certainly be deducible that the slightly asymmetric position of µ-PIIIA isomer 2 on 
NaV1.4 is an ultimate result of its simultaneous contact with the inner central pore duct, from which further 
contacts towards the outer surface area is possible for the toxin rather towards only one direction. The compact 
globular and relatively rigid toxin structure required for such a formation is further provided by the µ-PIIIA 
native isomer’s unique disulfide connectivity. The fact that the orientation to the side appears up to an only 
slight extent (Table 5) is still plausible from the same point of view, i.e. the further contact of the toxin to the 
inside of the channel. This typical binding mode can also be verified by simulations (chapter 4.4). 
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Table 5: H-bond analysis (H-bonds predicted by the HADDOCK docking calculations); valid "channel halves" are always 
defined by adjacent domains (I-II, II-III, III-IV or IV-I as possibilities); the halves and thus the proportion of contacting 
H-bridges are defined by that adjacent domain pair which proportionately has the majority of H-bridges (the proportion of 
H-bonds to the other half is thereby determined); docking results relating to highly active isomers are highlighted in light 
green (very highly active isomer 2 - darker green), moderately active isomer results are highlighted in light yellow and 
docking results of weak or inactive toxin isomers are highlighted in light orange.   
  domain   
Isomer 
total 
number of 
H-bonds 
I 
H-bonds to 
loops / SS1-
SS2 / sum 
II 
H-bonds to 
loops / SS1-
SS2 / sum 
III 
H-bonds to 
loops / SS1-
SS2 / sum 
IV 
H-bonds to 
loops / SS1-
SS2 / sum 
percentage of 
H-bonds to channel 
half 1 [%] 
(domain/domain) 
percentage of 
H-bonds to channel 
half 2 [%] 
(domain/domain) 
1  19 3 / 4 / 7 0 / 4 / 4 3 / 1 / 4 2 / 2 / 4 57.89 42.11 
2  12 1 / 1 / 2 2 / 1 / 3 0 / 1 / 1 4 / 2 / 6 66.66 33.34 
7  17 2 / 3 / 5 1 / 4 / 5 0 / 3 / 3 1 / 1 / 2 58.82 41.18 
11  19 0 / 3 / 3 4 / 4 / 8 2 / 4 / 6 0 / 2 / 2 73.68 26.32 
12  22 1 / 3 / 4 4 / 5 / 9 2 / 3 / 5 1 / 3 / 4 63.63 36.37 
14  17 2 / 3 / 5 1 / 1 / 2 0 / 3 / 3 3 / 4 / 7 70.59 29.41 
15  18 4 / 1 / 5 0 / 3 / 3 1 / 1 / 1 5 / 3 / 8 72.22 27.78 
     average: 66.21 33.79 
3  17 2 / 4 / 6 0 / 4 / 4 2 / 1 / 3 2 / 2 / 4 58.82 41.18 
4  23 6 / 3 / 9 1 / 1 / 2 4 / 1 / 5 6 / 2 / 8 73.91 26.09 
9  23 1 / 5 / 6 4 / 3 / 7 5 / 2 / 7 1 / 2 / 3 60.87 39.13 
13  20 2 / 7 / 9 1 / 2 / 3 2 / 3 / 5 0 / 3 / 3 60.00 40.00 
     average: 63.4 36.6 
5  17 4 / 2 / 6 2 / 3 / 5 0 / 3 / 3 1 / 2 / 3 64.71 35.29 
6  21 0 / 4 / 4 1 / 7 / 8 2 / 3 / 5 2 / 2 / 4 61.90 38.1 
8  26 3 / 7 / 10 1 / 4 / 5 0 / 2 / 2 3 / 6 / 9  73.08 26.92 
10  21 3 / 4 / 7 1 / 2 / 3 2 / 1 / 3 5 / 4 / 9 76.19 23.81 
     average: 68.97 31.03 
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4.3.1. Conclusions and future perspectives 
 
With the docking studies conducted here, we were able to gain detailed insights into the binding patterns of the 
disulfide bond isomers of the µ-conotoxin PIIIA on the sodium channels such as the channel NaV1.4. It could be 
demonstrated that there is an ultimate correlation between the cysteine disulfide bridge pattern of a toxin, which 
determines its structure and flexibility, and finally its extent of ability to block certain channel subtypes.  
 
The observations from the docking experiments were in line with the experimental observations pointing out 
that the native and most active isomer 2 exhibits coincident pore-diving and outer located contacts, evenly 
spread on the pore surface (Figure 23a). In contrast, the moderate or poorly active isomers either lack the 
central pore contact and/or the distributed covering contacts to the outer pore surface (Figure 23, Figure 24). 
Moreover, the corresponding H-bond distributions of the isomers with the four channel domains, suggests a 
more sideward directed positioning for the more inactive isomers (Table 5). 
 
More precisely considering the native isomer 2 typical binding mode and the prerequisites for efficient pore 
blockages, the toxin’s arginine (and other basic) residues play a key role. In the case of native isomer 2, they 
centrally immerse into the channel pore and simultaneously establish a fixation of the bound conformation by 
hydrogen bond contacts to the more outer located pore loops (Figure 23a). The coincident presence of pore-
diving and surface contacts possibly leads to a stabilizing position of the toxin on the channel. Further, these 
contact formations may allow the toxin to span over the central pore on the one hand and to establish additional 
interactions with the selectivity filter region on the other hand. The basic toxin residues predominantly interact 
with acidic channel residues that are located in particular on the pore loops and are represented by the amino 
acids Asp (D) and Glu (E) within the known "DEKA" motif of the selectivity filter. In the case of native µ-PIIIA, 
the apparently neutralizing influence of Arg14 on the native acidic pore residues (such as Glu758), which serve 
to increase the effective Na+ concentration at the outer pore mouth, is particularly noteworthy. 
 
Another feature supporting efficient pore block by µ-conotoxins is their particular intrinsic topology of cysteine 
disulfide bridging which can facilitate the formation of compact globular toxin structures. 
Upon inspection of each isomer’s structre (Figure 19) under consideration of the respective block efficacies 
(Figure 20), the limitation of disulfide bridge combinations showing potent inhibitory effects on NaV1.4 to a 
subset among all bridging patterns clearly shows up. This is not least due to the rigidity of the toxins or parts 
thereof, which follows directly from their disulfide bridging pattern. Here it becomes clear that those patterns 
of disulfide connectivity which result in lower toxin (backbone) flexibility, i.e. higher rigidity and thus in a more 
globular toxin structure rather promote an increased rate of pore block of the toxin.  
In contrast, previous modelling studies on μ-PIIIA do exist,215 in which not a certain and fixed toxin 
constellation, but several conformations for the binding and blocking of the pore centre are suggested. However, 
these findings are to be considered from the point of view of differing prerequisites, i.e. the missing loop areas 
in the study-related NaV1.4 models used. This can explain why the contacts to the outside area have not yet 
been discovered in those studies, but have turned out to be important anchor points for enabling the covering 
toxin span across the central pore area in our proposed models. 
 
However, the connection between disulfide topologies and (segmental) toxin flexibilities and the impact on their 
bioactivities underpins the necessary consideration of flexibility aspects for a reasonable explanation of the 
blocking potencies on a virtual level. In these respects, it would be especially important to complement the 
docked representations by further simulation experiments which would allow for a full interpretation of the 
docked images. 
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4.4. In silico analysis of the subtype-selective block of KCNA ion channels through the μ-
conotoxins PIIIA, SIIIA and GIIIA 
 
As previously outlined the understanding of subtype specificity in the ion channel blockage by peptide-based 
toxins is crucial for developing such compounds into promising drug candidates.6 In this context, knowledge of 
which conotoxins are active on which channel subtypes and which are inactive is beneficial. However, the 
number of addressed channels can widely vary: μ-GIIIA, for instance, exclusively inhibits the skeletal muscle 
voltage-gated sodium channel NaV1.4, whereas μ-PIIIA and μ-SIIIA additionally block the neuronal sodium 
channels NaV1.2 and NaV1.7 (Table 3).6, 7 Furthermore, μ-PIIIA and μ-SIIIA were recently shown to not be 
exclusively specific for NaV channels.6, 7, 57-59  
More precisely, Leipold and co-workers were able to prove that μ-PIIIA and μ-SIIIA are inactive on the 
potassium channel subtypes KV1.2 to KV1.5 and also on KV2.1, while however μ-SIIIA at least partially inhibited 
KV1.1 and KV1.6 and μ-PIIIA even blocked both, the KV1.1 and KV1.6 subtypes, revealing a nanomolar affinity 
(Figure 25b, Table 3).6, 7 Additional evaluations on constructed chimeric channels obtained from KV1.5 and 
KV1.6 yielded the inclusion of pore regions into the channel block by µ-PIIIA whereby the subtype-specific 
interactions are mainly determinded by the so-called turret domain (P1 outer loop, Figure 25a) and partly by 
the sequence close to the selectivity filter (P2 inner loop, Figure 25a).6, 7 
 
 
Figure 25: (a) Aligned amino acid sequences of the central, toxin-interacting channel region shown for one subunit of the 
KV1 family (KV1.1– KV1.6), KV2.1, and of the chimeric channels KV1.6-5P2 and KV1.6-5P1, which were all tested against μ-
PIIIA, μ-SIIIA, and/or μ-GIIIA, respectively, by Leipold et al.7 Amino acids are coloured according to their 
   58 
physicochemical properties (basic – light blue, acidic – magenta, polar/neutral – green, non-polar polar/hydrophobic – 
orange). The secondary structure elements are indicated above the alignment. (b) Activity rates [%] of μ-PIIIA, μ-SIIIA, 
and μ-GIIIA on potassium channels KV1.1–KV1.6, KV2.1, and KV1.5–KV1.6 chimera channels, as published by Leipold et al.7 
Lower percentage values of Iremaining correspond to higher blocking activities. (Illustration modified from Kaufmann et al.6) 
 
Further exapmples outlining the obscure venom specificity on KV1 channel subtypes are given by a research 
study of the Iranian scorpion toxin OdK1 showing its selective inhibitory effects on KV1.2 channels but 
ineffectiveness on KV1.3, KV1.4 and KV1.5216 and a further work on scorpion Hemitoxin which selectively blocks 
the rat KV1.1, KV1.2, but also KV1.3 channels.217  
 
Unfortunately, the analgesic potential of μ-conotoxins is clearly limited by such special behaviors.6 Despite these 
disappointing findings, the high number of well-resolved potassium channel crystal structures present these 
days would certainly allow for deep and detailed in silico analyses of the binding of µ-conotoxins to KV channels.6 
In addition, the experimental data provided by Leipold and his team could enable us to clarify the question of 
how toxins attain their subtype specificity at a much higher qualitative level than it would be currently possible 
for µ-conotoxin binding on NaV channels.6 
 
Thus, in this section we will show on how powerful state-of-the-art in silico approaches can be used to unravel 
the subtype-specific inhibition of potassium channels by μ-conotoxins. Since an adequate understanding of the 
observed bioactivity differences of the toxins on the particular channels is only provided when dynamic 
information is taken into account, molecular dynamics simulations were performed in addition to docking 
experiments in order to elucidate the distinct specificities.6 (A summarizing workflow scheme is given in Figure 
26.) We particularly addressed the three conotoxins μ-PIIIA, μ-SIIIA and μ-GIIIA in combination with 
different representatives of the KV1 voltage-gated potassium channel family and artificially created chimeric 
channels. Correlations of conformational flexibilities and the experimental activities as recently reported by 
Leipold et al.7 could be determined. In this context and for reasons of comparison, µ-SIIIA was investigated as 
a partially channel blocking semi-active system, while µ-GIIIA was investigated as an inactive candidate. In 
particular, the different pore blocking modes – full or partial pore coverage – were of special interest, and were 
intended to achieve more insight into the origin of the remaining currents, especially observable for semi-active 
systems.6 
 
In detail, our dataset of  consideration was set up as follows: in silico investigations were performed respectively 
on μ-PIIIA, μ-SIIIA and μ-GIIIA on virtual models of  the KV1-channel subtypes KV1.1, KV1.5, KV1.6 and two 
further artificially constructed KV1.6/1.5 chimera channels. The chimeric channels are further designated as 
“KV1.6-5P1”, having exchanged the outer P1 loop of  KV1.6 by the KV1.5 P1 loop, and as “KV1.6-5P2”, having 
exchanged the inner P2 loop of  KV1.6 by the inner P2 loop of  KV1.5, respectively (see Figure 25a). More 
precisely, we studied μ-PIIIA on KV1.1, KV1.5 and KV1.6 as well as on the chimera channels KV1.6-5P1 and 
KV1.6-5P2, while μ-SIIIA- and μ-GIIIA-binding was analyzed on KV1.6, respectively, in order to decipher 
subtype-specific features with respect to progressive alterations from the perspective of  the targeted channel as 
well as with respect to the toxin applied. We thus also made sure to cover at least one case of  active, semi-active 
and inactive representative among our data set of  investigated systems. 
Especially, different pore blocking modes, ranging from partial to full pore coverage (named active systems 
thereafter), were of particular interest as being intended to provide insights into the origin of the remaining 
currents that are observable for the partly blocked ion channel pores (named semi-active systems thereafter).6 
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Figure 26: Workflow overview showing the docking outputs being subjected to subsequent MD calculations. 
 
 
4.4.1. Homology modelling 
 
In a fist step a homology model of the KV1.6 potassium channel was created. Starting from the KV1.6 model, the 
model structures for KV1.1 and KV1.5 as well as the chimera channels “KV1.6-5P1” and “KV1.6-5P2” were 
reconstructed.6 The loop segments of the particular models were respectively substituted according to the 
sequences as shown in Figure 25a, while maintaining the backbone secondary structure.6 For more information 
on the modelling process please refer to chapter 5.5 in the methods section. Finally, all models were energy-
minimized for further use.6 The voltage-sensor domains KV1 channel models were omitted in the further steps, 
as they are not involved in the µ-conotoxin binding area focused in this work.6 
 
 
4.4.2. HADDOCK docking  
 
In order to obtain an adequate starting point for our simulations, we first performed HADDOCK docking using 
the toxin NMR structures applied on our homology models of the target channels.6 The homology modelling 
and docking processes are described in more detail in the methods section (chapters 5.5 and 5.6). 
 
On the basis of the user-specified active and passive residues, the HADDOCK algorithm generates a set of so-
called Ambiguous Interaction Restraints (AIRs).218 Those restraints are meant to drive the docking by 
incorporation of experimental information – just in a similar manner as ambiguous distance restraints based on 
NOE data that drive the structural calculation of an NMR structure (see e.g. 219).218 
In HADDOCK, for every active-set residue, a single AIR restraint is defined between that residue and all active 
and passive residues on the partner molecule.218 The docking process then models and predicts the three-
dimensional conformation of the complex based on the known single constituents in their free, unbound form218 
and under consideration of the predefined restraints. The ideal positioning of the ligand molecule into the target 
however describes a local minimum state in most cases. 
 
Re-scoring of the best scoring HADDOCK clusters using VINA Autodock scoring function yielded binding 
energy values of noticeably high correlation regarding the toxin activity rates reported by Leipold et al.7 (Table 
6),6 further encouraging our decision to take these docked conformations as starting structures for subsequent 
equilibration simulations.220 
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Table 6: Scoring summary for the best scoring μ-conotoxin-channel systems as obtained from HADDOCK docking218 and 
Vina re-scoring220 calculations; assigned blockage activity levels as reported by Leipold et al.7 are given. (Table source: 
Kaufmann et al.6) 
 
  HADDOCK 
Z-score 
HADDOCK 
score 
Vina score 
[kcal/mol] 
μ-PIIIA on Kv1.6 active -1.0 174.3 ± 8.7 10.5 
μ-PIIIA on Kv1.1 active -1.4 202.1 ± 5.9 9.5 
μ-PIIIA on Kv1.6-5P1 semi-active -1.4 178.2 ± 14.0 9.7 
μ-PIIIA on Kv1.6-5P2 semi-active -0.9 196.0 ± 12.7 10.0 
μ-SIIIA on Kv1.6 semi-active -1.3 231.1 ± 14.7 10.2 
μ-PIIIA on Kv1.5 inactive -1.6 202.6 ± 10.5 8.5 
μ-GIIIA on Kv1.6 inactive -1.7 187.1 ± 14.0 8.0 
 
 
4.4.3. Toxin dynamics and cluster analysis 
 
Since all docked toxin structures were centred in the middle of the pore (Figure 27), which complicated the 
interpretation of their bioactivity, the best scoring docked structures were equilibrated through molecular 
dynamic simulations in a membrane environment for 0.5 to 1.0 µs (for more information considering the MD 
experiments see chapter 5.7 in the methods section).6 Such subsequent MD simulation applications will take any 
kind of residue contacts into account and equilibrate the whole system without wrongly omitting any potential 
interactions. At this point it should briefly be mentioned that MD equilibrations are to be considered as ensuing 
refining step, anyway “filtering” essential contacts from the false-positive ones, eventually being present in the 
initial state.  
The simulations thus aimed to provide more accurate descriptions of the toxin binding and dynamics when 
bound to a target channel, especially since the toxins did not only show a full pore block, but also partly blocked 
ion-channel pores.6, 7 At this point, it has to be noted that the corresponding docking results and simulation data 
of inactive systems (toxins which do not block the pore) might be difficult to construe.6 Nevertheless, these data 
were also shown and analyzed for the sake of comparisons and completeness.6 
 
 
Molecular dynamics simulations as a complementary measure to docking experiments 
 
To attain more detailed descriptions of protein-ligand binding, dynamic information of such systems is of utmost 
importance, especially in the sense of completing the imagination of a rigid docked representation of an 
interacting target-ligand complex. In particular, meaningful target-ligand constellations which differ from the 
docked start position can occur, that would not have been recognizable or predictable by simple docking studies.  
 
This can already be recognized by comparison of the docked initial structures with the calculated average 
structures from the respective simulations, revealing a toxin displacement over time and the corresponding 
direction of movement (Figure 27). The different degrees of deviation from the initial state further lead to the 
assumption that varying rates of bioactivities can be mirrored by their corresponding dynamics. In this sense, a 
stronger deviation from the initial state generally indicates a higher detachment from the pore surface and thus 
suggests more inactivity. 
 
We thus aimed to gain more informative states beyond the docked starting structure by trapping the systems 
in an energetically favourable local minima, i.e. equilibrated states. Based on the occurrence of such states we 
aspire to figure out essential residue contacts and structural features ultimately accounting for subtype-specific 
recognition events. Such crucial contacts can hardly be determined from a rigid state alone and without any 
supporting dynamic data.  
 
We anyhow consider the docked states proposed as appropriate starting point from which inferences about 
further blocking or unbinding events can be drawn by subsequent MD calculations. 
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Figure 27: System-wise comparison of start and average simulation structure. Toxin-channel systems are shown in 3D 
secondary structure representation with docked toxin starting structure and superimposed simulation average structure. 
Colour scheme: start toxin structure – yellow, simulation average toxin structure – cyan, channels – gray. The respective 
toxin RMSD values are indicated below each system. The systems are arranged according to their activity level (active – 
top, semi-active – middle, inactive - bottom) and are respectively shown from above (left) and from the side (right). Subunits 
are designated by Roman numerals (red, SI – SIV). 
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Cluster analysis 
 
Figure 31 illustrates the system-varying dynamics using representative structures of  calculated simulation data 
clusters, each of  which differs by 4Å RMSD over the total simulation run (Figure 28). At the same time, the 
start structure of  the docked state is shown for each system. According to our simulation data, less active 
systems (exhibiting less pore coverage) show higher toxin dynamics, i.e. a higher number of  representative 
cluster structures, while semi-active or active systems show lower toxin dynamics by less cluster representatives, 
i.e. an overall higher stability (Figure 31).6 For all systems, structural deviations from the initial docked state 
were observed (Figure 27, Figure 28, Figure 31). Here we could identify the toxin as the main moving part in 
a channel-toxin system by further comparison of  the complete systems’ Cα root mean square deviation (RMSD, 
data not shown) and the toxin Cα RMSDs, revealing negligible variations. 
 
Moreover, toxin  dynamics are equally reflected by the toxins’ Cα RMSD over time, altogether showing higher 
deviations for more flexible (inactive) toxin-channel complexes and less deviations for better pore blocking 
systems (more active) (Figure 28, Figure 31). As the simulations were performed until a nearly linear behavior 
of the RMSDs was achieved, simulation times varying between 0.5 and 1.0 µs were reached.6  
 
Altogether, dynamics analyses suggested a unique, stable channel blocking mode, while revealing a more diverse 
behavior for semi- and in-active systems (Figure 28, Figure 31).6 In this context it is noticeable, that active 
representative systems μ-PIIIA on KV1.6 and KV1.1 show a very similar course development over the whole 
simulation time, indicating their tightly bound condition, whereas semi- and inactive systems exhibit differences 
in these respects (Figure 28). These findings substantiate the uniqueness of subtype-specific active channel 
blockage.6 
 
On the other hand, recurring movement patterns in semi- and inactive systems allow us for a further 
classification or differentiation within these systems. More precisely, two different binding modes respectively 
describable for semi- and inactive systems: in the semi-active systems, one group is built by the less fluctuating 
and more stable systems μ-PIIIA on KV1.6-5P1 and μ-SIIIA on KV1.6 and another, more dynamic and less stable 
one only represented by μ-PIIIA on  KV1.6-5P2 (Figure 28).6  
 
Likewise, two different modes of toxin movement were identified for the two inactive toxin-channel systems. 
For KV1.5-bound µ-PIIIA, the toxin displacement occurred more gradually, whereas for μ-GIIIA, it was moving 
more rapidly on the channel surface (Figure 28, Figure 31).6 
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Figure 28:  Toxin Cα RMSD over the whole simulation. Toxin RMSD traces up to 1 μs for semi-active systems μ-PIIIA 
on KV1.6-5P1, μ-PIIIA on KV1.6-5P2 and for the inactive system μ-PIIIA on KV1.5. Arrows indicate simulation times at 
which our representative simulation structures were selected for subsequent analyses. (Illustration modified from 
Kaufmann et al.6) 
 
Closer inspection of  the toxin movements with respect to the four channel subunits (Figure 29, Figure 30) 
further supported the stated differences within the semi- and inactive systems: Cα RMSD traces of  μ-PIIIA on 
KV1.6-5P2 (semi-active) and μ-GIIIA on KV1.6 (inactive) clearly unveils a toxin movement towards the side of  
a channel subunit, in contrast to the other semi- or inactive systems (Figure 29, Figure 30).6 More specifically, 
μ-PIIIA on KV1.6-5P2 and μ-GIIIA on KV1.6 both move towards the channels’ P1 outer loop of  subunit II (SII) 
and coincidently away from the P1 loop of  the opposite located subunit I (SI) (Figure 29, Figure 30).6 For the 
case of  μ-PIIIA on KV1.6-5P2 this drift away seem to be triggered by the Y429R mutation in the P2 loop that 
is closely located to the selectivity filter.6 This would entail a reduced covering or blockage of  the pore.6 μ-PIIIA 
thus moves towards the outer P1 loops of  KV1.6-5P2 subunits SII and SIII and at the same time away from the 
opposite SI and SIV outer and inner loops (Figure 29, Figure 30).6 μ-GIIIA moves towards SII and SIV of  
KV1.6 and at coincidently drifts away from the SI and SIII loops (Figure 29, Figure 30). 
In contrast, semi-active systems μ-PIIIA KV1.6-5P1 and μ-SIIIA KV1.6 and the inactive μ-PIIIA KV1.5 system 
do not show toxin displacements towards any subunit.6 Rather, similar to the active μ-PIIIA KV1.1 and KV1.6 
systems, a more center-positioned state of  the on the pore is maintained (Figure 27, Figure 28, Figure 29, 
Figure 30).6  
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Figure 29: Cα RMSD traces showing the movement, i.e. changing distance of the toxin mass centre with respect to the 
outer loops (P1) of the individual channel subunits (P1 outer loops – light green, P2 inner loops – light yellow). (Illustration 
modified from Kaufmann et al.6) 
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Figure 30: Cα RMSD traces showing the movement, i.e. changing distance of the toxin mass centre with respect to the 
inner loops (P2) of the individual channel subunits (P1 outer loops – light green, P2 inner loops – light yellow). (Illustration 
modified from Kaufmann et al.6) 
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These differences within semi- and inactive systems with regard to the movement direction of  the toxins allow 
for a general differentiation between toxin movement modes where the toxin either stays central with respect 
to the channel pore – hereinafter referred to as “centrally located” mode (a) – and systems where the toxin moves 
towards the outside of  a channel moiety – hereinafter referred to as “side-directed”  mode (b). As for the two 
considered active systems μ-PIIIA on KV1.1 and μ-PIIIA on KV1.6 there were no such movement differences 
observable, we assume a unique binding mode for active potassium channel blockage by μ-PIIIA. It can further 
be noted that the movement of  μ-PIIIA on KV1.6-5P2 towards a subunit moiety is reasonable because of  
mutations in the central inner P2 loops triggering the toxin to drift away from the center to the outside (Figure 
25a).  
 
Apart from the RMSD analyses, the intrinsic higher flexibilities exhibited by toxin-channel systems with a toxin 
moves away from a central starting position was quite obvious, as also extracted from the simulations per atom 
b-factors (Figure 31, Figure 32).6 (Here, it should be considered that the docked start position is already central 
by default, as far as the pore is concerned.) Further examinations of the different simulation cluster 
representatives (Figure 31) equally confirm this observation, pointing out a higher number of cluster 
representatives for the more flexible side-directed systems and a lower number of cluster representatives for 
centrally equilibrated systems (Figure 31, Figure 32). Movement patterns can thus be directly correlated with 
the overall dynamics and flexibility of the toxin. Additionally, the equal numbers of resulting cluster 
representatives for μ-PIIIA on KV1.1 and KV1.6 confirm our abovementioned proposal of a unique binding mode 
for active systems (Figure 31).6 
 
 
 
 
   67 
Figure 31: Toxin dynamics as cluster representatives. Toxin-channel systems are shown in secondary structure 
representation. The identified main simulation clusters are designated by respective 3D structures (4 Å toxin RMSD 
threshold) for active (top), semi-active (middle) and inactive (bottom) systems. The total numbers of identified clusters are 
given below each toxin-channel system. The colour scheme was set as follows: toxins: μ-PIIIA on KV1.6 – red, μ-PIIIA on 
KV1.1 – violet, μ-PIIIA on KV1.6-5P1 – dark orange, μ-PIIIA on KV1.6-5P2 – yellow green, μ-SIIIA on KV1.6 – dark yellow, 
μ-PIIIA on KV1.5 – dark green, μ-GIIIA on KV1.6 – cyan, docked toxin start structures – light yellow; channels: P1 outer 
loops – dark blue, P2 inner loops – light blue, KV1.6/5 differing channel mutations – orange, KV1.6/1 differing channel 
mutations – green, remaining channel – gray. Channel subunits are designated by Roman numerals (red, SI – SIV). 
(Illustration modified from Kaufmann  et al.6) 
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Figure 32: b-Factor coloring of the interacting toxin and channel residues (flexible – yellow, rigid – blue); the toxin is 
shown partly in molecular surface (interacting residues) and in secondary structure representation (remaining residues) in 
the top view and in complete molecular surface representation in the side view; interacting channel residues are shown as 
ball and sticks; remaining channel is shown as secondary structure (gray); the displayed structures are energy-minimized 
and depict the selected representative snapshots from the simulation data; channel subunits are indicated by Roman 
numerals (red, SI – SIV). (Illustration modified from Kaufmann et al.6) 
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Nevertheless, one may ask why, in comparison to the active systems μ-PIIIA-KV1.6/KV1.1, the semi-active 
systems μ-SIIIA-KV1.6 and μ-PIIIA-KV1.6-5P1 show a similar low overall fluctuation, suggesting even better 
binding stabilities pretended by the lower number of calculated cluster representatives over the whole 
simulation (Figure 28, Figure 31).  
 
However, whereas μ-PIIIA on KV1.6 and KV1.1 both exhibit a more pronounced pore coverage, forming contacts 
that are equally distributed towards all four channel subunits, the toxins in μ-SIIIA-KV1.6 and μ-PIIIA-KV1.6-
5P1 seem to be more compressed by a higher number of contacts towards the centre of the pore (Figure 32).  
In the case of μ-PIIIA-KV1.6-5P1, this effect was certainly caused by the mutations in the outer loop. 
Concurrently, when the P2 loop of KV1.6 was replaced by the corresponding part of the toxin insensitive KV1.5 
channel, an even more lateral orientation of the toxin can be noticed, presumably being triggered by the newly 
inserted positively charged Arg429 (Figure 27, Figure 32).6 
 
Altogether, the experimental activities could be rationalized from the simulation data, even though one would 
expect somehow higher flexibilities or dynamics for μ-SIIIA-KV1.6 and μ-PIIIA-KV1.6-5P1 in order to 
understand the remaining currents for these semi-active systems.6  
 
Most likely, the rather short simulation times (up to 1 µs) were insufficient to fully unveil all critical pore blocking 
determinants.6 This was especially true for the binding of  μ-PIIIA towards the toxin insensitive channel KV1.5.6 
Here, one would expect no binding, or at least a relatively fast toxin detachment movement, as observable for 
the case μ-GIIIA on KV1.6.6 Despite unbinding events were not observed even during our extended 1 µs 
simulation, μ-PIIIA remained only bound to the center of  the KV1.5 pore, only showing very poor contact 
towards the pore surface, being clearly different from the situation of  toxin binding at the active and semi-active 
systems, indicating that μ-PIIIA was about to dissociate from the pore soon.6 
 
For subsequent analyses however, we stick on the assumption that a stable and (partially) blocking conformation 
can be observed within a simulation period where the system is in a steady and energetically favorable state that 
has stabilized over time. Our further examinations will therefore be focused on the corresponding interactions 
between toxin and channel arising at such equilibria.6 These are thought to hold the toxin in a specific 
positioning on the channel and thus to stabilize the different orientations on the pore.6 It seems to be 
straightforward to conclude the level of pore coverage or blockage from the interactions of the toxin with the 
channel surface.6 The adopted toxin positioning on the pore will therefore influence the channel’s overall 
permeability. The identification of such representative states thus forms an essential basis for the further 
detection of key interactions responsible for the resulting toxin positions and the blocking activities.  
 
For the identification of such system-wise representative snapshots, we developed and applied a selection 
protocol,6 which is supposed to filter out predominantly assumed system states or modes. For this purpose, we 
have used two automated clustering methods in combination, each finding a stable main cluster and forming the 
intersection (or union) of both results (for more details see chapter 5.8 in the methods section). The selection 
protocol respectively parses a periodically pre-filtered subset of eleven simulation snapshots (in the interval 
from 0ns up until 500ns, spaced at 50ns).6  
 
Further, our clustering computations drastically reduced the amount of data to be parsed and hence also brought 
a lot of savings in computing time. We count on this approach based on the presumption that a stable, 
equilibrated state can be represented as a cluster of maximum size out of the eleven pre-selected snapshots and 
– consequently – a representative snapshot candidate is probably present in this main stable cluster. At the same 
time we took into account the distances of the individual cluster members to the average simulation structure, 
ensuring a smallest possible RMSD of a representative candidate to the average.  
 
In addition, we included the observation of principal detachments towards a subunit side for the semi-active 
system μ-PIIIA on KV1.6-5P2 and μ-GIIIA on KV1.6; these sidewards-drifting systems are further differentiable 
by the different points in time of toxin detachment. To take this into consideration, we included a final revising 
step to check the instances falling under category semi-active and side-directed mode (b) and adapted our 
selection methodology accordingly. For more information see methods section, chapter 5.8. 
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For μ-PIIIA on KV1.6-5P2 in particular, our latest checks resulted in a further revised final representative 
replacing the first proposed representative snapshot at 200ns by snapshot at 450ns of the latest simulation 
quarter (Table 7). All other result snapshots of our selection procedure are given in Table 7 based on their 
simulation times (including intermediate steps of the selection procedure). For details regarding the partial 
results, please also refer to chapter 5.8 in the methods section. 
 
Immediately noticeable, the identic main clusters are detected by clustering method 1 and 2 for the active system 
μ-PIIIA on KV1.6 (Table 7, 1st row, 2nd and 4th column), actually considerable as a number-based confirmation 
of  the stability and specificity the unique active blocking mode entails. The conclusiveness of  our methodical 
approach can also be confirmed by looking at the corresponding results of  μ-GIIIA on KV1.6, which show almost 
the opposite in this respect (Table 7, last row, 2nd and 4th column), demonstrating the high fluctuation and 
instability of  the inactive system.  
  
Further to be noted is the constant decrease of  the main clusters’ sizes obtained from both clustering methods, 
considered over the entire activity levels and starting from the active systems. (This also includes the total 
number of  clusters detected by method 2.) Thus matching the performed clustering calculations shown in 
Figure 31, the systems’ different flexibilities were also adequately reflected with our own method. 
 
For more detailed information on the intermediate clustering results please refer to Table 12 – Table 14 in the 
methods section. 
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Table 7: Cluster result summary showing intermediate and final resutls of our clustering selection protocol (chapter 5.8); 
main cluster obtained by cluster analysis 2 is highlighted yellow (4th row). (Table adapted from Kaufmann et al.6) 
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Altogether, our systematized selection protocol constitutes a useful addition for further interaction analyses 
since arbitrariness for the determination of representative states out of large volume of data is restricted by a 
profound and computationally underpinned method which combines two different clustering approaches and a 
final revising step.6 In addition, our implemented selection procedure could mirror the systems’ differing 
flexibilities similarly to the independent clustering analysis applied previously (Figure 31).6 This is reflected in 
the comparable distribution of  the respective resulting numbers of  clusters that equally correlate with the 
flexibilities of  the particular systems (Table 7, Figure 31).   
 
As will finally be seen, our selected snapshots further confirm the presumed binding modes, subdivided into to 
central (a) and side-directed systems (b), coupled with the activity levels. Appropriate RMSD values, indicating 
the distance from the docked starting structure also substantiates this subdivision, revealing larger distance 
from the respective starting position for sideward moving systems (b) and generally smaller movement distances 
for toxins which remain in a central position on the channel pore (a) (Table 8).  
Table 8: RMSD of finally selected representative snapshots to the corresponding docked structure used as start for MD 
calculations (Table adapted from Kaufmann et al.6) 
 
mode of activity selected snapshot 
at time [ns] 
RMSD from start 
[Å] 
µ-PIIIA on Kv1.6 at 200ns  active (unique) 200 6.066 
µ-PIIIA on Kv1.1 at 400ns active (unique) 400 6.077 
µ-PIIIA on Kv1.6-5P1 at 250ns semi-active (a) 250 4.462 
µ-SIIIA on Kv1.6 at 250ns  semi-active (a) 250 4.652 
µ-PIIIA on Kv1.6-5P2 at 450ns semi-active (b) 450 10.064 
µ-PIIIA on Kv1.5 at 150ns inactive (a) 150 8.914 
µ-GIIIA on Kv1.6 at 400ns inactive (b) 400 17.471 
 
 
Analysis of ion channel-toxin interactions 
 
As previously outlined the extent of the channel blockage is a direct consequence of the different adopted toxin 
orientations on the pore, motivating further investigations on the corresponding interactions arising in 
equilibrated states.6 In particular, we aim to focus on emerging key interactions which are able to stabilize the 
toxin on a specific place on the channel and thus allow for either more or less blocking conformations.6 
 
Figure 34 shows the chosen representative snapshots as energy-minimized 3D structures resulting from our 
cluster-analysis. It provides a preliminary indication of the correlation between the extent of overall channel 
blockage, structural characteristics and the toxin positioning on the pore which is stabilized by the related 
interactions.6  
 
In the following sections we will provide a detailed describtion of the toxin-channel interactions and resulting 
structural properties that occur in the representative constellations.  
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μ-PIIIA on Kv1.1/6 – a symmetric core motif accounts for a unique binding mode 
 
Structural superposition of  both representative structures reveals a very similar conformation of  μ-PIIIA on 
KV1.6 and on KV1.1, confirming the uniqueness of  the active μ-PIIIA blocking mode on the potassium channels 
(Figure 33, Figure 34a).6 This emerges as a pore-protruding and simultaneously channel covering situation, 
which is made possible by the central toxin positioning and coincident contacts to outer and inner pore loops 
(Figure 33, Figure 34a, Figure 37). 
 
 
 
Figure 33: Superposed representative bound states of μ-PIIIA on KV1.1 (purple) and on KV1.6 (red) in top and side view. 
 
This highly specific blocking mode is primarily stabilized by central toxin residues that evenly address at least 
three of the four channel subunits (Figure 34a) through an intensive hydrogen bond pattern.6 In the case of μ-
PIIIA bound to KV1.6 the blocking constellation is further strengthened by the N-terminal Arg2 of μ-PIIIA 
that forms hydrogen bonds towards residues from the inner P2 loops of the KV1.6 subunit I (SI) (Figure 34a).6 
In case of μ-PIIIA on KV1.6, hydrogen bonds are primarily formed towards the inner (P2) pore loop residues, 
whereas for μ-PIIIA on KV1.1 more residues of the outer (P1) loops are involved in toxin channel interactions 
(Figure 34a).6  
 
In these respects, the central Arg12 and Arg14 seem to be essential for the pore block of  KV1.1 and KV1.6, 
respectively forming hydrogen bonds towards the outer located (P1) loop by either interacting acidic glutamic 
acid (Glu353/SI) in the case of  KV1.1 or aspartic acid (Asp401/SIV) in the case of  KV1.6 (Figure 34a).6 Equally, 
Asp427/SII of  the inner (P2) loop is also addressed in the case of  μ-PIIIA on KV1.6 (Figure 34a).6 Consequently, 
there seem to be no major impact on the physicochemical composition of  the channel surface, when aspartic acid 
(Asp) in KV1.6 is converted to glutamic acid (Glu) in KV1.1 (and also from hydrophobic valine to hydrophobic 
alanine), enabling the similar binding modes for μ-PIIIA on both channels (Figure 25a, Figure 33, Figure 
34a).6 
 
Neutral serine Ser13 which is also located in the centre of the toxin contacts the equally neutral glycine or larger 
tyrosine residues (Gly426/SIV and Tyr429/SIV in KV1.6 and Tyr379/SI in KV1.1) of the inner P2 loops that 
are closely located to the selectivity filter (Figure 34a).6  
Gln15 also appears to be of  relevance for the specific block of  KV1.6 and KV1.1 as well, as it forms hydrogen 
bonds with the inner glycine residues of  the selectivity filter (Gly424/SIII, Gly424/SIV, Gly426/SIII of  KV1.6 
and Gly376/SIV of  KV1.1) (Figure 34a).6 Thus, the pore-protruding orientation of  Gln15 occluding the central 
cavity of  the channel is equally present in both bound states of  µ-PIIIA to KV1.1 and KV1.6 (Figure 34a, Figure 
37). In KV1.6, Gln15 further stabilizes its pore blocking orientation by another hydrogen bond to Tyr429/SII 
(Figure 34a).6 As the cavity addressed by Gln15 is intrinsically located in the centre of  the pore, Gln15 might 
be of  vital importance for the positioning of  µ-PIIIA on the channel.  
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Figure 34: 3D visualization of  the representative binding poses and corresponding hydrogen bond interactions shown for 
(a) active, (b) semi-active and (c) inactive systems. The shown snapshots are energy-minimized and were obtained from 
our clustering calculations. Left panel – top view, middle panel – side view, right panel – table listing the particular 
interactions. Toxin-channel colour scheme is adopted as indicated in Figure 31. Channel subunits are designated by Roman 
numerals (italic gray, SI – SIV). (Illustration modified from Kaufmann et al.6) 
 
In summary, the key interactions are primarily built with neutral residues (tyrosine and/or glycine) of the inner 
P2 loops that reside close to the selectivity filter and coincidently stabilized by hydrogen bonds to glutamic acid 
(for the case of KV1.1) or aspartic acid (for the case of KV1.6) in the P1 loops (Figure 34a).6 The increased number 
of hydrogen bonds of µ-PIIIA towards the P1 outer loop in KV1.1 compared to KV1.6 is mainly due to the 
replacement of aspartic acid of KV1.6 by glutamic acid in KV1.1 at the corresponding positions (Figure 25a, 
Figure 34a).6 For both cases the key binding motif consists of the adjacent residues Arg12, Ser13, Arg14 and 
Gln15, located in the central part of the toxin.6 In the binding mode to KV1.1, the interacting segment of µ-
PIIIA is expanded by the H-bond forming Hyp8, whereasin KV1.6 Arg2 forms an additional stabilizing H-bond 
with the inner P2 loop residues of subunit I (SI) (Figure 34a).  
 
Closer inspection of  the central toxin region reveals that it lies within the α-helical section of  µ-PIIIA whose 
amino acid sequence is composed as alternating symmetric pattern considering the physicochemical amino acid 
properties, primarily consisting of  alternating basic or neutral amino acids, reaching from Hyp8 to Hyp18 
(Figure 35a).6 Thereby, the KV1.1 and KV1.6 binding motif  of  the toxin corresponds to the central K--R-R--K-
like motif  (Figure 35a).6 Interestingly, the µ-SIIIA and µ-GIIIA lack such or a similar symmetric motif  in the 
corresponding central regions, i.e. the regions that are aligned with Hyp8 – Hyp18 of  µ-PIIIA (Figure 35a).6 
However, at least µ-GIIIA features a remotely similar motif  KK-K-R--K at corresponding positions (Figure 
35a),6 but obviously not sufficient to block KV1.6 or KV1.1. Hence, as this distinct sequence pattern is exclusively 
carried by µ-PIIIA, it can be hypothesized that it is preserved by evolution as specific feature and may provide 
an explanation for the high µ-PIIIA specificity towards KV1.1 and KV1.6.  
 
Further investigations of  the central segment yielded that especially its densely packed helical conformation 
contributes to the pore-blocking position. Apparently, the α-helical central structure ensures (in the bound state) 
that the positively charged residues are directed towards the channel surface (Figure 34a, Figure 35b).6 
Compared to µ-SIIIA and µ-GIIIA that lack the corresponding sequence and structural characteristics, the 
affected residues are uniformly oriented and are not buried or hidden by the non-helical fold of  the toxin (Figure 
35b).6 We assume that these features further strengthen the KV1.1- or KV1.6-bound state of  µ-PIIIA by 
stabilizing the pore-blocking position of  the interacting residues.6 For both cases however, KV1.1 and KV1.6, a 
horizontal, crosswise direction of  the central symmetric toxin region (Hyp8 – Hyp18) parallel to the pore 
surface is enabled, supporting the overall coverage of  the pore (Figure 35).  
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Figure 35: (a) Alignment of the µ-conotoxins µ-GIIIA, µ-SIIIA and µ-PIIIA. Residues are coloured by their 
physicochemical properties (acidic – purple, basic – cyan, nonpolar/hydrophobic – orange, polar/neutral – green). The 
“symmetric” µ-PIIIA centre is given below the alignment, highlighting the central interacting motif of µ-PIIIA in yellow. 
(b) KV channel-bound toxin structures of µ-PIIIA (superposition of all docked structures), µ-SIIIA and µ-GIIIA after 
HADDOCK docking. (Image source: Kaufmann et al.6)  
 
A similar constitution of  a straight toxin centre, horizontally located on the pore with simultaneous pore-diving 
contacts cannot be found in semi- and inactive systems (Figure 37), again underpinning the uniqueness of  the 
µ-PIIIA blocking mode towards KV1.1 and KV1.66 and the presence of  both of  these attributes as a premise for 
achieving effective pore blockage. 
 
The “kinked” deformation of  the overall central segment (Hyp8 – Hyp18 corresponding residues), i.e. being not 
“in line” with the motif-corresponding segment (Arg12 – Gln15), either results in a mere pore protruding state 
of  the core residues or in a crosswise positioning onto a channel moiety, such as can be seen for semi-active and 
inactive systems (Figure 37).6 The overall pore coverage is thus significantly reduced.6 For µ-GIIIA even the 
whole toxin centre remains completely flexible, impeding any blockage or binding event (Figure 32).  
 
However, a general tendency of  the toxins to maintain a more rigid and stable central part can be observed for 
all systems, which especially becomes evident when analyzing the per residue RMSFs, i.e. their flexibility over 
the toxin sequence when bound to the channel (Figure 32, Figure 37).6 In particular the symmetric toxin centre 
exhibits the lowest fluctuation rates for µ-PIIIA on KV1.1 and on KV1.6 being located in the global minimum 
area regarding the complete toxin sequences (Figure 37).6 
 
On this basis one can also conclude for the other systems and in general that not the quantity of  the interactions, 
but their "quality", i.e. their stability and rigidity, but also the provoked toxin positioning, essentially constitutes 
the extent of  a blocking event (Figure 32, Figure 34).  
 
   77 
 
 
Figure 36: Per residue RMSF summary of the toxins shown per simulation (a) according to the toxin alignment as shown 
in Figure 35a, (b) for simulation μ-SIIIA on KV1.6 – yellow, (c) for μ-PIIIA simulations (on KV1.6 – red, on KV1.1 – purple, 
on KV1.6-5P1 – orange, on KV1.6-5P2 – yellow-green, on KV1.5 – dark green) and (d) for μ-GIIIA on KV1.5 – cyan. (Image 
source: Kaufmann et al.6) 
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Figure 37: Overview of the channel bound toxin states regarding the orientation of the symmetric toxin centre for active 
(top), semi-active (middle) and inactive systems (bottom). The representative snapshots are shown in secondary structure 
representation (channels are coloured grey, residues which account for the µ-PIIIA core motif Arg12 – Gln15 are shown 
as yellow sticks, together with their molecular surface (transparent light green). Dashed lines indicate the overall channel 
coverage by the (binding) motif-corresponding core. The motif’s surrounding area, corresponding to the symmetric µ-
PIIIA central segment Hyp8–Hyp18 (see Figure 35a), is coloured dark blue, and the remaining toxin endings are coloured 
correspondingly to their individual systems (µ-PIIIA on KV1.6 – red, µ-PIIIA on KV1.1 – violet, µ-PIIIA on KV1.6-5P1 – 
dark orange, µ-PIIIA on KV1.6-5P2 – light green, µ-SIIIA on KV1.6 – sun-yellow, µ-PIIIA on KV1.5 dark green, µ-GIIIA 
on KV1.6 – cyan). Delineated arrows indicate the orientations of the correspondingly coloured toxin centre regions with 
respect to the channel surface. Channel subunits are indicated by Roman numerals (red, SI—SIV). (Illustration modified 
from: Kaufmann et al.6) 
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Our observations considering the significance and structure of  the symmetric toxin centre within μ-PIIIA and 
its positioning regarding channel blockage events are further supported by mutagenesis and molecular dynamics 
simulation data published by Chen et al.200, 221 that point out the highest significance of  Arg12, Arg14, Lys17 
and Arg20 for μ-PIIIA in the blockage of  NaV1.4.6 Three out of  these four (Arg12, Arg14 and Lys17) account 
for our stated the symmetric motif  (Figure 35a) whereby the two residues Arg12 and Arg14 have also been 
found by our representative interaction analysis to form key players considering the blockage of  KV1.1 and KV1.6 
(Figure 34a, Figure 35a).  
 
A further study suggests that Lys9 and Arg2 protrude into the NaV1.4 channel pore (beyond Arg14, Arg12, 
Lys17 and Arg20) as concluded from two equally populated binding modes,200 of which Lys9 and Arg2 also rank 
among the key interactive residues for the block of KV1.6 according to our data (Figure 34a, Figure 35, Figure 
38). The striking similaritiy between the related binding poses, comparing the binding towards KV1.1 and a 
proposed pore blocking mode on NaV1.4 (including contacts from Lys9 and Arg14),200 further supports the 
crucial role of the symmetric segment considering the blockage of KV and NaV channels by µ-PIIIA (Figure 
38).6 All these common features and especially the demonstrated significance of the central Arg12 and Arg14 
residues underpin the functional importance of the central toxin segment.6 In this context it is noteworthy that 
only a small part of µ-PIIIA, represented by the four amino acid long centric motif Arg12 – Gln15, seem to be 
sufficient for maintaining a stable blockage and an according suitable toxin positioning on the pore.  
 
 
Figure 38: Comparison of predicted µ-PIIIA binding mode to (a) KV1.1 as revealed in this work and to (b) NaV1.4 (Fig. 
adapted from Chen et al.200). (Illustraion modified from Kaufmann et al.6) 
 
 
µ-PIIIA on Kv1.6-5P1 
 
Even though the case of KV1.6-5P1 the selected snapshot pretends a blocked pore when µ-PIIIA was bound to 
the channel, it was completely lacking the necessary and stabilizing interactions of the µ-PIIIA residues with 
the P1 loops, as they were exchanged with P1 loops of KV1.5 (Figure 25a, Figure 34a and b, Figure 37).6 More 
precisely, aspartic acid and the non-polar/hydrophobic valine and proline residues of the outer P1 loops are 
mutated to polar/neutral amino acids – except from leucine, which is mutated into basic histidine and except for 
the position of serine that remains neutral by a mutation to threonine, none of the physicochemical features from 
the outer KV1.6 loop are maintained (Figure 25a). The outer loop modification into a mainly polar/neutral 
environment obviously triggers a toxin displacement and a coincident toxin deformation that differs from the 
equilibrating binding mode towards KV1.1 or KV1.6 (Figure 25a, Figure 34a and b, Figure 37).6  
 
The resulting binding pose is accompanied with an increase of interactions with the center of the pore (Figure 
34b), similar to the low affinity situation at the toxin-insensitive KV1.5 channel. However, sole contacts to the 
inner P2 loops do not satisfy to reach a complete blocking condition, since the crucial simultaneous contact to 
the P1 loops of the outer channel loops is missing. Rather the symmetric toxin segment in its central part is 
tilted by ~ 90° with respect to the channel surface plane compared to the binding towards KV1.1 and KV1.6 
(Figure 34a and b, Figure 37) resulting in a  partial channel block as observed by Leipold et al.7.6 
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The resulting toxin deformation is also reflected by the lack of contacts from the central Ser13 residue to the 
channel and also the “diving” key contact usually performed by Gln15 which is excluded from any interactions 
with KV1.6-5P1 (Figure 34a and b, Figure 37).6 
 
 
µ-PIIIA on Kv1.6-5P2 
 
When polar/neutral Tyr429 in KV1.6 – or the corresponding Tyr379 of KV1.1 – is mutated into a positively 
charged arginine as for the case of KV1.6-5P2 (Figure 25a), some of the crucial Ser13 and Gln15 interactions as 
observed for the binding on KV1.6 and KV1.1 are eliminated (Figure 34b).6  
Likewise, key residue Arg14 is not involved in the representative interactions, however basic Arg12 forms an 
additional bond to the mutated position of the equally basic Arg429/SII, previously being placed by hydrophobic 
methionine (Figure 25a, Figure 34b). 
 
As anticipated previously, positively charged Arg429 forces or pushes the toxin into another binding pose 
compared to KV1.1 and KV1.6 (Figure 34a and b).6 As a result, Ser13 and Gln15 form H-bonds with Asp427/SII 
and polar/neutral Gly420/SIII of the non-altered P1 loops (Figure 34b).6  
Further on, the preferred addressing of µ-PIIIA towards the more acidic P1 outer loop is demonstrated by the 
interactions of the central Arg12, Lys9 and Hyp8 residues with Asp401/SII, Val402/SII, Asp403/SII and 
Ser404/SII (Figure 34b).6 Hence, a pore moiety is still partly covered.6 The observations indicating a partial 
pore coverage are further substantiated by the high conformational flexibility rates on the pore surface (Figure 
31, Figure 32).6 
 
The said modifications result in a complete shift of the toxin compared to its positioning on KV1.1 or KV1.6, such 
that the helical segment points towards the outside of the channel instead of a more central orientation (Figure 
37). We assume that this partial covering state of the channel maintains for our pre-defined simulation 
conditions appearing as a possible circling movement of the toxin onto the channel surface. Most likely, this 
phenomenon accounts for the remaining currents in this system.  
 
 
µ-PIIIA on Kv1.5 
 
As could be shown previously with the cases of µ-PIIIA on KV1.6-5P1 and µ-PIIIA on KV1.6-5P2, the stepwise 
modification of the channel from KV1.6 towards KV1.5 consistently leads to a lack of most of the interactions 
observed for µ-PIIIA on KV1.6: As neither the physicochemical composition of the outer nor the inner loops is 
maintained from KV1.6 (Figure 25a), a different orientation of the toxin is induced compared to on KV1.6/1, 
resulting in an upright positioning of the toxins core segment (Arg12 – Ser13 – Arg14) (Figure 34c).6 
Consequently, instead of forming contacts to the outer loops like in KV1.6 and KV1.1 the central Arg12 residue 
interacts with inner residues at the pore cavity resulting in a plethora of further toxin centre H-bonds towards 
residues next to the selectivity filter motif (Figure 34c).6 Thus a much smaller portion of the pore surface is 
covered which suggests a low affinity binding pose (Figure 34c, Figure 37).6 
Consistently with the inactivity of µ-PIIIA at KV1.5, VINA rescoring suggests the second lowest binding energy 
among all toxin-channel systems analysed in this work (Table 6).6 Equally, the high degree of local per residue 
flexibility rates outside the central core of µ-PIIIA (Figure 32) underpin the poor pore coverage.6   
 
All in all, the cases of µ-PIIIA binding to various KV channels considered so far teach us that the composition of 
the residues in the inner P2 loops contributes significantly to the µ-PIIIA binding and its orientation on KV 
channels.6 
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µ-SIIIA on Kv1.6 
 
Since µ-SIIIA shows a similar moderate activity as the semi-active instances of µ-PIIIA on the KV1.6-1.5 
chimera, we also investigated the binding of µ-SIIIA on KV1.6 (Figure 34b).6  
Despite the identical disulfide-bond patterns, sequence comparison of µ-SIIIA and µ-PIIIA reveals overall 
different compositions and a somewhat different central segment, lacking the symmetric sequence pattern 
(Figure 18, Figure 35a).6 
 
Interestingly, our analysis unveiled that the central region of µ-SIIIA (Ser9 to Trp12), which corresponds to 
the symmetric centre of µ-PIIIA, was mainly forming H-bonds with the central pore region, as it was observed 
for µ-PIIIA binding at KV1.6-5P2 (Figure 34b, Figure 35a).6 Similar to Gln15 within µ-PIIIA, polar/neutral 
Ser9 and Ser10 respectively address Tyr429/SIII and Gly426/SI of the inner P2 loops (Figure 34b).6  
 
The further contacts to the outer P1 loops of  the opposite subunits SI and SII altogether stabilize an overall 
centrally oriented positioning of  the toxin at the pore, despite involving a sideward oriented central core of  µ-
SIIIA (Figure 34b, Figure 37). More precisely, these concern the symmetric hydrogen bonds of  basic Lys11 
and acidic Trp12 to the outer located acidic Asp401/SI and Asp403/SI and of  the equally basic Arg18 to the 
proportionate residue Asp403/SII of  the opposite subunit SII (Figure 34b).6  
 
Remarkably, µ-PIIIA’s centrally located Arg12 residue equally connects to Asp401 in KV1.6 (Figure 34a), which 
also endorses the overall central positioning of  µ-SIIIA.6 The resulting positioning allows for the interaction 
of  the starting residues with the pore centre, more specifically of  Pyr1 to Gly426/SII and Asn2 to Tyr425/SIII 
at the inner P2 loops of  the pore center, however resulting in an incomplete pore block (Figure 34b).6 This is 
due to a more lateral position of  the toxin core on the pore compared to µ-PIIIA on KV1.6 despite the overall 
central toxin position given by the contacts to the opposing subunits SI and SII (Figure 34, Figure 37).6  
The incomplete block can further be substantiated by the conformational and local flexibilities of  the outer P1 
loops provoking a decrease of  the binding pose’s stability (Figure 32).6 
 
 
µ-GIIIA on Kv1.6 
 
In accordance with experimental studies, all our data show clearly that µ-GIIIA is not capable of binding to 
KV1.6. This is especially reflected by the low binding energy of µ-GIIIA towards KV1.6 revealed from our VINA 
resoring calculations as well as the high motion and dynamics of this system during the equilibration 
simulations.6 Therefore, in this case no further statements about a bound state can be made. 
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4.4.4. Conclusions and future perspectives 
 
Our in silico data could provide thorough insights into the dynamics and different adopted binding states of  the 
µ-conotoxins µ-PIIIA, µ-SIIIA and µ-GIIIA on the voltage-gated potassium channels of  the KV1 family.6 
The data clearly indicate that different system activities can only adequately be understood under consideration 
of their dynamic information and the conformational space the toxin can sample in its channel-bound state.6 
Since for all of the channel-toxin systems investigated a certain flexibility of their conformational arrangement 
as well as deviations from the initial docked state could be shown through our molecular dynamics simulations 
(Figure 31, Table 8), we hypothesize that these flexibilities ultimately explain remaining currents as especially 
observed for semi- and inactive systems.6 In particular, the semi-active and inactive systems µ-PIIIA/KV1.6-
5P2 and µ-GIIIA/KV1.6 showed significantly higher conformational flexibilities than the other semi- and 
inactive systmems, further rationalizing their incomplete pore coverage.6 More precisely, this is demonstrated 
by the clearly visible sideward orientation of their toxins.6 In contrast, less flexible semi-active systems µ-
PIIIA/KV1.6-5P1 and µ-SIIIA/KV1.6 and inactive µ-PIIIA/KV1.5 whose toxins remain more centrally located 
cannot be fully rationalized by this criterion, however do not exhibit the interactions identified in the active 
systems, resulting in a more detached toxin positioning.6 In contrast, the unique active systems are generally 
less flexible and dynamic, exhibiting more stabilized and rigidly bound toxins.  
Altogether the two different modes of interaction observable for semi- and inactive systems can be distinguished 
by more centered toxin positions (in less flexible systems) and more sideways drifting toxin movements (in more 
flexible systems). Our findings further suggest a similar and unique binding mode for the active blockage of the 
channels KV1.1 and KV1.6 through the µ-conotoxin µ-PIIIA.6 This is made up by a “pore-diving” and coincident 
“crosswise” positioning of the central toxin core residues onto the channel surface, achieved by toxin contacts 
to the inner and the outer pore loops.6 The resulting central toxin position is made up by a plethora of hydrogen 
bonds formed by the µ-PIIIA α-helical core residues with the central pore duct and with outer surface residues.6  
In these respect it was found that for µ-PIIIA binding at KV1.6, KV1.5 and the respective chimeras the inner P2 
loop composition mainly destines the resulting toxin orientation where further contacts to the outer P1 loops 
stabilize the pose.6 Further, the crucial role of the “physicochemically symmetric” µ-PIIIA helical core segment 
Hyp8 – Hyp18 could be pointed out: in particular the arginines within the centric Arg12 – Ser13 – Arg14 – 
Gln15 binding motif included (Figure 35a) show a stabilizing effect on the positioning of the toxin onto the 
pore.6 The importance of the central µ-PIIIA region on KV1.1/6 has also been shown by further studies 
suggesting comparable bound states for µ-PIIIA on NaV1.4 (Figure 38); here, stabilizing contacts of Arg12 and 
Arg14 to the channel are also reported to strongly influence the channel blocking efficacy.6, 200, 221 
In addition, the predicted µ-PIIIA orientation on KV1.6 was also similar to the experimentally determined 
binding pose of the structurally related µ-conotoxin KIIIA on NaV1.2 (PDB ID 6J8E) further suggesting a 
unique pore blocking motif included in µ-conotoxins (data not shown).6, 222 
Interestingly, partial mutations such as the insertion of the µ-PIIIA-insensitive KV1.5 channel pore loop residues 
into KV1.6 could be shown to trigger a reorientation of the toxin in the sense of either clearly sideward or pore-
diving toxin cores (Figure 37).6 A similar sideward oriented toxin centre could also be observed for the 
corresponding region within µ-SIIIA (Figure 37).6 
The interactions which stabilize the toxin placement are mainly defined by positively charged Arg or Lys toxin 
residues contacting the negatively charged Asp or Glu residues of KV1.6 or KV1.1, respectively, being located in 
the outer P1 loops.6 Here in particular the third Asp401 in the case of KV1.6 and the corresponding Glu353 in 
KV1.1, both being located closer to the pore centre compared to the other Asp and Glu residues, are addressed.6 
Related analyses pointed out that the subtype-specific binding of µ-PIIIA to the KV1 family members does not 
tolerate positively charged amino acids in both the inner and outer pore loops, as shown by comparison of KV1.6, 
KV1.3 and KV1.1 (Figure 25a).6 Rather, a strong reorientation and repulsion of the toxin is enforced by such 
amino acid constellations which is deducible from our data provided for µ-PIIIA/KV1.6-5P2.6 Especially the lack 
of the essential third aspartic acid residue in the outer P1 loop of KV1.3 points out the exclusive µ-PIIIA binding 
to KV1.6 and KV1.1.6 However, as the Asp- and Glu-rich KV1.6/1 outer P1 loops are rather small in size, a very 
compact toxin fold is required to achieve a proper pore blockage where the toxin’s Arg and Lys residues can 
simultaneously orient towards the outer channel surface and the inner P2 loops.6 The lack of such residue 
constellations in µ-GIIIA can, among others, provide an explanation for its inactivity (Figure 35b).6    
Lastly, even though our MD simulations were not fully able to unveil a toxin’s conformational landscape, the 
importance of system dynamics even for the channel-bound toxin state could be proven with our in silico studies 
after all, encouraging our strong recommendation of combined docking and MD simulation approaches 
concerning in silico analyses of protein-ligand systems and their coincident evaluation.6  
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Future perspectives 
 
The new insights into subtype-specific channel blockage by μ-conotoxins can provide a basis and new impulses 
for future rational peptide-based design approaches. Here, especially the more targeted and specific addressing 
of distinct ion channel subtypes should be focused, for instance for the purpose of preventing unintended side 
effects. 
 
Additional discoveries considering recurrent modes of toxin movement events in semi-active and inactive 
systems (that either exhibit centrally or sidewards oriented toxins) allow us to take a subsequent step towards 
a proposal of a preliminary classification model for the description of toxin movement patterns in channel-toxin 
systems: unique binding modes, being assumed in an equilibrated state as observed for active systems can be 
distinguished from two further types of toxin detachment movements attributable to semi- and inactive systems. 
In these respects we formulated the corresponding recognition determinants for each mode of activity based on 
our simulation data analyses (Table 9). Although too few determinants may still be defined for an extensive 
automated learning or classification procedure, we assume that our stated modes can also be transferred to 
systems that haven't been investigated in more detail yet (Table 3). 
 
Table 9: Preliminary classification model for the categorization of channel-toxin systems established from our simulation 
data evaluations; assignments can be done according to our suggested classification scheme (to active, semi-active (a) / (b) 
and inactive (a) / (b) modes) and on the basis of different determinants: cluster-specific features – highlighted gray, 
interaction-specific features – highlighted pale blue and core-position and coincident shape-specific features – highlighted 
light turquoise; for unique classification, each mode is assigned an individual combination of determinant settings. 
 
Considering all evaluations conducted, we conclude that the active systems µ-PIIIA on KV1.6 and KV1.1 can 
serve as prominent model systems and will form an instructive basis regarding further developments and the 
testing of newly designed ion channel blockers. In consequence, µ-PIIIA holds a very high capacity to serve as 
precursor for the detection of preliminary μ-conotoxin-pharmacophores, being equipped by its unequivocal core-
motif embedded in a physicochemically symmetric central toxin segment that lack its competitors µ-SIIIA and 
µ-GIIIA. Its additional potential of being adjusted for an exclusive targeting of NaV and various other channels 
by pointed modifications further encourages its employment as lead structure.  
Mode of 
activity 
Main 
cluster 2 
size ≥ 3 
 
 
Index of 
preli-minary 
represen-
tative is 
located in  
~ the first 
three sim. 
quarters 
(ϵ [0ns, 
350ns]) 
Revising 
step 
positive 
 
 
Represen-
tative 
interac-
tions to at 
least three 
subunits 
|interactions to 
P1 loops| / 
|interactions to 
P2 loops|  
> 0 
Position and shape 
of residues 
corresponding, i.e. 
aligned to µ-PIIIA 
core motif (Arg12 
– Gln15): 
 
“diving” / 
“horizontal“ 
(central or lateral 
w.r.t. channel) 
 
Please refer to 
Figure 37 
Resulting shape of 
toxin central 
segment 
(corresponding to 
µ-PIIIA Hyp8 – 
Hyp18)  
w.r.t. core motif 
residues 
(corresponding to 
µ-PIIIA core motif 
Arg12 – Gln15) 
 
Please refer to 
Figure 37 
active 
(unique) yes 
yes no yes yes 
diving AND 
horizontal 
(central) 
stretched out / 
“in line” 
semi-
active a) 
yes 
 
yes 
 
no yes no 
diving OR 
horizontal 
(lateral) 
bending 
semi-
active b) 
no 
 
yes 
 
yes no yes 
horizontal 
(lateral) 
bending 
inactive a) no 
 
yes 
 
no yes no diving bending 
 
inactive b) 
 
no no no no yes none bending 
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Therefore, motivated by our findings and by a further reported correlation of the overexpression of KV1.5 
channels in some human cancer cell lines,223 we elaborated a further preliminary proposal for a putative KV1.5 
blocker, derived from µ-PIIIA as precursor structure and its discovered binding mode to KV1.6 (Figure 39). 
Additional research on various studies indicating the sole presence of reported small molecule compound and 
no larger polypeptide blockers of the KV1.5 channel7, 216, 224-226 further motivated our ideas of hypothesized µ-
PIIIA redesigns.  
 
 
 
Figure 39: Attempt to derive a KV1.5 blocker toxin based on the active model system μ-PIIIA on KV1.6. (a) KV1.5 aligned 
to KV1.6 as also obtained from Figure 25a; the differing residues are colored by physicochemical properties (alkaline – light 
blue, acidic – magenta, polar/neutral – green, non-polar/hydrophobic – orange); μ-PIIIA-KV1.6 interacting residues are 
equally coloured and indicated below the KV1.6 sequence; interactions to KV1.6 (and possible interactions to KV1.5) are 
shown as black lines between the channel and the toxin residues; proposed modifications for μ-PIIIA are stated above the 
KV1.5 sequence, separated from the original μ-PIIIA residues by a dashed line. (b) Resulting modified sequence of μ-PIIIA, 
also including a symmetric physicochemical sequence pattern (and unmodified cysteines); amino acids are equally coloured 
by amino acid type.   
 
Thereby we propose the replacement of µ-PIIIA residues that interact with KV1.6 residues of mutated positions 
arising by the modification from KV1.6 to KV1.5 and causing the ineffective binding mode (Figure 25a, Figure 
34, Figure 39). For the replacement, residues empirically known to contact the concerning channel positions 
would be considered. By coincidently ensuring the maintenance of the outlined essential features such as the 
presence of an internal physicochemical symmetry and the µ-conotoxin disulfide bridge pattern, we obtain a 
modified sequence of µ-PIIIA as shown in Figure 39b. 
However, it should be kept in mind that other arising interactions such as Hyp8 to Arg487/SII of µ-PIIIA to 
KV1.5 should be considered when performing such mutations (Figure 34).  
 
In addition it should be recalled from these perspectives, that in recent protein structure prediction research 
there has been a great interest using amino acid interaction preferences (e.g. contact potentials or potentials of 
mean force) to align or “thread” a protein sequence to a known structural motif. In these respects it could be 
shown that finding the globally optimal protein threading is NP-hard227 and we therefore sticked to a more 
intuitive approach considering our outlined proposal. 
To address the open questions outlined – peptide-based ligand optimizations and the extension of the predefined 
determinants in our established classification model (Table 9) – further in silico investigations of not yet 
examined systems would be required, especially in view of possible training data setups. In addition, the 
presumed significance of found internal toxin symmetries or sequence motifs for the blockage of specific ion 
channels could be verified or better understood.   
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A further topic of interest considering these respects and the elucidation of its severe side effect causes would 
be provided by distinct investigations of the ω-conotoxin ω-MVIIA on KV1.1, KV1.6 and NaV1.4 as targeted 
channels.  
 
Lastly, further in silico analyses and the ongoing increase of knowledge with the assistance of modern 
technologies will hopefully contribute to the specification and optimization of therapeutic pain or even cancer 
treatment towards a substantial reduction of unintended side-effects. Our study results uncovering the binding 
of μ-PIIIA on KV1.1 as well as on KV1.6 and others, being aware of its intrinsic specificity towards NaV1.4, may 
already provide essential contributions at least for some of these aspects. 
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5. Methods section 
 
5.1. Gq – YM / FR (analogues) docking protocol 
 
 
Figure 40: Schematic overview of the complete docking workflow as applied for the analysis of docked YM/FR analogues. 
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5.1.1. In silico generation of YM-254890 and FR900359 analogues 
 
The molecular structures of the YM-254890 and FR900359 analogues were built on the basis of the Gq-bound 
YM-254890 crystal structure (PDB ID 3AH81), employing the YASARA molecular modelling program44, 228 
(Figure 40, step 1). Each structure was geometry optimized using the YASARA YAPAC module. Therefore, 
we employed semi-empirical quantum chemical methods followed by an energy minimization step in explicit 
water (Figure 40, step 1). The energy minimization was performed under physiological conditions (0.9% NaCl, 
298 K, pH 7.4229) using the PME method229 and a cut-off distance of 8 Å to describe long-range electrostatics as 
well as making use of the YASARA2 force field230 (Figure 40, step 1). 
 
 
5.1.2. VINA Docking and energy minimizations 
 
The Gαq target structure was extracted again from the YM-bound Gq structure (PDB ID 3AH81). The docking 
setup was accomplished with the aid of the YASARA molecular modelling program,44, 228 applying default 
parameter settings for the actual docking process of the prepared analogues which was then carried out 
employing the Vina docking algorithm (Figure 40, step 2). 220 The virtual docking cell was placed around the 
YM(/FR) binding epitope as reported by Nishimura et al.1 in order to optimally guide the docking runs. 
Moreover, ligands and receptor residues were kept flexible during the docking.  
 
The respective best scoring result of 32 individual docking runs was subjected to succeeding energy 
minimization runs prior to subsequent Gαq-inhibitor interaction analyses (Figure 40, step 3 case “fits”, step 4). 
The individual energy minimization steps were carried out by employing steepest-descent minimizations 
followed by simulated annealing minimizations until convergence (<0.05 kJ/mol/200/steps). Ewald 
summation229 was used to assign charged amino acids according to their individual predicted side chain pKa 
values. Further neutralization of the (previously) charged amino acids was achieved by the adding of counter 
ions (NaCl). The further assignment of the ligands’ force field parameters was performed applying YASARA’s 
AutoSMILES approach.231, 232  
 
Unless otherwise stated TIP3P water model as well as the Yasara2 force field230 was used to conduct the energy 
minimizations233, 234 employing the PME method235 to describe long-range electrostatics at a cut-off distance of 
8 Å at physiological conditions (0.9% NaCl, 298 K, pH 7.4229). 
 
 
5.1.3. MD simulations of selected YM/FR analogues 
 
From all best scoring docking results a real subset of outlier structures was determined that, regarding the 
average dissociation constant given by the according docking experiment, did not appropriately reflect their 
corresponding IC50 values (Figure 40, step 3 case “does not fit”). If the initial docking result didn’t properly fit 
the experimentally expected outcomes, we undertook further searches for a more reliable and stable 
conformation of the structure, being able to be re-docked for further analyses. To that end, we performed  
molecular dynamic simulations experiments of 100ns duration on all these selected outlier structures, employing 
the AMBER14 force field.236  
For re-docking the most stable conformations from the simulations were selected as indicated by the Cα 
backbone atom RMSD (Figure 40, step 3 case “does not fit”). To allow for approach consistency, the selected 
structures were energy-minimized prior to and after the re-dockings. To carry out the latter, we made use of 
the approaches as described in the previous section (5.1.2). Interaction analysis (hydrophobic interactions and 
hydrogen bond analysis, Table 11) was performed on the representative ligand-protein complex as outlined in 
Table 11 after each structure was energy minimized as described above.  
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5.2. Gq – YM / FR supplementary docking data 
 
Table 10: Binding energy calculated from the docking experiments before (1st docking run) and after the 100ns 
equilibration step. 
Outlier 
Activity 
level 
Docked binding energy from 
1st docking run [kcal/mol] 
Docked binding energy after 
previous equilibration [kcal/mol] / 
(sim. time of selected structure) 
YM-254890 (YM) high 8.58 ± 0.54 - 
FR900359 (FR) high 8.63 ± 0.67 - 
21 (YM-14) high 7.70 ± 0.49 8.83 ± 0.38 (40ns) 
18 (YM-11) high 7.97 ± 0.51 9.01 ± 0.38 (79ns) 
23 (YM-1) high 8.22 ± 0.73 9.18 ± 0.51 (20ns) 
30 (YM-9) medium 8.33 ± 0.69 9.55 ± 0.50 (45ns) 
31 (YM-3) medium 9.02 ± 0.24 8.80 ± 0.79 (52ns) 
29 (YM-L / YM-385780) medium 8.16 ± 0.50 8.04 ± 0.30 (65ns) 
32 (YM-4) low 8.50 ± 0.47 8.50 ± 0.34 (35ns) 
33 (YM-6) low 8.79 ± 0.78 9.83 ± 0.34 (52ns) 
34 (YM-17) low 8.40 ± 0.78 8.14 ± 0.44 (37ns) 
35 (YM-5) low 8.62 ± 0.78 9.28 ± 0.14 (48ns) 
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Table 11: Overview of Gq-inhibitor interactions. Hydrophobic interaction cutoffs: strength ≥ 1.0; length ≤ 5Å. (Table 
source: Reher et al.5)  
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5.3. Homology modelling of NaV1.4 
 
We used the YASARA molecular modelling program230, 237 to create the homology model of the NaV1.4 channel 
pore module to perform molecular dynamics simulations and energy minimization steps. Further, the crystal 
structure of CaV1.1 (PDB ID 3JBR201), showing an overall sequence identity of 21 %, turned out to serve as 
suitable template to model the NaV1.4 sodium channel. Loop regions that were hypothesized to rank among the 
toxin binding epitope were modelled either as a whole or in part, however always with respect to their sequence 
conservation score (Figure 21)201 and also according to the UniProt sequence alignment205 of NaV1.4 (UniProt 
ID P35499) and the template sequence (UniProt ID P07293, Figure 21). To properly identify loop-regions and 
transmembrane segments, we created a structural alignment of the the CaV1.1 template structure and the crystal 
structure of the bacterial sodium channel NaVAB (PDB ID 3RVY238) employing the MUSTANG algorithm.239 
If necessary, Yasara’s build loop command was used to extend loops by insertion of the particular residues into 
the loop sequences of the template as outlined in Figure 21.240 If it was required to shorten loops, the relevant 
residues were eliminated and the resulting gap was closed. To finalize the loop modelling step, an energy 
minimization was applied on the remodelled loops in vacuum employing the NOVA237 force field. During the 
loop energy minimization, the remaining part of the protein was kept fixed using the LINCS241 method. In two 
final refining preparation steps to perform the docking, the whole homology model was first energy minimized 
an equilibrated through an unrestrained all-atom molecular dynamics simulation of 2 ns duration in a membrane 
environment (PEA) and explicit water, and secondly energy minimized again using the AMBER14234, 236 force 
field.  
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5.4. µ-PIIIA NaV Docking 
 
To perform the docking, we employed the Easy Interface of the HADDOCK web service 
(https://haddock.science.uu.nl/services/HADDOCK2.2/haddockserver-easy.html).209, 218 
As required for the individual docking of the µ-PIIIA isomers to the homology model of NaV1.4, we first defined 
all the specific residues within the channel's surface as active as they are assumed to interact with the toxin 
(analogously to Figure 25a). The lowest energy conformation of the NMR ensemble of the respective µ-PIIIA 
isomer54, 151 was selected for the docking process. The lowest energy conformation of the predicted structural 
ensemble of the µ-PIIIA isomer 12, 13 and 7 was selected for the docking process. Further, the whole toxin, i.e. 
all 22 residues were also set as active, as being considered to be equally involved in any interaction. We extracted 
each best-scoring cluster from the HADDOCK results, i.e. those exhibiting the lowest Z-score respectively, to 
perform further analyses. For these purposes, a subsequent energy minimization on each best scoring 
HADDOCK cluster was carried out using the Yasara2230 force field after the N-terminal glutamate was 
transformed into γ-pyroglutamate. The resulting Z-scores are listed in Table 4. 
 
 
5.5. Generation of KV models and chimera 
 
For the creation of our KV1.6 homology model, we employed the YASARA molecular modelling program 
YASARA “structure” Vers. 18.3.23.44 We built the model of the complete potassium channel, including the 
naturally associated voltage-sensor domains for the sake of sequence data completeness, necessary for the 
accurate detection of high amounts of related homologues. The modelling parameters for the complete process 
were set as follows: 
 
In order to identify a structure template as a first step, three subsequent PSI-BLAST242 iterations were run on 
the complete target sequence of KV1.6, yielding 89 possible templates identified. In a second step the Protein 
Data Bank (PDB) was searched for a match for a position specific scoring matrix (PSSM), that has been extracted 
from UniRef90243 in advance. (Hits were detected by an E-value below the cutoff 0.5.) A total of four hits (PDB-
IDs 2R9R-B, 3LNM-B, 3LUT-B and 2A79-B) among the 89 structures could be found as possible suitable 
templates for KV1.6. 
 
A secondary structure prediction for the target sequence was used for purposes of alignment correction and loop 
modelling supports. The predicted secondary structure was obtained by again running PSI-BLAST242 to first 
get a target sequence profile and subsequently feeding the profile to the PSI-Pred secondary structure prediction 
algorithm.244 A target sequence profile has been created from a multiple sequence alignment in order to aid 
aligning the target and template sequences. The multiple sequence alignment was built from related sequences 
from the aforementioned PSI-BLAST-obtained UniRef90 sequences. Alternative alignments of the target and 
the respective template protein sequences yielded 29 generated models for the four template PDBs in a total. 
Side chains were added using YASARA’s SCWRL3240 implementation and further fine-tuned by taking into 
consideration solvation effects and electrostatic, knowledge-based packing iterations. In addition, the hydrogen 
bond network was optimized245 before subjecting each model to an unrestrained energy minimization with 
explicit water molecules. The energy minimization was performed by simulated annealing employing the 
Yasara2 force field.230  
All 29 models were ranked according to their overall quality Z-scores and in addition a YASARA-designed 
hybrid model was constructed by combining the best (scoring) parts of each model. Due to its highest rank 
among all models, the hybrid model was accepted as the final channel model for KV1.6. 
A more detailed description of the complete YASARA homology modelling protocol can be seen online 
(http://yasara.org/homologymodeling.htm).  
 
On the basis of the obtained KV1.6 homology model, further model structures were also built for KV1.1, KV1.5 
and for the chimera channels “KV1.6-5P1” and “KV1.6-5P2” by incorporating the respective mutations: individual 
substitutions of KV1.6-differing residues in the “P1”-loops in the outer surface area of the KV1.6 model yielded 
the structure for KV1.6-5P1 and, correspondingly, in the “P2” inner pore-loops of the KV1.6 model yielded our 
final KV1.6-5P2 channel structure. Analogously we mutated both, the P1 and the P2 loops in order to obtain 
KV1.5 or KV1.1. The model for KV1.1 was finished by an additional mutation within the pore helical segment of 
the KV1.6 model. This mutation is contained in KV1.1 compared to KV1.6 (see Figure 25a). For further use, all 
five models were energy-minimized in a finalizing step. 
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5.6. µ-PIIIA, µ-SIIIA and µ-GIIIA docking on KV1 channel subtypes  
 
As the outer located voltage-sensor domains of the modelled KV1 channels are not considered to be involved in 
µ-conotoxin binding, they do not account for our focused region of interest and were therefore declared as being 
negligible for any further investigations. We hence omitted these parts in any further work step, additionally in 
view of data reduction and time-saving aspects.  
In order to start the pursued simulations from an appropriate initial state where both, channel and toxin, are 
present in a bound form, predicted conformations from docked clusters of the respective systems were used. 
These were obtained by docking the lowest energy member of the NMR ensemble of μ-PIIIA151 (PDB ID: 
1R9I246), μ-SIIIA (BMRB ID: 20023) and μ-GIIIA (PDB ID: 1TCG247) to the potassium channel models of 
KV1.1, KV1.5 and KV1.6 and to the chimera homology models. The dockings were performed using the Easy 
Interface of the HADDOCK online platform209, 218, 248 
(https://haddock.science.uu.nl/services/HADDOCK2.2/haddockserver-easy.html), a web service known to be 
suitable for the handling of more complex peptide ligand structures, apart from small molecule compounds.248 
 
For technical reasons concerning recognition problems of γ-pyroglutamic acid (Pyr) by the HADDOCK 
program, γ-pyroglutamic acid at toxin position one (Pyr1) of any system containing μ-SIIIA or μ-PIIIA was 
replaced by glutamic acid (Glu1) before performing the docking routine (and re-converted afterwards for further 
work steps).  
As requested by the HADDOCK user interface and equally due to computing power-saving reasons, “active”, i.e. 
contact-forming residues within the complex were predefined, distinguished from “inactive” or “passive” 
residues not being part of  the interactive area. 
Residues within regions that are part of the channel’s upper surface as well as all toxin residues were defined as 
“active”. More precisely, the channel’s upper surface region comprises the last three residues of the outer S5 
helix, the subsequent outer P1 loop on the channel’s outer surface, the pore helix, connecting the outer P1 and 
the inner P2 loop of the pore duct followed by the first three residues of the outer S6 helix (see segment shown 
in Figure 25a). Considering the docked μ-conotoxins, all toxin residues were set as active part in the system to 
ensure equal preconditions i.e. an equal general probability for each toxin residue to be predicted to form 
interactions with the channel’s surface.  
 
According to the HADDOCK protocol, passive residues can either be limited to residues that surround the 
active-defined ones or generally that are part of the overall protein’s surface.218 In order to avoid data 
redundancy and to provide further time-saving benefits, we decided to restrict the quantity of passive-set 
residues by choosing them to be automatically defined around the active-specified ones within the system. This 
option takes all residues into account that are both, on the surface or within a radius of maximum 6.5 Å of any 
active-set residue.218  
 
From each docking result, the individual best scoring structure from the respective highest scoring cluster 
(exhibiting the lowest Z-Score within the set of resulting clusters) was respectively selected as starting structure 
for further analyses (Table 6). 
In addition, each selected structure was rescored employing the AutoDock Vina algorithm220 under default 
settings.249 The corresponding setup was performed using the YASARA molecular modelling software (Table 
6).44  
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5.7. µ-PIIIA, µ-SIIIA and µ-GIIIA simulations on KV1 channel subtypes 
 
All further energy minimization and MD simulation steps described below were performed using the YASARA 
molecular modelling software.44 
 
Our previous modifications from γ-pyroglutamic acid to glutamic acid for reasons of meeting the requirements 
of the HADDOCK web interface,218 were retransformed by reconversion of the concerning residues of the chosen 
docked complexes to γ-pyroglutamic acid for µ-SIIIA and µ-PIIIA. Prior to further MD simulations, the 
reconversion was followed by a subsequent energy minimization step in water under application of the 
AMBER14 Force Field234, 236 to ensure the proper formation and positioning of the reconverted γ-pyroglutamic 
acid until system convergence is achieved as soon as the energy improves by less than 0.05 kJ/mol per atom 
during 200 time steps (<0.05 kJ/mol/200/steps). 
 
MD simulations of the particular selected lowest energy structure form the best-scoring docking clusters were 
performed under the use of YASARA’s incorporated routine for the simulation of membrane proteins in a lipid 
membrane environment.  
The macro firstly scans the protein for secondary structure elements with hydrophobic surface residues, orients 
it accordingly and embeds it in the membrane of adjustable lipid composition. Finally a 250 ps restrained 
equilibration simulation is run, which ensures that the membrane can adapt to the newly embedded protein, 
before the actual simulation starts.228 
The simulations were performed within a cuboid simulation cell, containing the membrane 30 Å larger than the 
protein and of a height 20 Å higher than the protein (rest of the cell was filled with an aqoueus potassium 
chloride solution of 0.9% concentration). The membrane was chosen to be completely composed of phosphatidyl-
ethanolamine (PEA), the most stable lipid membrane,228 in order to mimic the native membrane environment 
during our simulations. 
The energy minimizations and refinement simulations of the complexes were performed as unrestrained all-
atom molecular dynamics simulations in explicit water (TIP3P250) using the PME method235 to describe long-
range electrostatics at a cut-off distance of 8 Å. In addition, physiological conditions (0.9% KCl, pH 7.4229) were 
maintained during our simulations as well as a constant temperature of 298 K using a Berendsen thermostat 
and a constant pressure of 1 bar.  
Charged amino acids were assigned according to the predicted pKa of the amino acid side chains by Ewald 
summation and were neutralized by adding counter ions (KCl).229  
A multiple time step algorithm together with a simulation time step interval of 5 fs was chosen In order to 
increase the simulation performance.228 Further, the AMBER14 Force Field.234, 236 was applied and high 
frequency bond and angle vibrations of hydrogen atoms were removed employing constraints through the 
LINCS241 and SETTLE250 approach.  
Simulation times ranged from 0.5 to 1µs, whereby simulation snapshots were saved every 250000 fs, i.e. 250 ps 
(employing the simulation macro in fast speed mode). 
For energy minimization by simulated annealing the Yasara2230 force field was used including optimization of 
the hydrogen bond network245 and equilibration of the water shell until convergence of the system was achieved.  
 
 
All molecular graphics were created with YASARA (www.yasara.org) and POVRay (www.povray.org). 
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5.8. Combined clustering for structure selection 
 
In order to provide a more sophisticated than just an arbitrary snapshot selection for the representative toxin-
channel structures, we implemented and applied two clustering approaches and combined them for the final 
selection of representative snapshots at appropriate simulation times. The particular clustering approaches are 
described below. Prior to the clustering applications, each data set was subdivided into eleven snapshots 
respectively, equally spaced at a distance of 50 ns. This preselection defined the starting point for the clustering 
applications. Correspondingly, snapshot 1 represents the structure at the simulation start time of 0ns, snapshot 
2 contains the simulated structure at 50 ns and so on. Finally snapshot 11 represents the simulated structure at 
500ns simulation time. 
 
Figure 41 shows the overall selection process as a whole workflow. 
 
We endorsed both of the presented clustering approaches and especially a complementary combination of them, 
as each of the methods relies on the assumption that an equilibrated state of stable condition can be represented 
as a detected cluster of maximum size. Consequently, the wanted representative candidate is most probably 
present within this cluster. As the first method is however more specific than the second one considering its 
selection criterion, we intersect both methods’ results for the further selection process to provide a more 
sensitive approach. In these respects, clustering method 2 depicts the more sensitive supplementation for the 
first one, also taking the overall data dispersion as well as the location of the main data focus into account. 
 
The intersection cluster yields a subset out of  the 11 pre-selected snapshots, having ensured to contain members 
satisfying the criteria given in the two clustering approaches. For the selection of  the final representative out 
of  the intersection it is thus secured that it designates a snapshot of  preferably minimum distance to the average 
simulation structure and simultaneously being located within an area of  high data density. (The preferably low 
distance to the average structure is even considered until the proposal step for the preliminary representative.) 
 
In these respects, the second clustering method can be considered as completion or refinement revision of  the 
first one. We thus recommend the use of  a combination of  both approaches in terms to achieve an adequate, i.e. 
enough sensitive and specific selection process for the detection of  representatives.   
 
 
Figure 41: Cluster computation workflow summarizing the combinded usage of clustering methods 1 and 2 up to the 
selection of the final representative snapshot. (Illustration adapted from Kaufmann et al.6) 
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5.8.1. Clustering method 1 – cluster close to the average structure 
 
This method extracts all snapshots of toxin distance < 3Å RMSD to the average simulation toxin structure and 
defines them as members of the main cluster. This approach of “clustering” only yields a single cluster of filtered 
snapshots as the data subset searched needs to satisfy just one criterion. As the rest of the data is not further 
considered, the yielded main cluster size directly represents the system’s degrees of stability and dynamics. 
Employing clustering method 1 to our data yields the particular snapshot clusters as shown in Table 12 (3rd 
column). In a worst case scenario like for the highly fluctuating System μ-GIIIA KV1.6, the algorithm yields an 
empty set, i.e. a non-existing main cluster (Table 12, 8th row, 3rd column). 
 
We will further use the term "MCL1" to denote the main cluster obtained by our first clustering approach. 
 
Table 12: Cluster analysis 1 results. Detection of a main cluster by threshold RMSD [avg. structure] < 3.0 Å (3rd column); 
7th column contains the snapshot exhibiting the lowest toxin RMSD to the average toxin structure among all, i.e. out of 
the main cluster members.   
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5.8.2. Clustering method 2 – graph-based cluster search 
 
In order to provide some refinement step for our first clustering approach considering the sensitivity of selection, 
we implemented and applied a further clustering approach as illustrated in Figure 42. The algorithm used is 
explained by means of a graph representation of the snapshot preselection: the eleven nodes (or snapshots) are 
successively traversed by calculation of the pairwise distance, i.e. their respective toxin RMSD, to the other 
nodes. In theory, this would require an all-pairwise distance calculation between each pair of nodes, i.e. pair of 
toxins within the snapshots. The computing effort of such a calculation would result in a polynomial run time 
of O(𝑛2) complexity in a worst case scenario, due to the number of edges = (𝑘
𝑛) =  
𝑛(𝑛−1)
2
 in a complete graph 
(yielding 55 node distances in our case of eleven snapshots).  
 
We try to circumvent this calculation effort by omitting the consideration of  already compared and assigned 
nodes (to a cluster), similar to a decision tree: The nodes are considered chronologically and, if  not yet assigned, 
a node’s distances to all remaining nodes is calculated. At this, a node will be assigned to the cluster of  the 
currently considered node (that defines the actual cluster instance) up to a threshold of  < 3 Å toxin RMSD to 
the currently considered node. (The threshold was set to maintain consistencies with the threshold set for 
clustering method 1.) Figure 42 illustrates the course of  such an iteration. The next node that is has not yet 
been assigned to any cluster as a member will depict the further node instantiating a new cluster for the 
subsequent iteration. Consequently, nodes that are already assigned to a cluster, are not considered in any further 
iteration. In all scenarios better than the worst case, redundant calculations of  pairwise distances are avoided 
(due to the decision tree model). In a best case scenario the number of  pair-wise distance calculations is even 
reduced to n-1 (according to O(𝑛)) distance calculations, corresponding to a linear effort. (A transitive relation 
considering a close distance of  two pairs of  nodes sharing one cluster, but of  unknown pairwise distance as 
they are already assigned, is given by their common close distance to the node of  the cluster they were assigned 
to.) 
 
Dealing with data from molecular dynamics as in our case, a chronological way of  data inspection seems to be 
useful and obvious since the observed data intrinsically holds an even continuity (describing the transitions 
between the different states.) 
 
Results yielded by our second clustering approach are listed in Table 13. The implementation was done using 
YASARA’s Yanaconda macro language (http://www.yasara.org/yanaconda.htm). 
 
In contrast to cluster method 1 the second clustering approach takes into account information about the internal 
data spread, seen by the number of  clusters generated (Table 13, 4th column Table 13), why we wanted to profit 
from those benefits despite theoretical algorithmic complexities. Information about the location of  the data focus 
and the intensity of  the overall data scattering, not necessarily given by method 1, is provided. 
As each toxin snapshot is considered and compared to all other ones, instead of  to the toxin average only, the 
main cluster is not detected only by comparison with a theoretically calculated size, but rather with respect to 
the “real” quality or nature of  the inspected data. This approach offers considerable advantages, for instance in 
the case of  precise analyses of  data sets of  high unequal distribution.  
 
The cluster of  largest size or, in case if  same maximum sizes occur, the union of  the clusters of  largest sizes is 
finally determined as the main cluster out of  all generated clusters (Table 13, 4th column, yellow highlighted 
set). A system’s stability and dynamics are therefore deducible by the overall size of  its calculated main cluster, 
as well as by the actual number of  clusters generated (and obviously again by their correlated respective sizes).  
In a worst case scenario however, the algorithm yields eleven (or the number of  existing snapshot nodes) 
clusters of  respective size one. 
 
We will further use the term "MCL2" to designate main cluster 2, obtained by our second clustering approach. 
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Figure 42: Clustering approach 2 workflow diagram. A graph-based clustering calculation is applied on a preselection of 
eleven snapshots out of a 500ns simulation; the preselection snapshots are equally spaced at 50ns; each snapshot is 
represented by a vertex node while the edge lengths designate the pair-wise toxin RMSD values [Å] of the particular 
snapshot pair considered; the clustering process is finished when each node is assigned to a cluster; the main cluster(s) is 
(are) determined by the highest number of members (vertices) or by the union of the clusters of largest sizes (in case if same 
maximum size clusters occur). (Illustration adapted from Kaufmann et al.6) 
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Table 13: Results yielded by cluster analysis 2. The main cluster(s) out of the preselection of eleven snapshots is (are) 
respectively determined by the highest cluster size among all clusters detected (highlighted yellow); 8th column contains 
the snapshot out of the detected main cluster(s) exhibiting the lowest toxin RMSD to the average toxin structure. 
 
 
5.8.3. Selection of the final representative 
 
a) Generating the final preselection set 
  
In a third finalizing step regarding cluster formations, we computed the intersection cluster out of  both 
methods’ main clusters to generate a final preselection set out of  which the final representative should 
(preferably) be chosen. The intersection was built to make sure to only maintain snapshot members that 
concomitantly fulfil the following two criteria considering their position within the space of  simulation 
data: first, being located in close proximity to the average simulation structure and second, being located 
at a position of  high data density, if  possible. 
For cases where the intersection of  the two obtained main clusters would result in an empty set, such 
as for instance in the case of  μ-GIIIA on KV1.6, we took the union cluster to be able to perform further 
investigations and in order to take at least one resulting main cluster out of  the two methods into 
consideration. 
 
We will further use the term "PreSel" to designate the final preselection set resulting from the operations 
on the two main clusters from method 1 (MCL1) and method 2 (MCL2). 
 
A formal description of  building the final preselection set is given by 
 
𝑃𝑟𝑒𝑆𝑒𝑙 = {
𝑀𝐶𝐿 1 Ո 𝑀𝐶𝐿2,   𝑖𝑓 𝑀𝐶𝐿 1 ≠  ∅ 𝑎𝑛𝑑 𝑀𝐶𝐿 2 ≠  ∅  
𝑀𝐶𝐿 1 U 𝑀𝐶𝐿 2 ,                                                          𝑒𝑙𝑠𝑒
 
 
The resulting preselection sets are listed in Table 14 (3rd column). 
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b) Determine the preliminary representative 
 
For further analyses we picked the snapshot out of  the preselection set exhibiting the minimum RMSD 
distance to the respective average structure, being denoted as “preliminary” representative snapshot (see 
Table 14, 4th column). 
It has to be noted that this preliminary representative is not necessarily identical to the snapshot of  the 
generally smallest distance to the average structure regarding the complete simulation data set, since at 
least method 2 is able to yield a main cluster not containing this snapshot. As the result obtained by 
clustering method 2 defines a highly weighted prerequisite in the context of  generating the preselection 
set, the aforementioned overall closest to the average snapshot consequently does not necessarily have 
to be included in the preselection set as well. Such cases may for instance occur when dealing with very 
one-sided, not evenly distributed data.  
In our dataset this case could be observed by the example of  µ-PIIIA at KV1.1 (Table 12, Table 13, 
Table 14, 3rd row): snapshot 10, which according to method 1 has the lowest RMSD to the average 
structure was eliminated during the selection process by the intersecting operation and replaced by 
snapshot 9, yielded by method 2. Actually the updated preliminary representative (snapshot 9) has a 
higher distance to the average structure than snapshot 10, but interestingly (in contrast to snapshot 10) 
contained the crucial interaction Gln15 to Gly376/SIV (Figure 34a). 
This additionally supports the above mentioned facts considering the method’s (clustering method 2) 
sensitivity, especially considering that the preliminary snapshot is revised again by a further final 
revision step, which is described in the following. 
 
 
c) Revision and final selection – check for case “semi-active b)” 
 
As among the systems μ-GIIIA on KV1.6 and μ-PIIIA on KV1.6-5P2 a principal detachment towards a 
channel moiety or a side of  a channel’s subunit could be observed, we aimed to trap a snapshot of  such 
already detached state as representative structure for these two instances.  
For both cases the detaching movement occurs at different simulations times (for the semi-active μ-
PIIIA on KV1.6-5P2 within around the last simulation quarter, also referred to as mode “semi-active b)” 
as per our own designation and for inactive μ-GIIIA on KV1.6 within the first simulation quarter, also 
called “inactive b)”, see Figure 28, Table 9). As the state of detachment is however adopted at later 
simulation times for semi-active “μ-PIIIA on KV1.6-5P2”-like cases, it would not be represented by the 
majority of simulation data. 
We therefore decided to perform a final revising step on any preliminary representative for checking a 
later detaching behaviour in the last third to quarter of a simulation. For this purpose, we 
counterchecked the toxin RMSDs between our preliminary representatives and the corresponding toxin 
structures of the associated last three simulation snapshots (i.e. at simulation times 400ns, 450ns and 
500ns). The cutoff was set to 6.0Å. For RMSD values below and up to and including this threshold we 
retained the preliminary representative and took it as final snapshot. In cases of higher RMSDs the 
preliminary representative was rejected and substituted by the snapshot out of the last three compared 
ones which still exhibited the lowest RMSD to the preliminary representative. (If more than one values 
>6.0Å of identical minimum size have occurred, one of these concerned snapshots would have been 
randomly selected as representative). For μ-PIIIA on KV1.6-5P2 our latest checks resulted in a revision 
and replacement of the proposed preliminary representative at 200ns simulation time by snapshot 10 at 
450ns (Table 14, 6th row). The “inactive-alike” high fluctuation rate of μ-PIIIA on KV1.6-5P2, shown 
by the results of clustering method 2, i.e. the comparatively high number of generated clusters (Table 
13, 4th column, 6th row) further underpinned our revision steps and the concomitant replacement of the 
preliminary representative by a snapshot of later simulation time.  
All results of our revising step are listed in Table 14 (6th column). 
Last but not least, it should be noted that, in the (unlikely but still possible) worst-case of  an empty 
preselection set, out of  the set of  all eleven snapshots generated at the beginning, the structure of  
general lowest RMSD to the average structure would be selected as final representative. This is to 
maintain consistency with regard to the entire approach. 
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Table 14: Detection of  the final representative snapshot. Combination (intersection or union) of  cluster analyses 1 and 2 
main clusters is applied (3rd column), followed by a final check for case semi-active (b) by reconciliation with the snapshots 
of  the last simulation quarter (5th column); final representatives are listed in the 6th column. 
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